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ABSTRACT 
The study of the interface between chemistry, biology, and materials science not only advances 
the fundamental understandings of phenomena and materials at the nanoscale regime, but also produces 
novel functional materials with promising applications. Nanomaterials with size similar to biological 
molecules and systems have shown great promise for diagnostic and therapeutic applications due to their 
unique properties, such as fluorescent, plasmonic, magnetic, electrochemical, and other physical 
properties. To realize the full potential of nanomaterials for biomedical applications, nanomaterials have 
further been engineered with various surface functions. Among them, functional DNA (fDNA), as an 
analogue of antibodies and enzymes, has emerged as a new class of recognition agents for the 
functionalization of nanomaterials to allow specific binding against biological targets. Despite great 
achievements over the past decades, three major challenges still remain in developing nanomaterials 
towards better clinical theranostics. First, a general method for quantitative detection of biological 
substrates in vitro and in vivo has to be proposed. Second, the development of multifunctional 
nanomaterials for multimodal detection and targeted drug delivery should be achieved. Third, fine-tuning 
of the physical characteristics and biological properties of nanomaterials at the molecular level is required. 
In this document, new diagnostic and therapeutic strategies and tools are demonstrated correspondingly to 
address the above-mentioned challenges by integrating fDNA with well-designed nanomaterials. First, the 
development of a quantitative ratiometric probe by using fDNA-Janus nanoparticle conjugates is 
presented. Second, a general platform using fDNA and liposomes is developed for the multimodal 
detection of small molecules and targeted breast cancer chemotherapy. Third, a novel single chain 
polymer-based organic nanoparticle system is demonstrated with a variety of carefully fine-tuned 
functionalities. The fDNA-nanomaterial conjugates demonstrated in this document not only possess 
attractive properties for diagnosis and therapeutic applications but also inspire the design and 
development of future biomedical tools. 
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CHAPTER 1 
INTRODUCTION 
Part of this chapter was published as:  
1. “DNA Aptamer Functionalized Nanomaterials for Intracellular Analysis, Cancer Cell Imaging 
and Drug Delivery”, Hang Xing, Ngo Yin Wong, Yu Xiang, Yi Lu, Current Opinion in 
Chemical Biology, 2012, 16, 429-435;  
2. “DNA Aptamer Technology for Future Personalized Medicine”, Hang Xing, Kevin Hwang, Ji 
Li, Seyed-Fakhreddin Torabi, Yi Lu, Current Opinion in Chemical Engineering, 2014, 4, 79-87; 
3. “DNA as a Powerful Tool for Morphology Control, Spatial Positioning and Dynamic 
Assembly of Nanoparticles”, Li Huey Tan, Hang Xing, Yi Lu, Accounts of Chemical Research, 
2014, 47, 1881-1890. 
1.1. Overview 
In the last decade, the study of inter- and intra-cellular biochemical processes has made 
enormous contributions to our understanding of basic human biology and disease pathogenesis 
and treatment. Technologies such as fluorescent resonant energy transfer (FRET), single 
molecular imaging, and gene regulation have allowed unparalleled insights into cellular 
functions and mechanisms in drug delivery. Clinical tools for detecting genetic, proteomic, or 
metabolite biomarkers have been greatly advanced to promise the precise diagnosis and 
improved therapy.1-3 Despite significant progress, challenges still remain. For instance, clinical 
tools for detecting genetic, proteomic, or metabolite biomarkers are required to cater individual 
conditions in order to make proper medical decisions. Similarly, therapeutic methods for treating 
diseases need to shift from the administrating broadly acting drugs towards using more specific 
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drugs and dosages effective for each patient. Among the many approaches to meet these 
challenges, using functional DNA and nanomaterial to develop a new generation of theranostic 
tools an emerging and promising one (Figure 1.1). 
1.2. Nanomaterials and Their Applications 
Nanomaterials have shown enormous promise as the next-generation materials in many 
areas from catalysis to photonics, environmental detection, clinical diagnostics and therapy.4-7 
Such a promise arises from unique properties conferred by the nanomaterials, i.e., their 
plasmonic and quantum confinement effects that changes with morphology including shape 
surface structure,8 and interparticle distances.9,10 
Metal nanoparticles is one of the most widely used nanomaterials for the studies of 
cellular uptake and analysis due to their simple synthesis, easy modifications, and 
biocompatibility. For applications in cellular analysis, gold and silver nanoparticles have been 
especially common owing to their excellent plasmonic properties, which have enabled significant 
advances in localized surface plasmon resonance (LSPR) for applications such as surface 
enhanced Raman spectroscopy.11 When in close proximity to the surface of a plasmonic metal, 
the Raman signal can achieve 1014 enhancements, due to electromagnetic enhancements from 
plasmonic “hot spots”. Nanoparticles,12 nanoshells,13 nanoflowers,14 nanorods15 and many other 
nanostructures 16 have all been recently been explored for their plasmonic properties in cell 
imaging, uptake mechanisms, and detection of various analytes.17,18. 
Other types of nanomaterials such as silica nanoparticles, quantum dots (QDs), and 
upconversion nanoparticles, and carbon based nanomaterials have also been applied in cellular 
applications.19-21 Nanosized silica is widely known for excellent compatibility and has been used 
extensively in cellular studies.22 More recently, mesoporous structures dramatically increased the 
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surface area of silica nanoparticles and enabled high loading of cargo for cellular imaging and 
delivery.23 Another material of interests is semiconducting QDs. Because of their fluorescence 
stability, board absorption and narrow emission band, they are uniquely suited for high 
resolution and multiplex imaging of cells.24,25 Carbon based nanomaterials such as carbon 
nanotubes, fullerenes, and most recently graphene and graphene oxide are also promising 
nanomaterials for cellular applications, including the use of stabilized graphene oxide in cellular 
imaging and drug delivery.26-28 
1.3. Introduction to Functional DNA (fDNA)  
Although nanomaterials have been demonstrated to be promising in in cellular 
applications as efficient reporters and carriers, the application of non-functionalized 
nanomaterials have been limited due to short of specific functionality, lack of target specificity, 
and low intracellular stability.  
Recent studies revealed functional DNA to be a promising tool for introducing target 
specificity to nanomaterials for intracellular imaging, diagnosis, and therapy.29,30 Besides its 
conventional function that encodes genetic information, DNA has been found to also serve as 
enzymes (called deoxyribozymes or DNAzymes) and recognition molecules like antibodies 
(called aptamers). This class of DNA, called functional DNA (fDNA), can be identified through 
a process called Systematic Evolution of Ligands by Exponential Enrichment (SELEX), in which 
fDNA is isolated from a library of ~1015 random DNA sequences. This process allows fDNA to 
be highly selective for almost any targets ranging from metal ions, small organic molecules, to 
proteins, cancer cells, bacteria and viruses with high affinity and specificity.31-34 Functional 
DNAs possess several advantages compared with other biological materials. Firstly, while 
aptamers may consist of either type of nucleic acids, fDNA is more stable against biodegradation 
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than its RNA congeners. Second, compared with antibodies, fDNA exhibits significant 
advantages to protein-based diagnosis and therapy in terms of size, stability, non-
immunogenicity, and synthetic accessibility. Furthermore, new fDNA can be selected through a 
well-established selection process towards any biomedical important target to advance 
pharmaceutical development, particularly small molecular targets such as metal ions and small 
organic molecular biomarkers. Owing to these advantages, research in the selection of new 
fDNAs, characterization of their physical properties, as well as application in a variety of 
biomedical systems has greatly increased over the past decade, and researchers have identified a 
range of fDNA with high binding affinity to target a wide range of protein families of clinical 
interest including kinases, growth factors, and cell-surface receptors (Figure 1.1).35-38  
1.4. fDNA-Nanomaterial Conjugate for In vitro Sensing Applications 
As mentioned above, a number of fDNA sequences that respond to a wide range of 
targets have been identified.39 By linking the fDNA with nanomaterials, previous studies have 
demonstrated various sensors in response to target molecules,40 allowing broad in vitro sensing 
applications. 
The first demonstration is the use of a Pb2+-specific DNAzyme that contains a substrate 
strand, D3, with a single RNA base as the cleavage site, and an enzyme strand, D4. The AuNPs 
assembled through the ends of D3 would appear purple due to plasmon coupling (Figure 1.2a).41 
In the presence of a certain metal cofactor, like Pb2+ for 8-17 DNAzyme, D3 will be cleaved into 
two shorter DNA fragments with melting temperatures below room temperature. 
Dehybridization of the DNA fragments will cause the disassembly of AuNPs and purple-to-red 
color change, making it a simple colorimetric sensor for Pb2+. This method can be generally 
applied to other DNAzymes, such as a uranyl-selective DNAzyme.42 Assembly of gold 
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nanoparticles can also be triggered, as demonstrated with the use of Cu2+ catalyzed DNA 
ligation.43 
In addition to metal ions, molecular triggers of assembly-disassembly of NPs can be 
performed through the use of aptamers. For example, the NPs assembled using a linker strand 
with aptamer sequence, D5 (Figure 1.2b) showed a color change upon binding of targets like 
adenosine and cocaine.44 This method to trigger the release of AuNPs was further extended to 
other nanomaterials, such as quantum dots (QDs),45 carbon nanotubes (CNTs),46 and iron oxide 
NPs,47 resulting in fluorescent, electrochemical and magnetic resonance outputs for sensing of 
different targets. One of such examples is shown in Figure 1.2c,45 where two QDs of different 
emission wavelength (525 nm, QD525 and 585 nm, QD585) were functionalized with adenosine 
and cocaine aptamers respectively. The QD525 emission was initially quenched due to energy 
transfer with AuNPs. In the presence of adenosine, the AuNPs bound to the QD525 would be 
released, resulting in an increase of 525 nm emission. By the same mechanism, 585 nm 
fluorescence would increase in the presence of cocaine. With narrow emissions of QDs, 
simultaneous detection of both cocaine and adenosine was demonstrated.   
Detection of Multiple Targets 
In biological processes, multiple events can be triggered simultaneously, often with 
cooperativity. Similarly, NP assembly can be designed to respond to multiple stimuli and 
increase the selectivity for sensing, as it relies on the cooperation between two or more targets.48 
One such example is the use of aptazymes, consisting of an aptamer and a DNAzyme, whose 
activity can be modulated in the presence of the aptamer target. As shown in Figure 1.2d, an 
adenosine aptamer sequence was inserted into a Pb2+-specific DNAzyme, inactivating the 
DNAzyme even in the presence of Pb2+. Once adenosine is added, the aptamer sequence would 
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fold to regenerate the catalytic site,49 restoring the Pb2+-dependent DNAzyme activity. When 
conjugated to AuNPs, the color change observed from disassembly of AuNPs only occurred 
when both Pb2+ and adenosine were present. 
In addition to aptazymes, two aptamers can be designed to trigger disassembly in 
response to either one or both of the targets cooperatively (Figure 1.2e).50 In the design where 
AuNPs were linked by a DNA strand with two aptamer sequences, the disassembly process 
occurred in the presence of either target of the aptamers. When both aptamer sequences were 
linking all the AuNPs, the disassembly process can occur only in the presence of both targets. 
The color change was observed and quantified using the ratio of absorbance at 522 nm over the 
absorbance at 700 nm (Figure 1.2f). These designs were also expanded to respond to K+ ions 
with a G-quadruplex forming aptamer in addition to either cocaine or adenosine triggers.50  
1.5. fDNA-Nanomaterial Conjugate for Analysis of Intracellular Components 
Among all different kinds of nanomaterials, gold nanoparticles (AuNPs) are the most 
characterized nanomaterials for intracellular analysis. AuNPs exhibit high stability, good 
biocompatibility, excellent optical and electronic properties, and diverse surface 
functionalizations. In addition to cellular applications shown below, fDNA-modified AuNPs 
have also been extensively applied for detecting metal ion and biomolecular targets.51,52 
Mirkin and co-workers developed an aptamer-AuNP hybrid with fluorescent reporters, 
termed as “nanoflare”, which can quantitatively detect analytes inside living cells.53 The aptamer 
modified nanoflares are highly stable, readily taken by cells, and were used to detect intracellular 
ATP concentrations at 1 ~ 2 mM (Figure 1.3).54 Similar methodology have been be applied to 
detect gene expression, message RNA in living cells by using antisense DNA strand or 
molecular beacon constructs 55,56. 
7 
 
Recently, our group used this method to develop the first DNAzyme-based probe for 
metal ions in live cells by conjugating a fluorescent uranyl-specific 39E DNAzyme onto 
AuNPs.57 The AuNP-DNAzyme probe was demonstrated to respond to uranyl and provide 
enhanced fluorescence signal in live cell. When applying DNAzyme-AuNP conjugates for 
intracellular diagnosis, a major barrier is the “always-on” property of first-generation DNAzyme 
sensor. To address this issue, 8-17E DNAzyme with 2′-O-nitrobenzyl adenosine photo-caging 
group was designed and synthesized. The photoactivatable DNAzyme-based sensor was 
demonstrated to have temporal control over the sensing activity, allowing the monitor the 
concentration change of Zn2+ in living cells.58 
Another kind of fDNA-nanomaterial conjugate that has attracted considerable interest is 
carbon-based materials, such as single-walled carbon nanotubes (SWCNTs) and graphene due to 
their high surface area, mechanical strength, high electrical conductivity, and photoluminescence. 
These unique properties offer SWCNTs and graphene good opportunities for biosensing and 
bioimaging applications. For example, DNA strands can be adsorbed onto SWCNT/graphene 
through strong pi-stacking interactions and released through hybridization or structure 
switching.59 By taking advantage of the high quenching efficiency of carbon structures, Cha et al. 
was able to develop an intracellular insulin sensor with wide detection range from 10 μM to 2 
mM.60 
Graphene derivatives featuring excellent optical and electrical properties recently 
emerged as another promising carbon-based nanomaterial for in situ analysis of small molecules 
in living cells. For example, Wang et al. reported the usage of graphene oxide nanosheet as 
quenchers for aptamer-based intracellular APT detection.61 They synthesized a nanocomplex 
with carboxyfluorescein (FAM) modified ATP aptamer strands absorbed on graphene oxide 
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nanosheets (GO-nS) resulting in significant quenching of fluorescent intensity. They further 
demonstrated the effective uptake of aptamer-FAM/GO-nS nanocomplex into JB6 cells and 
fluorescence recovery after adding ATP molecules (Figure 1.4). They reported in situ 
intracellular ATP detection with a detection limit as low as 10 μM. 
1.6. fDNA-Nanomaterial Conjugate for Cancer Diagnosis 
Cancer has a major impact on society today. The World Health Organization (WHO) has 
reported that 7.6 million people die of cancer every year.62 Identification of cancer cells at the 
earliest stage is the key for successful prevention and efficient treatment of cancers. Therefore, 
developing DNA aptamer-based diagnostic tools for cancer cells with high sensitivity and 
selectivity is critical for clinical cancer management to maximize long-term survival.63 
DNA Aptamer-Targeted DNA Nanostructures as Cancer Probes 
DNA Aptamer capable of recognizing biomarkers or cancer cells can be obtained through 
in vitro selection or cell-SELEX.64 When modified with fluorophores, these functional DNA 
strands can be used as molecular probes for in vivo identification and imaging of cancer cells. 
The cell-SELEX approach has been adopted to obtain aptamers that specifically bind to 
glioblastoma (GBM) tumor-initiating cells (TIC), which were shown to selectively internalize 
into GBM TIC cells, and were able to differentiate cells with high tumorigenic potential from 
GBM xenografts.65. Another example showed that the use of a DNA aptamer against the A549 
lung carcinoma cell line allowed in vivo fluorescence imaging of carcinomas.66 
To enhance the performance and functionality, aptamers can further be incorporated into 
DNA nanostructures. An activatable aptamer probe (AAP) featuring a sgc8 aptamer targeting 
protein tyrosine kinase-7 (PTK7), a poly-T linker and a short DNA strand can form a molecular 
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beacon structure.67 Animal studies confirmed that such AAPs could be activated through cell 
membrane protein-triggered conformational changes, resulting in enhanced fluorescence signals 
at CCRF-CEM tumor sites. To increase the stability of DNA aptamer probes, branched 
polyethyleneimine (PEI) was used as a vector to deliver a TD05 aptamer-based probe (Figure 
1.5a).68 Such PEI/aptamer probes showed higher stability against DNase degradation and were 
used for in vivo imaging of a Ramos tumor in mice. Moreover, a more sophisticated DNA-based 
nanorobot made by DNA origami method was reported for delivery of biologically active 
payloads for cell-targeting.69 This stimuli-responsive device was locked with DNA aptamers in a 
dual-lock mode so that the nanorobot would open and release its payload only in the presence of 
two different target molecules. 
DNA Aptamer-Conjugated Nanomaterials as Cancer Probes 
The conjugation of nanomaterials with unique optical or magnetic properties to aptamers 
with high specificity has resulted in effective imaging agents for cancer diagnosis. One 
prominent example is luminescent upconversion nanoparticles (UCNPs) capable of converting 
near-infrared (NIR) excitation photon into shorter wavelength visible luminescence, which is 
ideal for deep tissue bioimaging. However, functionalization of such UCNPs for targeting is 
difficult. Recently, our lab reported a one-step strategy to prepare uniform DNA-modified 
UCNPs through ligand exchange at the liquid−liquid interface (Figure 1.5b).70 The nucleolin 
DNA aptamer remained functional on the UCNP surface and enabled specific targeting of MCF-
7 cancer cells and cell membrane penetration, with high internalization efficiency. 
Besides UCNPs, other DNA aptamer-modified nanomaterials allow different techniques 
to be used for imaging of tumors. Aptamer-modified, monodisperse silica nanoparticles have 
been synthesized as probes for multimodal imaging of lymph nodes (LN) (Figure 1.5c).71 
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Positron emission tomography (PET) and NIR fluorescence imaging confirmed that a nucleolin 
aptamer directed silica nanoparticles were accumulated in LNs with metastatic breast tumors 
using a 4T1 tumor model. In addition, an AS1411 aptamer-modified cobalt–ferrite nanoparticle 
was used for targeted multi-model imaging of C6 tumors in mice.72 Moreover, aptamer-modified 
nano/micro-sized micelle bubbles,73 quantum dots,74 as well as iron oxide nanoparticles75 have 
also been recently reported for cell-specific ultrasound, fluorescence, and magnetic resonance 
imaging respectively. 
DNA-aptamer templated fluorescent silver nanoclusters (AgNCs) are also shown to be 
applied in specific cancer cell targeting and imaging.76 The Sgc8c aptamer strands were 
immobilized onto AgNCs through cytosine-rich sequence, and the resulting Sgc8c-modified 
AgNCs showed specific targeting and fluorescent labeling capabilities to CCRF-CEM cancer 
cell over control cells. In addition to the fluorescence properties, the tunable LSPR properties of 
AgNPs were also utilized for cellular imaging. Chen et al. reported that the prion protein (PrPc) 
aptamer modified AgNPs could be used as targeted contrast imaging agents for both dark-field 
light scattering and TEM imaging of SK-N-SH cells. They further observed that PrPc-AgNPs 
could be internalized into plasma membrane, lysosome and endocytic structure through aptamer-
mediated endocytosis.77 
Kim and co-workers reported a cancer-specific multimodal imaging probe consisting of 
cobalt–ferrite nanoparticle protected by a silica shell and coated by fluorescent rhodamine. They 
demonstrated that the AS1411 aptamer-multimodal nanoparticle system not only enabled the 
targeted fluorescence imaging of nucleolin-expressing C6 cells, but also allowed radionuclide 
and MRI imaging in vivo and in vitro. In addition, Colin et al. combined fluorophore-doped silica 
and silica-coated magnetic nanoparticles modified with highly selective aptamers to detect and 
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extract CCRF-CEM targeted cells in a variety of mixtures.78 They also systematically studied the 
effect of nanoparticle size, conjugation chemistry, and aptamer sequences on the selectivity and 
sensitivity of the dual-particle assays. 
Besides aptamer modified metal and silica nanoparticles, an extracellular supramolecular 
reticular DNA-QD sheath was reported by Zhang and co-worker in high-intensity fluorescence 
imaging.79 At physiological temperature, the DNA-QD sheath readily recognized and bound to 
Ramos cells in a cell-specific manner, and was used to accurately quantify the Ramos cells 
within the range of 10 to 1000 cells. In addition, electrochemical sensors and electro 
chemiluminescence methods have also been reported as detection methods for aptamer-QDs 
based cancer cell detection.80,81 
1.7. fDNA-Nanomaterial Conjugate for Cancer Therapy 
 Traditional cancer chemotherapy suffers from severe side effects and low therapeutic 
index. Using fDNA either alone or in combination with nanomaterials as therapeutics or 
targeting agents is a promising approach for improving anticancer efficacy while reducing side 
effects. 
DNA Aptamers as Anticancer Therapeutic Agents 
DNA aptamers can be selected to bind specific protein targets of clinical interest. Among 
them, some aptamers have been found to have therapeutic effects in a manner similar to 
monoclonal antibodies, as the binding of aptamers may shield the active site of protein or inhibit 
ligand-receptor interactions, and thus may function as anticancer therapeutics.63,82 The first DNA 
aptamer-based anticancer drug entering clinical trials was AS1411, which is a 26-mer G-
quadruplexed oligodeoxynucleotide that binds to nucleolin.35 Although AS1411 is currently in 
12 
 
phase II clinical trials for the treatment of acute myeloid leukaemia, its mechanism of action is 
not completely clear. A recent study suggests that the anticancer activity of AS1411 might be 
caused by hyperstimulation of macropinocytosis after binding to nucleolin.83 Besides AS1411, 
several new DNA aptamers have been discovered with anticancer properties. For example, a 
serum-stabilized DNA aptamer for immunotherapy of CD30-expressing lymphoma was 
generated.84 In addition, two DNA aptamers which bind to carcinoembryonic antigen (CEA) 
were selected and used for the pre-treatment of a CEA-expressing tumor model in vivo.85 
Moreover, a DNA aptamer recognizing human epidermal growth factor receptor 2 (ErbB-
2/HER2) was reported recently with antitumor efficacy two-fold higher than that of a 
monoclonal anti-ErbB-2/HER2 antibody against human gastric cancer cells.86 
DNA Aptamer-Targeted DNA Nanostructures for Cancer Therapy 
While DNA aptamers can be used directly as therapeutic agents, they require a relatively 
large dosage in order to be effective. Since delivery of the highly negatively charged DNA is a 
major hurdle, an alternate approach using DNA as a targeting agent in combination with other 
drugs may be more promising, as this approach takes advantage of the high selectivity of 
aptamer with the strong therapeutic potential of known drugs; even if not many DNA strands are 
delivered to the target, the high loading of the drug may still allow the combined system to be 
effective. Along this line, it has been shown that DNA nanostructures can be used as delivery 
system with antitumor drugs intercalating within strands of double-stranded DNA (dsDNA).87 
Together with cancer cell-specific aptamers, different DNA nanostructures have been 
demonstrated as targeting vectors for the delivery of anticancer agents. Furthermore, an aptamer-
tethered, long linear dsDNA structure, named a “DNA nanotrain” (aptNTr) has been developed 
to deliver anticancer drugs and bioimaging agents to tumor cells (Figure 1.6a).88 The long 
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dsDNA chain serves as a carrier in which doxorubicin may be loaded to a high capacity. The 
enhanced antitumor efficacy and reduced side effects of drugs delivered by aptNTrs were 
demonstrated in a xenograft tumor model in vivo. Similarly, a poly-aptamer-drug system was 
constructed by rolling circle amplification using a leukemia cell-binding aptamer and 
doxorubicin-loading strands. Enhanced targeting effects and improved cellular uptake were 
observed as compared to the monovalent counterpart, due to aptamer multivalency.89 Another 
example is reported from Huang and co-workers by using 3D DNA Icosahedral as a carrier for 
doxorubicin. MUC 1 aptamers were conjugated to distinct five-point-star and six-point-star 
motifs through DNA hybridization before the formation of DNA polyhedra. They demonstrated 
that aptamer-conjugated doxorubicin-intercalated DNA icosahedra showed a specific and 
efficient therapeutic effect for epithelial cancer cells.90 
Aptamers as targeting agents in Drug Delivery 
Compared to conventional passive anticancer drug delivery system, targeted delivery 
attracts more attention and can be achieved by disease-specific recognition of tumor cells. 
Liposomes are one of the most successful drug delivery platforms in clinical use now. To confer 
selectivity upon this system the AS1411 aptamer was conjugated to a 200 nm liposome loaded 
with doxorubicin (Figure 1.6b).91 Cellular and animal studies demonstrated that these highly 
stable liposomes were able to target MCF-7 cells specifically and improve the inhibition of 
tumor growth, attributable to enhanced tumor tissue penetration. More importantly, because the 
DNA aptamer sequence is known and it can bind its complementary DNA strongly through 
hybridization, the effectiveness of this system can be tuned with different concentrations of the 
complementary DNA strand of the aptamer as an antidote.92 
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In collaboration with Wong and Cheng groups, our group recently reported cell-specific 
drug delivery system based on aptamer modified liposomes. Liposomes encapsulated with 
anticancer drug cisplatin were conjugated with AS1411 DNA aptamers that specifically bound to 
nucleolin overexpressed on the cancer cell membrane. We demonstrated that the aptamer-
liposomes-cisplatin composite could be delivered into the target MCF-7 cancer cells but not into 
LNCaP cells as control. Moreover, the release of cisplatin was successfully controlled by 
introducing a complementary DNA strand of the aptamer as an antidote.92 
Other delivery systems, such as polymer nanoparticles and micelles, have also been used 
in combination with cancer-specific DNA aptamers. For example, PEG-PLGA nanoparticles 
have been functionalized with the AS1411 nucleolin aptamer for targeted delivery of paclitaxel 
(PTX) to mice bearing C6 gliomas.93. The biodistribution test showed enhanced tumor 
accumulation for the aptamer-functionalized nanoparticles compared to the nanoparticles alone 
and free drug. Prolonged circulation time and the targeting effect of the system facilitated tumor 
inhibition. In 2011, Gao et al. reported the application of thrombin aptamer-functionalized TBA-
tethered lipid-coated mesoporous silica nanoparticles (TBA-lipid-MSN) and demonstrated 
effective recognition of thrombin and suppression of HeLa cell growth by extracellularly 
disturbing PAR-1 receptor signaling. In addition, the efficient delivery of anticancer drug Dtxl 
also contributed to the effective cytotoxicity in the cytoplasm.94 Moreover, a lipid tail was 
attached onto the end of TDO5 aptamer, forming an aptamer-micelle with high binding affinity 
to Ramos cells and extremely low binding off rate (10-5-10-6 s-1).77 Finally, the aptamer-
conjugated micelle could be used not only for targeted imaging of cancer cells but also specific 
destruction of them, via ultrasound-mediated acoustic droplet vaporization.95 
 
15 
 
1.8. Perspective 
Much progress has been made in developing functional DNA-nanomaterial conjugates 
for diagnostic and therapeutic applications. The recent development of nanotechnology has 
brought about many nanomaterials as signal reporters and delivery carriers that are more 
efficient than classic materials for cellular applications. Along with the advantages of 
nanomaterials, the functionalization of fDNAs as recognizing and targeting molecules onto these 
nanomaterials has successfully realized highly selective and efficient cellular analysis, imaging 
and targeted delivery. Despite the progress, it has been slow for fDNA research in the laboratory 
to reach the market. So far, only one DNA aptamer-based drug has been approved by the US 
Food and Drug Administration (FDA) to be marketed, with several others currently under 
clinical evaluation.96 While many fDNA have been well characterized and show promise, most 
work has only demonstrated proof-of-concept models, with a few showing application in animal 
models. Their action and effectiveness in vivo still need further investigation in order to be used 
for future theranostic applications.  
In addition, even though a number of fDNAs for targets of biological importance have 
been identified, fDNA for many other targets of clinical significance have yet to be selected, 
such as small molecules that serve as disease markers in the blood or urine.97 Another potential 
target of interest may be metal ions, which are critical in many aspects of health and disease, 
including cancer.98 The ability to obtain fDNA selective for a specific metal ion has already been 
demonstrated and will likely serve as the basis for such future work.99 Beside in vitro selection 
from random nucleic acid pools, the introduction of unnatural nucleotides into the nucleic acid 
pools to improve the diversity of functional groups may further enhance the chance to obtain 
fDNA for more cellular targets.100 
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For future clinical applications, diagnostic tests must become more portable, using simple 
devices for real-time and on-site detection and monitoring, instead of the laborious and time-
consuming diagnostic tests currently available only in clinical labs.101,102 For therapy, there is 
still huge untapped potential to develop a general drug delivery platform with physiochemical 
stability, stimuli-responsiveness, controlled release profile and desired in vivo biodistribution.  
Finally, the combination of diagnosis and therapy in one system (theranostics) holds the 
key to the future success. To achieve such a goal, a development loop is required, in which the 
development of medicines will start from identification of disease markers from an individual 
patient, proceed through the expedited in vitro selection of fDNA for these markers, and finally 
facilitate the production of theranostic tools specifically designed for that patient by combining 
fDNA with appropriate nanomaterials (Figure 1.7). Successful implementation of this 
development loop will make fDNA and nanomaterials key drivers for the future clinical 
diagnosis and therapy. 
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1.10. Figures 
 
Figure 1.1. Top: Graph showing the number of publications over the past ten years with title 
containing “aptamer”, according to Web of Science. *The number of publications in 2014 is 
counted until November. Bottom: Representative DNA aptamers to protein targets of therapeutic 
interest. 
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Figure 1.2. (a) AuNP-DNAzyme conjugates responding to the absence and presence of Pb2+ 
leading to assembled (blue) and disassembled (red) nanostructures respectively. (b) AuNP-
aptamer conjugates responding to adenosine. (c) Multiplex detection with assemblies of AuNPs 
and QDs with 525 nm emission for adenosine and 585 nm emission for cocaine. (d) Aptazyme 
responsive to both adenosine and Pb2+. (e) Two cooperatively triggered disassemblies of NPs in 
the presence of different cocaine and adenosine combinations. (f) Graph of ratio at 522 nm over 
700 nm of absorbance for the two designs in (e) with time. 
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Figure 1.3. (a) Schematic view of the basic design and stimuli-responsive mechanism of aptamer 
nano-flare. (b) Fluorescence microscopy images of HeLa cells incubated with aptamer nano-
flares and control particles. (c) Flow cytometry results of fluorescent intensity (Cy5) of cells 
treated with aptamer nano-flares and control particles. Adapted from ref 54.54 
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Figure 1.4. (a) Schematic illustration of in situ molecular probing in living cells by using 
aptamer/GO-nS nanocomplex. (b) JB6 cells specific uptake of ATP aptamer-FAM/GO-nS 
samples (b) and random DNA-FAM/GO-nS samples (c) Images were taken under differential 
interference contrast and wide-field fluorescence. Adapted from ref 61.61 
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Figure 1.5. (a) Schematic illustration of the protection of PEI on DNA and targeted imaging 
with PEI/aptamer complexes. Adapted from ref 68.68 (b) Schematic view of the synthesis of 
DNA aptamer-functionalized UCNPs from as-prepared hydrophobic UCNPs and targeted 
imaging using aptamer-modified UCNPs. Confocal microscopy images of MCF-7 cells treated 
with aptamer-UCNPs (left) and control-UCNPs (right). Adapted from ref 70.70 (c) Schematic 
view of the preparation of aptamer-functionalized dual-labeled silica NCs for PET and NIR 
fluorescence imaging. In vivo whole-body PET/CT imaging of BALB/c mice after hock injection 
of dual-labeled control-NCs and aptamer-NCs. Adapted from ref 71.71  
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Figure 1.6. (a) Schematic of the self-assembly of aptamer-tethered DNA nanotrains (aptNTrs) 
and the illustration of the drug transportation process via aptNTrs to target cells. Adapted from 
ref 88.88 (b) Schematic illustration of the assembly of aptamer-conjugated liposomes with 
encapsulated cargos and confocal microscope images of MCF-7 cells treated with non-aptamer-
conjugated liposomes and aptamer-conjugated liposomes in cell culture (left) and in tumor tissue 
sections (right). Adapted from ref 92.91 
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Figure 1.7. A scheme showing how functional DNA and nanomaterial power future clinical 
diagnosis and therapy. 
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CHAPTER 2 
ANISOTROPIC FUNCTIONALIZATION AND ASSEMBLY OF DNA-
JANUS NANOPARTICLE CONJUGATES 
Part of this chapter was published as:  
1. “DNA-Directed Assembly of Asymmetric Nanoclusters Using Janus Nanoparticles”, Hang 
Xing, Zidong Wang, Zhida Xu, Ngo Yin Wong, Yu Xiang, Gang Logan Liu, Yi Lu, ACS Nano, 
2012, 6, 802-809.  
2.1. Introduction 
With the development in nanotechnology, controlled assembly of nanoparticles into 
complex nanostructures has attracted extensive research attention.1 The organization of 
nanoparticles into nanoscale clusters or higher dimensional structures is of great importance to 
realize their novel optical, electrical, and chemical properties.2-6 In contrast to vast majority of 
research efforts in symmetrical assembly, asymmetric assembly of nanomaterials is much less 
explored, even though the unique anisotropic properties they exhibited not found in their 
symmetric counterparts.7-10 Despite these exciting properties and promising applications of 
asymmetric nanostructures, controlled fabrication of these materials remains a challenge.11 Up to 
now, methods of assembly to asymmetric nanostructures have been limited to either the use of 
interface of different phases as steric hindrance, or the formation of geometric defects in the 
nanoscale building blocks.12,13 The difficulties to achieve both spatial and chemical controls in 
previous processes limit the type, yield and thus application of the asymmetrically assembled 
nanomaterials.14,15 Therefore, there is a compelling need to develop novel methods that can make 
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asymmetric nanostructures with uniform scale, controllable composition, and tunable properties 
for future applications. 
A simple route to generate monodisperse, asymmetrically functionalized nanostructure is 
to utilize a nanoscale platform with predetermined, programmable, spatially separated 
functionalizations. Janus particle, which is termed from the double-faced Roman god, consists of 
one type of colloidal structures with two different physiochemical properties on opposite regions. 
This anisotropic property makes Janus particle suitable for applications such as optical probes, 
two-phase stabilizers, solid surfactants, as well as building blocks for supramolecular 
assemblies.16,17 Taking advantage of the asymmetric properties of Janus particles, researchers 
have demonstrated the assembly of dipolar and amphiphilic Janus particles through electrostatic 
and hydrophobic/hydrophilic interactions.17,18 However, both of these two types of interactions 
are non-directional and highly dependent on the environment. In contrast, due to high 
programmability through the specific Watson-Crick base pairing and ease of chemical and 
enzymatic modification,19-21 DNA has been used as a template to position nanoscale components 
on double-stranded backbones in well-defined 1-D,22,23 2-D,24,25 and 3-D patterns,26-28 or as 
linker to attach nanoparticles, proteins, and quantum dots to direct the formation of large periodic 
structures.29,30 However, DNA is much less explored for the design and assembly of asymmetric 
nanostructures. Most of efforts so far have focused on utilizing mono-functionalized 
nanoparticles.31-35 While these pioneering work demonstrated the power of directional 
interactions provided by DNA in templating different building blocks, the requirement of using 
complicated HPLC or agarose gel for purification, or using the surface of micro-sized magnetic 
particles as geometric restriction have made it difficult to relocate different DNA strands on 
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different regions efficiently, and thus generate limited types of structures and lack of the ability 
to provide high-yield and uniform asymmetric structures. 
Herein, we report a new approach of using DNA for directing the assembly of 
asymmetric nanoclusters on pre-fabricated JNP platform. The formation of asymmetric 
nanostructures with tunable optical properties has been demonstrated. We also showed that DNA 
used as linker between different building blocks allows programmable assembly and disassembly 
of Janus nanoclusters with tunable optical properties. Furthermore, the approach of incorporating 
DNA with Janus nanoparticles is modular and programmable. A series of asymmetric 
nanoclusters have been rationally designed and assembled through programmable base-paring 
interactions to study the size-dependent nanoparticle self-assembly process. 
2.2. Results and Discussion 
Fabrication of JNP 
The fabrication of JNPs with gold covered on one hemisphere is using a previously 
reported procedure (Figure 2.1).36,37 By manipulating the duration O2 plasma etching, we can 
control the shrinkage and inter-particle distance of the PS nanospheres (Figure 2.2a). The final 
diameter of PS nanospheres is around 160 nm. In order to grow gold layer on the top surface of 
PS nanoparticles, 2 nm chromium layer and 6 nm gold layer are deposited subsequently by using 
electron-beam evaporator (Figure 2.2b). The resulting JNPs can be released into water solution 
from the surface by ultrasonication. As shown in by scanning electron microscopy (SEM, see 
Figure 2.2c), monodisperse JNPs with half gold and half polystyrene were observed in high 
yield. 
Assembly of 15 nm AuNSs with JNP 
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Figure 2.3 illustrates schematically the approach of DNA-directed assembly. JNP with 
160 nm in diameter serves as the anisotropic platform for selective decoration. The active gold 
surface of JNPs can be functionalized with thiolated DNA linker, ssDNA-1, while the other 
polystyrene surface remains unmodified. The spatially separated regions with different chemical 
properties on single JNP building block enable us to assemble asymmetric structures. To 
demonstrate the nanoassembly process, 15 nm AuNSs were first treated with thiolated 
complementary ssDNA-1' and purified by using previously reported methods.38,39 Two types of 
particles, JNP-1 and AuNS-1', were then incubated in a ratio of 1:1000 in a buffer solution 
containing 5 mM HEPES buffer (pH 8.2) and 200 mM NaCl at room temperature for 24 h. 
During the incubation process, ssDNA-1 on JNP can hybridize to ssDNA-1' on AuNS through a 
12 base-paring 1-1' recognition to generate dark purple colored precipitates at the bottom of the 
test tube. SEM was employed to investigate the resulting precipitates. We observed that on every 
single JNP, the gold hemisphere was occupied by a number of 15 nm AuNSs while the PS 
hemisphere remained largely clear of any AuNSs, resulting in asymmetric nanoclusters. Excess 
15 nm AuNSs were been observed in the background (Figure 2.4). Asymmetric nanoclusters 
could be further purified by centrifugation, removing the supernatant and rinsing the precipitates 
for multiple times with buffer solution to remove excess 15 nm AuNSs. TEM image (Figure 2.5) 
confirmed that most of free AuNSs are removed and the purified asymmetric nanoclusters are 
uniform with 15 nm AuNSs selectively attached on the gold side but not on the PS side. 
Characterization of the Asymmetric Nanoclusters 
In order to understand the importance of bio-functionalization and DNA-directed 
nanoassembly process, we monitored the self-assembly process by ultraviolet-visible 
spectrophotometry (UV-vis) and photograph images of different DNA-functionalized JNP/AuNS 
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mixtures. JNPs functionalized with ssDNA-1 (JNP-1) were incubated with 15 nm AuNSs, 
functionalized either with its complementary ssDNA-1' (AuNS-1') as the assembly group, or 
with non-complementary ssDNA-1 (AuNS-1) were employed as a negative control group. After 
mixing JNP-1 particles with AuNS-1' and AuNS-1, each in a buffer containing 5 mM HEPES 
buffer (pH 8.2) and 200 mM NaCl, both assembly group and negative control group displayed 
similar purple color initially with UV-vis absorbance centered at 520 nm (see Figure 2.6). Since 
no UV-vis absorbance is observable for JNPs in wavelength range from 400 nm to 800 nm while 
a standard peak at 520 nm is commonly visible for 15 nm AuNSs, we conclude that the 520 nm 
peak in the fresh JNP/AuNS mixtures is from the surface plasmon absorbance of free 15 nm 
AuNSs. After JNP/AuNS mixtures were incubated at room temperature for 24 hours, the color 
and UV-vis spectrum of the negative control group remained almost the same as freshly prepared 
sample. In contrast, the assembly group formed dark blue precipitates during the same period, 
with the visible peak further shifted to 535 nm and the absorption intensity lowered (Figure 2.6). 
The red shift of the spectrum is attributable to the surface plasmon coupling between localized 
15 nm AuNPs and the gold surface of JNP. In order to confirm the DNA-induced optical 
property change after assembly, we further employed the dark-field microscope (DFM) coupled 
to a CCD digital camera to investigate the light scattering property. The measurement of 
localized surface plasmon resonance (LSPR) spectrum of JNP and nanoclusters was carried out 
by using a high-speed multispectral imaging system described in previous paper (Figure 2.7).40 
Under white illumination, AuNS-JNP asymmetric nanoclusters showed orange and light green 
colors (Figure 2.8a). The average scattering spectra obtained from multiple dots of JNPs and 
AuNS-JNP nanoclusters showed similar pattern, while AuNS-JNP nanoclusters displayed an 
increase in scattering intensity and a red shift of approximate 30 nm relative to the unlinked JNPs 
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(Figure 2.8b). Both the increased scattering and the band shift indicate the increased plasmon 
coupling and are consistent with the scattering properties observed previously in other multi-
particle systems.35,41-43 The asymmetric assembly can be further confirmed by comparing the 
SEM images of assembly group and control group. As shown in Figure 2.9, no AuNS and gold 
surface interaction was observed when non-complementary DNA strands were used to 
functionalize AuNSs. These results not only indicated the recognition property of DNA 
molecules but also confirmed the ability of directional base-paring interactions in guiding the 
assembly process of asymmetric nanostructures. 
Programmable Assembly of the Asymmetric Nanoclusters 
The power of DNA-directed nanoassembly lies in its programmability and reversibility. 
To demonstrate the use of DNA strands to control the degree and the reversibility of the 
asymmetric nanoassemblies, we first introduced a complementary DNA strand (cDNA-1'') with 
the same 12-base hybridization sequence as ssDNA-1' into the mixture of JNP-1 and AuNS-1' 
solutions to control the assembly process. Since cDNA-1'' strands are free DNA molecules in 
solution, the DNA-1/cDNA-1'' hybridization should be much facile than the DNA-1/DNA-1' 
hybridization on the particle surface. Therefore, cDNA-1'' could out-compete the DNA-1' on the 
AuNS for hybridization with DNA-1 on the JNP-1 and thus prevent JNP-1 and AuNS-1' 
assembly (Figure 2.10a). As shown in Figure 2.10b, in the presence of cDNA-1'' the spectrum of 
mixture solution remained the same and no red shift was observed. Having demonstrated the use 
of cDNA as the block agent to prevent the DNA-directed assembly process, we then want to 
show reversible assembly and disassembly process by using an invasive DNA strand.34 Thiolated 
DNA strands ssDNA-2 and ssDNA-2' were attached onto JNPs and 15 nm AuNSs respectively. 
After incubating the JNP-2 and AuNS-2' mixture for 24 h, asymmetric nanoclusters formed 
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through a 15 base-paring DNA-2/DNA-2' hybridization, similar to what observed in Figure 2.3 
based on DNA-1/DNA-1' hybridization. Then, we introduced a 23-based invasive DNA strand 
(iDNA-2'') to release 15 nm AuNSs from the surface of JNP by replacing the DNA-2/DNA-2' 
hybridization on the surface with the more stable DNA-2/iDNA-2'' hybridization (Figure 2.10c). 
As shown in Fig. 5d, introducing iDNA-2'' resulted in blue shifting of the plasmon absorbance, 
suggesting successful disassembly of the asymmetric nanoclusters using an invasive DNA. 
Assembly of Different Asymmetric Nanoclusters 
In order to demonstrate the generality of our approach, we applied the similar assembly 
process for fabrication of different asymmetric nanoclusters. AuNSs with different sizes from 15 
nm to 80 nm were employed as nanoscale building blocks. Due to the thermodynamic instability 
of large AuNSs, the NaCl concentration used in the assembly was decreased to 100 mM and the 
incubation time was shortened from 24 to 12 hours. By using AuNSs with five different sizes, a 
series of asymmetric nanoclusters were assembled onto the 160 nm JNP with well-controlled 
morphology and yield (Figure 2.11). Consistent with the prediction, with the increase of AuNS 
size, the number of AuNSs on each JNP decreased. Interestingly, although asymmetric 
nanoclusters can be observed in different orientations under SEM, the top view of nanoclusters 
with PS hemisphere on bottom is very rare. We hypothesized that gold hemisphere is more likely 
to precipitate onto the silicon substrate during the adsorption process, since attached AuNSs 
make it much heavier than the PS site.  
A representative statistical analysis of different asymmetric nanoclusters has been 
achieved based on SEM and TEM images (Figure 2.12). The analysis illustrates that within a 
certain number range, different AuNSs can be attached onto JNP platform with narrow number 
distribution (Figure 2.13a). The results further demonstrate that our approach is modular to 
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extend to different building blocks, producing products with high yield. To obtain deeper insight 
into the size-dependent self-assembly process, we used a theoretical model based on hexagonal 
closed-packing structure to calculate the number of AuNSs on each JNP. Effective diameters of 
DNA-capped particles were calculated based on reported worm-like-chain model.44 The 
calculated results accurately represented the experimentally observed changing trend (Figure 
2.13b). We further investigated the surface assembly degree by comparing the ratio of 
experimental number of AuNSs to theoretical number of AuNSs on a single JNP for different 
size AuNSs. Interestingly, we found that although the surface assembly degrees for different size 
AuNS are all ~ 50% of the predicted by calculation, a trend exists. As illustrated in Figure 2.13c, 
15 nm AuNS possess the highest self-assembly degree, while 80 nm AuNP has the lowest one. 
The differences between the experimental results and theoretical results might be due to AuNPs 
randomly attached to the gold surface in real case study. Unlike hexagonal closed packing model, 
the random attachment process of AuNPs results in large empty spaces between particles. 
Therefore, it is easier for small AuNPs to further occupy these empty spaces and thus reach a 
high surface assembly degree (Figure 2.14). 
Anisotropic DNA Functionalization of JNP 
Taking advantage of the asymmetric structure, prefabricated JNP can be further modified 
with spatially separated different DNA strands, providing a powerful platform for assembly of 
novel nanostructures. To provide functional groups on the PS hemisphere of JNP, 200 nm amine-
modified PS nanospheres were utilized to fabricate amine-modified JNPs through the same 
procedure mentioned above. After the gold deposition process, half of the amine-modified PS 
area was covered by gold, while the other half area was protected and the remaining amine 
groups are still functional. Two types of thiolated DNA strands, ssDNA-2 and ssDNA-3, were 
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employed to modify two separate surface of JNP respectively (Figure 2.15a). DNA-2 was firstly 
modified onto the gold hemisphere through gold-thiol interaction. After purification, ssDNA-3 
was then covalently attached to the amine-modified polymer hemisphere via sulfo-SMCC 
coupling, forming a dual-DNA-functionalized JNP (3-JNP-2). To demonstrate the dual 
functionalizations and potential novel assembly, different sized AuNSs, functionalized with 
ssDNA-2' or ssDNA-3', were prepared respectively. After incubating the JNP with 40 nm AuNS-
2', AuNSs were selectively attached onto gold hemisphere through DNA-2/DNA-2' hybridization 
(Figure 2.15b). However, if JNP was incubated with 40 nm AuNS-3', few AuNSs could be found 
on the gold hemisphere. Instead, AuNSs were selectively immobilized onto the PS hemisphere, 
indicating the 3-3' DNA recognition (Figure 2.15c). If JNP was incubated with equal mixture of 
40 nm AuNS-2' and AuNS-3', JNP was found to be surrounded by 40 nm AuNSs in all directions 
(Figure 2.15d). Furthermore, if two different sized AuNSs with appropriate DNA modifications 
were introduced to attach to JNP, novel trivalent asymmetric nanocluster was formed with 80/60 
nm AuNSs-2' on gold site and 40/30 nm AuNSs-3' on the other side (Figure 2.15e and Figure 
2.16). These results further indicate the power of DNA-directed nanoassembly. By simply 
encoding AuNSs with different DNA strands, we could selectively modify the target region on 
JNP in a well-controlled manner. 
2.3. Conclusions 
In conclusion, we have demonstrated for the first time that DNA can be used for directing 
the assembly of asymmetric nanoclusters on the prefabricated JNP platform. Both cDNA and 
iDNA can be used to tune the assembly and disassembly of particles, indicating that DNA plays 
an essential role for programmable control the self-assembly process. Furthermore, this approach 
has been applied to construct a series of asymmetric nanoclusters. A theoretical model has also 
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been established to systematically study the size-dependent assembly process. To the best of our 
knowledge, this is the first report of functionalizing prefabricated Janus particles with thiolated 
DNA. By taking advantage of a simple fabrication technique, we can generate Janus 
nanoparticles (JNPs) with high yield and promote directed self-assembly with DNA modification. 
We have shown that our approach is reliable and modular. The combination of DNA linkers and 
JNPs provides both spatial and chemical control over the assembly process. This new strategy 
for the synthesis of using monodisperse DNA-functionalized JNPs is a promising route for 
construction of many different asymmetric structures with spatially separated functionalities for 
potential photonic, electronic, and biomedical applications. 
2.4. Experimental Section 
Chemicals and Materials 
(3-aminopropyl)-triethoxy-silane (APTES, C9H23NO3Si, 97%;), Tris(2-carboxyethyl)-
phosphine hydrochloride (TCEP, C9H15O6P∙HCl), and 4-(N-Maleimidomethyl)cyclohexane-1-
carboxylic acid 3-sulfo-N-hydroxysuccinimide ester sodium salt (sulfo-SMCC, C16H17N2NaO9S) 
were purchased from Sigma-Aldrich and used without further purification. Gold nanospheres 
(AuNSs) solutions with 15 nm, 30 nm, 40 nm 60 nm and 80 nm in diameter were purchased from 
Ted Pella (Redding, CA) and purified by centrifugation before use. Plain and amine-modified 
polystyrene nanospheres with 200 nm in diameter were purchased from Polysciences 
(Warrington, PA). All Olignucleotides used in this study were purchased from Integrated DNA 
Technologies Inc. (Coralville, IA), with following sequences: 
ssDNA-1: 5'-HS-(A)15-ACTCATCTGTGA-3' 
ssDNA-1': 5'-HS-(A)15TCACAGATGAGT-3' 
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cDNA-1'': 5'-TCACAGATGAGT-3' 
ssDNA-2: 5'-CTTGTGTCTACTTCCAATCCAAT-(T)15-SH-3' 
ssDNA-2': 5'-ATTGGATTGGAAGTA-(T)15-SH-3' 
iDNA-2'': 5'-ATTGGATTGGAAGTAGACACAAG-3' 
ssDNA-3: 5'-HS-(T)10-CAATGCTCTGGA-3' 
ssDNA-3': 5'-HS-(T)10-TCCAGAGCATTG-3' 
Fabrication of Janus Nanoparticle 
The fabrication of begins with the formation 200 nm polystyrene (PS) nanospheres 
monolayer. The glass substrates (3''×1''×1 mm, Fisher Scientific, PA) were cleaned in piranha 
solution for 2 h, and then carefully rinsed with deionized water and anhydrous ethanol 
subsequently. The clean glass slides were incubated into 1% 3-aminopropyltriethoxysilane 
(APTES) ethanol solution for 12 hours to form homogeneous APTES film. The APTES covered 
glass substrates were then rinsed with ethanol and dried by nitrogen gas. The 200 nm PS 
nanosphere solution was first 1:30 diluted in 5 mM HEPES buffer (HEPES = 4-(2-
hydroxyethyl)-1-piperazineethane-sulfonic acid, pH=7.0, 1 mM citrate), then dropped onto the 
APTES covered glass substrate. After 1 hour incubation, the glass substrates were rinsed with 
deionized water to form a monolayer of PS nanospheres by removing excess PS nanospheres. 
Completely dried substrates were then loaded into a non-directional oxygen plasma etching 
system (March Plasmod, 250 W) to tune the PS nanosphere size by varying the etching time. 
Metal evaporation (Cr/Au, 2 nm/6 nm) was then performed on the monolayer of PS nanospheres 
(Temescal six pocket E-Beam Evaporation System) to obtain the monolayer of JNPs. All JNPs 
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were further released from the surface by immersing the glass substrates in deionized water and 
sonicating for 2 min. The concentration of obtained JNPs solution is about 0.2 nM. 
Preparation of Thiolated DNA Functionalized AuNSs and JNPs 
Functionalization of thiolated DNA on 15 nm gold nanospheres was carried out by 
following previous published protocol with some modifications.38,39 Briefly, 3 µL of 1 mM 
thiolated DNA was first mixed with 0.5 µL of 10 mM TCEP solution and 0.4 µL of 500 mM 
acetate buffer (pH 5.2) to activate the thiolated DNA. After 1 hour incubation, the mixture was 
then transferred into 1 mL of 15 nm AuNS solution (10 nM) followed by incubation for 
overnight. The mixture solution was then added by 500 mM Tris acetate buffer (pH 8.2) to bring 
the buffer concentration to 5 mM. The solution was left to anneal for another 24 hours after 
gradually increase the NaCl concentration to 100 mM over 1 hour. To purify the nanospheres 
from the unreacted DNA, the excess DNA strands were removed from the solution by 
centrifugation at 16,110 g for 15 min. 
Functionalization of thiolated DNA on larger AuNSs (30 nm, 40 nm, 60 nm, and 80 nm) 
and JNPs was carried out in an analogous process. Sonication and magnetic stirring was applied 
to prevent precipitation and facilitate the reaction. 
Preparation of dual-DNA-functionalized JNPs 
Amine-modified JNPs was firstly functionalized with thiolated DNA-2 onto gold 
hemisphere by using above mentioned process. For functionalization of DNA-3 onto amine-
modified PS hemisphere, JNP was dispersed in Buffer A into 0.2 nM. Sulfo-SMCC of 1 mg was 
added into 500 µL JNP solution and then placed on a shaker for 1 hour at room temperature. The 
insoluble excess sulfo-SMCC was removed from solution and the sulfo-SMCC-activated JNP 
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was purified by using Buffer A for 5 times. Mix the purified sulfo-SMCC-activated JNP and the 
activated thiol-DNA-3 solution and gently shake for 1 min. The mixture was then incubated at 
room temperature for 48 hours. The final solution was applied to Amicon-100K 8 times using 
Buffer A without Tween-20 to remove any un-reacted DNA-3. Buffer A: 0.1 M NaCl, 0.1 M 
sodium phosphate buffer, pH 7.3. 
Assembly of Thiolated DNA functionalized JNPs and AuNSs 
The assembly of 15 nm AuNS-JNP clusters was performed in 1.5 mL centrifuge tube in 5 
mM Tris acetate buffer (pH 8.2) and 200 mM NaCl. AuNSs (10 nM) and JNPs functionalized 
with complementary thiolated DNA strands were mixed in a concentration ratio of 500:1 and 
incubated for 24 hours at room temperature to allow assembly. During this process, the color of 
the mixture solution gradually decreased from dark purple to optically transparent with blue 
precipitates formed at the bottom of the centrifuge tube. After incubation, the AuNS-JNP mixture 
solution was centrifuged at 2000 g for 5 min to remove the free 15 nm AuNSs in the supernatant 
and the blue precipitates were redispersed in buffer solution (5 mM Tris acetate, pH 8.2, 100 mM 
NaCl) for further characterization. The assembly of larger AuNS-JNP clusters was followed by 
similar process with the exception of lower AuNSs concentration ratios. Salt concentration and 
incubation time was decreased to 100 mM and 12 hours, respectively.  
The assembly and disassembly of AuNS-JNP clusters was achieved in identical buffer 
conditions to cluster fabrication mentioned above. Complementary DNA (cDNA) strands and 
invasive DNA strands were used respectively to manipulate the assembly process. For the usage 
of cDNA, 10 µL of 100 mM cDNA was added into the buffer solution together with thiolated 
DNA functionalized JNPs and AuNSs before the incubation. For the usage of iDNA, the final 
assembled blue precipitates were redispersed in fresh buffer and 10 µL of 1 M iDNA was added 
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followed by incubation for 6-12 hours at room temperature with gentle stirring. All the assembly 
processes can be monitored by UV-vis adsorption. 
Characterization Methods 
The size and morphology of nanoparticles as well as the nano-assembly structures were 
analyzed using a JEOL 2010LaB6 transmission electron microscope (TEM) and a Hitachi S4800 
high resolution scanning electron microscopy (SEM). Samples were prepared by dropcasting 
nanoparticle solutions onto a carbon-coated copper TEM grid or a silicon wafer (Ted pella), 
followed by removing excess solution with filter paper after 10 min. 
The UV-vis spectra of the nanoparticles and asymmetric nanoclusters were collected on a 
Hewlett-Packard 8453 UV-Vis spectrophotometry. Darkfield light-scattering images of 
nanoclusters were acquired using a Zeiss Axiovert 200M inverted microscope with an EC 
Epiplan 50X HD objective (NA=0.7) and CCD camera. The digital camera was white-balanced 
by using Zeiss Axiovision software before data acquisition. Therefore, the color observed in the 
digital images represented the true color of the scattered light. The localized surface plasmon 
resonance spectra were collected on a self-built multispectral darkfield imaging system with a 
0.42 NA objective. 
Measurement of Localized Surface Plasmon Resonance Spectrum 
For single-particle plasmon resonance scattering spectroscopy, a multispectral darkfield 
imaging technique with high speed and high throughput was established based on previously 
reported method.40 Compared with conventional spectrometry of single particle scattering, which 
relies on white light illumination and spectrograph thus an aperture is needed and the distribution 
of particles has to be sparse enough to capture the scattering spectra of single particle at one 
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time, this multispectral imaging system utilizes a sweeping monochromatic light source along 
with a darkfield condenser for illumination and a camera synchronized with the sweeping 
wavelengths for recording the intensity for all particles in the whole field of vision simultaneous. 
The scattering spectrum of each particle is plotted by its intensity in each frame with respect to 
its corresponding wavelength. In that case, spectra of all particles in the field of vision can be 
captured in a short time with no aperture needed and the sparseness of particles is not rigorously 
required. In our measurement, the monochromator sweeped from 400 nm to 700 nm with the 
step of 2 nm and standing or exposure time of 3000 milliseconds for each wavelength. The 
whole capturing process took 7.5 min. In order to calibrate the light-source and instrumental 
bias, all particle scattering spectra were corrected by the scattering spectrum of polystyrene 
particles with the diameter of 200 nm, which is supposed to have no resonance or peaks 
according to Mie theory. Scattering spectra were corrected and normalized before comparison. 
Calculation Details 
Effective Diameter of Thiolated DNA Functionalized AuNSs. In order to evaluate the 
effective diameter (Deff) of DNA functionalized AuNSs, we need to estimate the thickness of 
ssDNA layer capped on the AuNS surface. Based on previously reported worm-like-chain model 
for ssDNA, the mean square end-to-end distance (<R2>) of ssDNA is estimated by the equation: 
 
 
where P is the persistence length and L is the contour length.1,2 For ssDNA, P is ~1 nm and L 
equals to ~0.65 nm per base, so that the length of 27-based ssDNA-1' is estimated as ~6 nm.3 In 
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idea model, the particle-particle or chain-surface interactions were not taken into account. 
Therefore, the Deff of ssDNA1-1' functionalized AuNSs is calculated by following equation. 
Deff = DAuNS + 2RDNA = DAuNS + 12 nm 
For example, for ssDNA-1' functionalized 60 nm AuNS, the effective diameter is 72 nm. 
 
1. Tinland, B.; Pluen, A.; Sturm, J.; Weill, G. Macromolecules 1997, 30, 5763. 
2. Schallhorn, K. A.; Freedman, K. O.; Moore, J. M.; Lin, J.; Ke, P. C. Appl. Phys. Lett. 
2005, 87, 3. 
3. Rivetti, C.; Walker, C.; Bustamante, C. J. Mol. Biol. 1998, 280, 41. 
Maximum Number of AuNSs on a Single JNP Surface. To estimate the maximum 
number of AuNSs on a single JNP surface, we used a theoretical model in which small spheres 
(of radius r) are allowed to be packed onto the surface a large sphere (of radius R) in a hexagonal 
closed packing pattern. Finding the maximum number of small spheres on a large sphere is 
equivalent to the problem of finding the maximum number of points separated by each other at a 
minimum angle of 2θ on the surface of the sphere with radius R + r, where 
arcsin( )
r
R r
 
   
(1). 
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As shown in above figure, the solid angle Ω of a cone ① with apex angle 2θ is the area 
of a spherical cap ② on a unit sphere. Therefore, the solid angle Ω can be calculated by 
following double integral using the unit surface element in spherical polars. 
2
' ' ' '
0 0 0
sin 2 sin 2 (1 cos )d d d
  
                (2). 
Combining equation (1) and (2), we have
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The maximum number of points N can be estimated by dividing the solid angle of a 
sphere (4π) by the solid angle of a cone:  
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Since JNP is only half covered by small AuNSs, the theoretical number of AuNSs on a 
single JNP is: 
2
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where r is the effective diameter of AuNS and R is the diameter of JNP. 
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2.6. Figures 
 
Figure 2.1. Schematic view of JNP fabrication process; (a) Formation of APTES monolayer on 
glass slide; (b) Self-assembly of 200 nm PS particles monolayer; (c) Non-directional O2 plasma 
etching; (d) Gold deposition using electron-beam evaporator; (e) Release JNPs into solution via 
ultrasonication. 
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Figure 2.2. (a) The gradual etching of the polystyrene (PS) particles by using non-directional O2 
plasma under 250 W (scale bar = 200 nm). The plasma etching induces shrinkage of the PS 
particles with longer etch times. The surface morphology has been kept; (b), (c) SEM images of 
JNPs with half surface covered by gold. (b) JNPs on substrate; (c) Monodisperse JNPs released 
from substrate. 
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Figure 2.3. Schematic view of DNA-directed asymmetric self-assembly process. The gold 
surface of JNP is modified with thiolated ssDNA-1, while AuNS is functionalized with 
complementary ssDNA-1'. Asymmetric assembly occurs when thiolated ssDNA-1 pairs with 
complementary ssDNA-1'. For clarity, DNA molecules on nanoparticles are not shown in scale. 
The recognition sequences are listed below in colors. 
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Figure 2.4. SEM image of asymmetric nanoclusters formed by 160 nm JNPs and 15 nm AuNSs 
(scale bar = 400 nm). Three nanoclusters are highlighted to illustrate the structure details. 15 nm 
AuNPs only attach to the gold surface of JNPs. 
 
Figure 2.5. TEM image of asymmetric nanoclusters after the removal of excess 15 nm AuNSs 
(scale bar = 200 nm). 
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Figure 2.6. (a) UV-vis spectra of different solutions: 15 nm AuNS (dark red line), 160 nm JNP 
(dark blue line), freshly prepared mixture of JNP-1 and AuNS-1' particles (purple line), AuNP-
JNP asymmetric nanoclusters formed in assembly group after 24 hours incubation and further 
purification (red line), and the control group, the mixture of JNP-1 and AuNS-1 particles 
modified with non-complementary DNA strands after 24 hours incubation (blue line); (b) 
Photograph images of corresponding solutions in centrifuge tubes. 
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Figure 2.7: Photograph image of a self-built high-speed multispectral imaging system for the 
single dot LSPR spectra measurement. 
 
Figure 2.8. (a) Dark-field scattering image of AuNS-JNP asymmetric nanoclusters under white-
illumination (Scale bar = 20 µm). Two representative scattering spots are enlarged to illustrate 
the anisotropic scattering pattern of asymmetric assembly; (b) Ensemble scattering spectra of 160 
nm JNP (blue) and AuNS-JNP asymmetric assembly (red). 
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Figure 2.9. SEM images of the mixture of 160 nm JNPs and 15 nm AuNSs after 24 h incubation 
at room temperature. (a) The mixture of JNP-1 and AuNS-1. No attachment was found between 
AuNSs and gold surface; (b) The mixture of JNP-1 and AuNS-1'. AuNS-JNP nanoclusters were 
observed when using complementary DNA strands (Scale bar = 100 nm). 
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Figure 2.10. Schematic view of the usage of cDNA (a) and iDNA (c) for programmable control 
of the nanoparticle assembly and disassembly process. (b) UV-vis spectra of the mixture of JNP-
1, AuNS-1' and cDNA-1''. Freshly mixed solution (red line) showed same peak position and 
similar pattern with the mixture after 24 hours incubation (blue line); (d) UV-vis spectra of 
different solutions: freshly prepared mixture of JNP-2 and AuNS-2' solution (red line); same 
solution after 24 hours incubation and further purification (blue line), and same solution after 
further adding iDNA-2'' with another 24 hours incubation (blue line). During the whole process, 
the spectrum shifted to red and then shifted back. 
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Figure 2.11. SEM images of representative asymmetric nanoclusters in different orientations 
(Scale bar = 200 nm). 
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Figure 2.12. Representative SEM and TEM micrographs of asymmetric nanoclusters assembled 
from different–sized AuNSs and 160 nm JNPs  (a–e) with statistical analysis of the number of 
AuNSs on each nanocluster from samples a–e respectively. (a) 15 nm , (b) 30 nm, (c) 40 nm, (d) 
60 nm, and (e) 80 nm AuNS. 
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Figure 2.13. (a) Statistical analysis of the number of AuNSs per nanocluster; (b) Comparison of 
theoretical and experimental number of AuNSs per cluster; (c) Diagram of the relationship 
between surface assembly degree and the size of AuNS. 
 
 
Figure 2.14: Two different packing models of ssDNA-capped AuNSs on JNP surface, closed 
packing and random packing. The radom packing model results in less number of particles 
attached on the surface and larger empty space between particles. 
 
 
71 
 
 
 
Figure 2.15. (a) Schematic view of two different coupling chemistries on the surface of an 
amine-modified 200 nm JNP; (b-e) Schematic views and SEM images of representative 
asymmetric nanoclusters formed by dual-DNA-functionalized JNP and different DNA-encoded 
AuNSs: (b) 40 nm AuNS-2', (c) 40 nm AuNS-3', and (d) equal mixture of 40 nm AuNS-2' and 
AuNS-3'; (e) equal mixture of 80 nm AuNS-2' and 40 nm AuNS-3'(Scale bar = 100 nm). 
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Figure 2.16. Representative SEM micrographs of trivalent asymmetric nanoclusters assembled 
from dual-DNA-functionalized 200 nm JNP and two different sized AuNSs: (a-b) 40 nm and 80 
nm AuNSs; (c-d) 30 nm and 60 nm AuNSs (Scale bar = 100 nm). 
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CHAPTER 3 
USING FUNCTIONAL DNA-JANUS NANOPARTICLE CONJUGATES AS 
RATIOMETRIC PROBES FOR QUANTITATIVE INTRACELLULAR 
ANALYSIS  
3.1. Introduction 
Metal ions such as Ca2+, Zn2+, Cu2+, and Fe3+ are crucial for life, and their levels in 
biological systems must be carefully regulated to maintain normal function and prevent 
toxicity.1-6 Significant research effort has been applied towards developing small molecule and 
protein-based sensors for intracellular analysis of biologically important metal ions.7-13 At the 
same time, there is also a strong need to develop intracellular sensors for toxic metal ions, such 
as Hg2+, Cd2+, and Pb2+, as their concentrations must be precisely monitored in environmental as 
well as in biological systems to prevent harmful exposure. To address the concerns over the 
health impact of these metal ions, efforts have been applied over the past few years towards 
developing selective and efficient methods to monitor toxic metal ions in cells and organisms.14-
20 Despite these advances, there remains a significant challenge to rationally design probes with 
all criteria required for intracellular analysis, including quantitative evaluation ability, high 
sensitivity and selectivity, biocompatibility, as well as high stability. To meet this challenge, 
DNA-based sensors have been demonstrated as an effective method for analyzing targets of 
biological interest.21-26 In comparison to traditional small molecule sensors, DNA-based sensors 
possess many attractive properties, including natural biocompatibility, high sensitivity and 
selectivity, the capacity for rational design of sensors, as well as the ability to easily synthesize 
DNA with different functional groups. Moreover, it is relatively simple to incorporate DNA-
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based sensors with different imaging modalities and nanomaterials to further expand the scope of 
applications.27-30 All of these features make DNA-based sensors an ideal candidate for 
developing intracellular diagnostic tools for metal ions.  
In order to apply DNA-based sensors for intracellular analysis, a novel DNA and gold 
nanoparticle (AuNP) conjugate was developed as a delivery and probing system.31-34 In this 
approach, the AuNP surface is functionalized with a probe DNA sequence targeted toward 
intracellular targets of interest. AuNPs can deliver probe DNA strands into live cells without the 
need of transfection reagents, increase the resistance of probe DNA strands to enzymatic 
degradation, and serve as a quencher for fluorophores.35,36 Upon intracellular binding with target 
molecules, the fluorescent strand is displaced and released from AuNP surface, resulting in “turn-
on” of the fluorescence signal attributable to the intracellular presence of target molecules. 
Recently, this method was further applied towards the development of the first DNAzyme-based 
probe for metal ions in live cells by conjugating a fluorescent uranyl-specific 39E DNAzyme 
onto AuNPs.37 The AuNP-DNAzyme probe was demonstrated to respond to uranyl and provide 
enhanced fluorescence signal in live cells. 
 Although the AuNP-DNAzyme conjugate was shown to be useful for intracellular 
detection of uranyl, this previous work was able to provide only a qualitative understanding of 
the presence of uranyl, instead of quantitative measurements.37 Because background fluorescence 
and nanoparticle internalization rates are different for different cells and samples, metal ion-
independent variations in fluorescence may result in a different observed cell-to-cell fluorescence 
responses and thus, significant batch-to-batch variation. Although the use of Actin and Actin-
encoding mRNA were reported as standard molecules for detecting and quantifying genetic 
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targets,38 it is difficult to find a similar standard for metal ions within cells, making quantitative 
cellular measurements using DNA-based metal ion sensors is still very challenging. 
 Inspired by the design of small molecule-based ratiometric probes,39-41 a nanoparticle 
which can serve as both reference fluorophore and delivery platform would be ideal to develop 
nanoscale ratiometric probe for DNA sensors possible for quantitative analysis of metal ion in 
cells.42 A Janus nanoparticle was chosen as the candidate. Janus nanoparticles are a type of 
colloidal structure with two different physical and chemical properties on opposite regions.43 
This anisotropic property makes Janus particles suitable for applications such as two–phase 
stabilizers, theranostic tools, as well as building blocks for supramolecular assemblies.44-47 
Taking advantage of the two spatially separated regions, it is also possible for us to develop JNP-
based ratiometric probes by combining a gold shell on one side, mimicking gold nanoparticles, 
with a standard fluorophore on the other side, serving as an internal fluorescent standard, into a 
single Janus nanoparticle platform. 
 As an initial demonstration, we chose a DNA-based mercury sensor as an example. 
Mercury is one of the most prevalent toxic metals. It can easily pass through biological 
membranes, enter the human body, and can cause damage to the central nervous and endocrine 
system.48 Recently, we and other research groups demonstrated DNA-based mercury detection 
using mercury-specific thymine-thymine (T-T) mismatches with a detection limit of 3.2 nM (0.6 
ppb).49-52 However, all work to date has only uses these DNA-mercury sensors in buffer, serum, 
or environmental samples, without reaching the level of intracellular detection. In this study, we 
report the design, fabrication, and application of a fluorescent Janus nanoparticle-DNA conjugate 
as a ratiometric probe for quantitative analysis of mercury ions in live HeLa cells. The JNP 
serves as a reference fluorophore as well as a delivery platform for DNA sensors. The strategy 
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can be easily applied to other DNA-based sensors for the intracellular analysis of other metal 
ions of interest. 
3.2. Results and Discussion 
Design and Approach 
 The schematic illustration of the JNP-DNA ratiometric probe for intracellular analysis of 
mercury is shown in Figure 3.1a. The probe consists of a 200 nm fluorescent JNP and a tripartite 
DNA-based mercury sensor. The fluorescent polystyrene (PS) hemisphere of the JNP was 
labeled with fluorescent dye with excitation/emission wavelength at 440 nm/485 nm, while the 
other active Au hemisphere was modified with DNA strands for mercury sensing. When JNP-
DNA probes were internalized by cells, the fluorescence emission of the PS site remained 
unchanged, serving as an internal reference. At the same time, DNA-based mercury sensors on 
the gold side interact with mercury ions in cells to release a fluorophore from gold surface, 
resulting in “turn-on” of the fluorescence signal. The detailed sequences of the three DNA 
strands of the mercury sensor are shown in Figure 3.1b. The unlabeled Hg-binding strand 
consists of a hybridization sequence complementary to the HS-BHQ2 strand on 5′ end and a 
mercury recognition sequence with five self-complementary base pairs (bps) separated by seven 
mercury-selective T-T mismatches on 3′ end. The mercury recognition sequence of the Hg-
binding strand hybridizes to the Cy3-releasing strand (containing a 5′-Cy3 fluorophore 
modification) through 12 bps of hybridization. The 3′ end of the HS-BHQ2 strand is modified 
with a thiol group (SH) for the attachment of the assembled DNA complex onto the gold surface 
through gold-thiol chemistry. The poly-A spacer in HS-BHQ2 strand next to thiol group prevents 
steric hindrance from JNP from affecting hybridization. The HS-BHQ2 strand was also labeled 
with a quencher (BHQ-2) at the 3′ end. After the attachment of HS-BHQ2 strand onto the gold 
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surface of JNP, the Hg-binding strand and Cy3-releasing strand were hybridized with HS-BHQ2 
strand by heating and annealing. After hybridization and immobilization, the fluorescence signal 
from Cy3 will be quenched by both gold shell of JNP and the BHQ-2 quencher in the absence of 
mercury ions. The dual quenching effects significantly decreased the background fluorescence 
resulting in increased signal-to-noise ratio. In the presence of mercury ions, the formation of T–
Hg(II)–T base pairs will induce the self-folding of the mercury recognition sequence into a 
hairpin structure, leaving only five base pairs remaining between two strands, not long enough to 
keep double-stranded DNA (dsDNA) stable at physiological conditions even at room 
temperature. Therefore, the Cy3-releasing strand is separated from both the gold surface and 
BHQ-2 quencher, resulting in an increase in fluorescence signal. 
Fabrication and Characterization of JNP Probe 
 The fabrication of fluorescent JNPs with gold shell covering one hemisphere is shown in 
Figure 3.2a. The fabrication process starts with the formation of a monolayer of 200 nm 
fluorescent PS nanoparticles on a positive-charged glass substrate. In order to grow a gold shell 
on the top surface of PS nanoparticle, the glass substrate is then loaded into an e-beam 
evaporator and a 2 nm chromium layer and 6 nm gold layer are deposited in order. The resulting 
JNPs can be released into a 0.05% Tween-20 solution from the surface by ultrasonication and 
purified by filtration through a 0.8 μm membrane. As shown in Figure 3.2b, monodisperse JNPs 
were fabricated in high yield and good quality. The high magnification SEM image showed the 
detailed structure of the JNP with half gold and half fluorescent PS. Since the formed metallic 
shell will quench the fluorescence of nanoparticle, a key question comes up whether the JNP 
with gold shell will remain fluorescent. The fluorescence spectrum was measured for both PS NP 
and the fabricated JNP of the same concentration with the excitation wavelength of 440 nm 
78 
 
(Figure 3.2c). The fluorescent PS nanoparticle featured a broad fluorescence emission peak 
centered at 480 nm. After gold deposition, the fluorescent JNP (F-JNP) showed a similar but 
lower fluorescence emission peak, because gold is known to quench fluorophores and the gold 
shell also prohibits photon transmittance. Further quantitative analysis of the fluorescence 
spectra revealed that the fluorescence intensity of the JNP decreased ~ 37% after the formation 
of the half gold shell. Despite the decrease in fluorescence intensity of the JNP versus the 
original fluorescent PS particle, the position of the emission peak position did not shift, 
indicating the preservation of the fluorescent property. Moreover, in order to pursue quantitative 
analysis, it is important to develop a method for quantifying the concentration of F-JNPs. To 
achieve this, we correlated the SEM images with the fluorescence spectrum of JNPs to carry out 
this estimation. Figure 3.2d showed the SEM image of a small area of the glass slide used for 
JNP fabrication after gold deposition. As JNPs formed a monolayer on glass slide with a surface 
density of ~ 30 JNPs in a 2 µm ˣ 2 µm area, there are ~ 5 ˣ 109 JNPs on a typical 40 mm by 20 
mm glass slide. Since the majority of JNPs will be released into solution, we can estimate the 
number of JNPs that are fabricated and are present in solution. Therefore we can generate a 
calibration curve showing the relationship between the concentration of F-JNP and fluorescent 
intensity for quantification if correlated with the corresponding fluorescence intensity.  (Figure 
3.2e).  Based on the calibration curve, the F-JNPs were adjusted to a ~ 0.2 nM concentration in 
0.05 % Tween-20 after fabrication as a stock solution for further use. 
 Besides the retained fluorescence property of the JNP, another attractive feature of the 
fluorescence-gold JNP is the strong scattering property. To demonstrate this dual functionality of 
JNP, we employed a fluorescent microscope coupled with dark-field filter to investigate the 
optical properties. Different dilute nanoparticles were spread on glass coverslips, resulting in 
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spatially isolated single nanoparticles on the surface. As shown in Figure 3.3, fluorescence and 
dark-field images showed that the uncoated F-PS NPs were fluorescent but not plasmonic, while 
60 nm AuNPs were plasmonic but not fluorescent. In contrast, the fluorescent-gold JNPs showed 
good overlap between the fluorescence and dark-field imaging micrographs, confirming the 
presence of both fluorescent and scattering properties and the formation of Janus structure. Most 
symmetric nanoprobes only possess one optical property that shows distinct advantages but also 
limitations. The fluorescent-gold JNPs exhibiting both fluorescent and plasmonic properties 
enable us to develop a ratiometric nanoprobe where both properties are required on one 
nanoplatform. 
Preparation of fDNA-JNP Probe and Hg2+ Detection in Buffer Solution 
 In order to use the fluorescent JNP (F-JNP) as a ratiometric nanoprobe, its fluorescence 
property must remain unchanged before and after DNA modification. The half gold shell on the 
JNP allows region-selective DNA modification through gold-thiol chemistry with the fluorescent 
PS site unmodified during DNA functionalization. To confirm the modification of DNA strands 
on JNP, a HS-Cy3 DNA strand with Cy3 on the 3′ end was used for conjugation, as the 
fluorescence spectrum of Cy3 (580 ex / 610 em) has almost no overlap with the spectrum of the 
JNP (440 ex / 485 em). As shown in Figure 3.4, fluorescence from JNP and Cy3 showed almost 
complete spatial overlap, showing an orange color, which indicated that the attachment of HS-
Cy3 DNA strands on the surface of JNPs. Moreover, the fluorescence spectrum of JNP remained 
unchanged after the modification of HS-Cy3 strand, which further confirms minimal interference 
between two different fluorophores. 
 To prepare the JNP-DNA ratiometric probe, JNP was first modified with the HS-BHQ2 
strand followed by annealing with excess amounts of the Hg-binding strand and Cy3-releasing 
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strand. The JNP-DNA mercury probe can be purified by removal of free DNA strands using 
Amicon-100K and further concentrated to 0.2 nM. The performance of the JNP-DNA ratiometric 
probe was first evaluated in 10 mM MOPS buffer (150 mM NaNO3, pH 7.2). The fluorescence 
spectra of the JNP-DNA mercury probe before and after the addition of Hg2+ ions with various 
concentrations ranging from 50 nM to 2000 nM were measured 10 min after the addition of 
Hg2+. As shown in Figure 3.5a, the fluorescence peak centered around 485 nm on the left is 
assigned to the emission of the fluorescent JNP internal standard, while the peak centered around 
610 nm is recognized as the peak of the Cy3 groups released from the mercury DNA probe. 
Higher concentrations of Hg2+ ions resulted in greater fluorescence emission intensity of Cy3, 
while the fluorescence emission of JNP at 485 nm remained unchanged with the addition of Hg2+ 
ions, as intended and allowing for ratiometric measurements using the JNP-DNA probe. To 
quantify the Hg2+-dependent response, the normalized fluorescence ratio of emission at 485 nm 
(Cy3 DNA) and the emission at 610 nm (JNP internal standard) was used to plot the calibration 
curve with different Hg2+ ion concentrations (Figure 3.5b). The fluorescence ratio increased 
faster at low concentration of Hg2+ ranging from 50 nM to 500 nM and reached a plateau after 
500 nM at a normalized fluorescent ratio of ~ 2.3. To further investigate the performance of the 
JNP-DNA ratiometric probe, the kinetics of the probe for the first 15 min after the addition of 
different concentrations of Hg2+ ions was collected and compared (Figure 3.5c). Normalized 
fluorescence ratio increased in the presence of varying concentrations of Hg2+ ions and reached a 
plateau about 10 min after Hg2+ addition. To determine the selectivity of the sensor, 2 µM of 
each metal ion was individually added to the probe solution and the increase in the normalized 
fluorescence ratio was monitored. As shown in Figure 3.5d, among all the metal ions tested, 
including Hg2+, Mg2+, Ca2+, Mn2+, Zn2+, Cu2+, Cd2+, and Pb2+, only Hg2+ yielded a significant 
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increase in the normalized fluorescence ratio. This suggests excellent selectivity of the DNA-
JNP probe for Hg2+ over other metal ions. Aiming at intracellular analysis, we further tested the 
stability of the probe in HeLa cell lysates. The JNP-DNA probe was incubated in a solution 
containing 50 % cell lysate for 6 h at 37 °C. Fluorescence spectrum measurements were used to 
monitor de-hybridization of DNA strands. No obvious fluorescence enhancement at 610 nm was 
observed, suggesting good stability of the probe in cellular environments.  
Intracellular Hg2+ Detection in Live HeLa Cells Using fDNA-JNP Probe 
 Next, we evaluated the cellular uptake ability of the JNP-DNA probe. HeLa cells were 
used as the model system. To study the position and distribution of JNP-DNA probes inside 
cells, Lysotracker was used to specifically stain the lysosomes of cells. HeLa cells were treated 
with JNP-DNA probes for different incubation times from 2 – 6 hours to investigate cell uptake. 
As shown in Figure 3.6a-d, JNP-DNA probes gradually enter HeLa cells with increased 
incubation time. After 2 hours of incubation, most JNP-DNA probes were adsorbed onto the 
membrane of HeLa cells. After 4 hours of incubation, some JNP-DNA probes are observed to 
enter HeLa cells but surface adsorption can still be observed. Finally, after 6 hours of incubation, 
most JNP-DNA probes were observed inside HeLa cells with very few remaining on the surface. 
Fluorescence from JNP-DNA probes and Lysotracker showed some co-localization. Considering 
~ 200 nm is about the upper size limit for receptor-mediated endocytosis through lysosome 
pathway, the JNP-DNA probes might use a combined endocytosis process to enter HeLa 
cells.53,54 
 Having demonstrated the effectiveness of the JNP-DNA ratiometric probe in MOPS 
buffer and its cell uptake ability, we finally tested the intracellular performance of the ratiometric 
probe for quantitative analysis of mercury ions in HeLa cells. HeLa cells were first incubated 
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with 20 pM of JNP-DNA probes for 6 hours to allow sufficient uptake. The JNP-DNA probe 
treated HeLa cells were incubated with DMEM medium containing different concentrations of 
mercury ions for 15 min followed by a thorough wash with PBS buffer and 30 min incubation 
before further experiments. 
 To ensure quantitative analysis for whole cell population, we examined differently treated 
HeLa cell samples using flow cytometry. Since both JNP fluorescence and DNA sensor 
fluorescence were monitored, a 2D contour plot was used to provide a straightforward estimation 
of fluorescence change of the cells. The X-axis of the contour plot corresponds to the 
fluorescence intensity from the DNA Hg2+ sensor while the Y-axis shows the fluorescence 
intensity from the fluorescent PS portion of the JNP. As shown in Figure 3.7, after incubation 
with JNP-DNA probes for 6 hours, the red contour lines of the treated cells significantly shifted 
up compared to the black contour lines of untreated cells, confirming the uptake of JNP-DNA 
probes in HeLa cells. The intracellular response to mercury ions was tested by incubating the 
JNP-DNA probe pretreated HeLa cells with cell medium containing five different mercury 
concentrations from 0 to 30 µM. Higher concentrations of mercury ions in cell medium resulted 
in a larger shift of the contour lines towards the right, indicating enhanced fluorescence from the 
DNA sensors (Figure 3.8). To show that the ratiometric response of the JNP-DNA probes 
worked in HeLa cells, the ratio of DNA to JNP fluorescence was plotted for each sample of cells 
(Figure 3.9a). With the increase of the mercury concentration in the cell medium, the position of 
the cell population peak shifts towards higher DNA to JNP fluorescence ratio, indicating a 
mercury-dependent fluorescence response. To further demonstrate the quantitative analysis, the 
calibration curve was established by plotting normalized DNA to JNP mean fluorescence ratio 
with mercury concentration (Figure 3.9b). The mean fluorescence ratio increased with the 
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increase of mercury concentration in medium. Moreover, the shape of the calibration curve for 
intracellular mercury analysis is consistent with those obtained in buffer. Furthermore, the range 
of mean normalized fluorescent ratio obtained from flow cytometry should be comparable to 
fluorometer results, further validating the capability of JNP-DNA for intracellular analysis. 
 Confocal imaging micrographs of HeLa cells with three different mercury concentrations 
are shown in Figure 3.10a-c. The FITC (green) channel shows the internal standard fluorescence 
from JNP and the Cy3 (red) channel shows the fluorescence of DNA mercury sensor. As shown 
in Figure 3.8a and b, HeLa cells incubated with JNP-DNA probes and a low mercury 
concentration of 10 μM are more fluorescent in the Cy3 channel (Figure 3.10b) than those 
without mercury treatment (Figure 3.10a), and Cy3 fluorescence of HeLa cells incubated with 
mercury concentration of 20 μM was stronger, compared to cells incubated with low mercury 
concentration (Figure 3.10c). Meanwhile, no significant differences of fluorescence intensity 
were observed in the FITC channel, confirming the function of JNP as the internal standard. The 
observations made via confocal microscopy are consistent with flow cytometry results, 
indicating that JNP-DNA probe works from individual cells to whole cell populations. 
3.3. Conclusions 
In conclusion, we have developed a Janus nanoparticle-DNA ratiometric probe for 
quantitative analysis of mercury ions in live HeLa cells. The intrinsic asymmetric structure of 
JNP enables the ratiometric property, with the unmodified fluorescent PS site serving as an 
internal standard and the DNA-modified gold site providing mercury detection ability. As the 
JNP-DNA conjugation chemistry can be easily applied to different functional DNA molecules, 
such as aptamers and DNAzymes, the method demonstrated here provides us with a general 
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platform to convert any functional DNA into ratiometric probes for intracellular detection of a 
wide range of targets. 
3.4. Experimental Section 
Chemicals and Materials  
Tris(2–carboxyethyl)–phosphine hydrochloride (TCEP, C9H15O6P∙HCl), MOPS (3-
(Nmorpholino) propanesulfonic acid) and other metal salts were purchased from Sigma–Aldrich 
and used without further purification. Fluorescent polystyrene nanoparticle (F-PS NP) solution of 
200 nm in diameter (Excitation max. = 441 nm, Emission max. = 486nm) was purchased from 
Polysciences (Warrington, PA). All oligonucleotides used in this study were purchased from 
Integrated DNA Technologies Inc. (Coralville, IA), with following sequences: 
HS-Cy3 strand:  
5' - HS - AAAA TCA TG T TTG TTT GTT GGC CCC CCT TCT TTC TTA - Cy3 - 3' 
Hg-binding strand:  
5' - ATTCTTTCTTCCCCCCGGTTGTTTGTTTGTACT ACTCATCTGTGA - 3' 
HS-BHQ2 strand: 
5' - HS - (A)10 - TCACAGATGAGT - BHQ2 - 3' 
Cy3-releasing: 
5' - Cy3 - AGTACAAACAAA - 3' 
Fabrication of Fluorescent Janus Nanoparticle 
The fabrication of JNPs begins with the formation of fluorescent 200 nm polystyrene 
nanoparticles (F-PS NPs) monolayer. The positive charged glass substrates (3''×1''×1 mm, Fisher 
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Scientific, PA) were carefully rinsed with deionized water and anhydrous ethanol successively. 
The 200 nm F-PS nanoparticles solution was first 1:30 diluted in 5 mM HEPES buffer (HEPES = 
4–(2–hydroxyethyl)–1–piperazineethane–sulfonic acid, pH=7.0, 1 mM citrate), then dropped 
onto the covered glass substrate. After 1 hour of incubation, the glass substrates were rinsed with 
deionized water to form a monolayer of PS nanoparticles by removing excess PS nanoparticles. 
Completely dried substrates were then loaded into a metal evaporation system (Temescal six 
pocket E–Beam Evaporation System) to deposit a thin layer of ~ 2 nm Cr and ~ 6 nm of Au, 2 
nm/6 nm on the monolayer of F-PS nanoparticles to obtain a monolayer of F-JNPs. All F-JNPs 
were released from the surface by immersing the glass substrates in deionized water and 
sonicating for 2 min. The F-JNP solution was further purified through a 0.8 μm membrane and 
stocked in 0.05 % Tween-20. A standard concentration for F-JNP is ~ 0.2 nM. 
Characterization of Janus Nanoparticles  
The size and morphology of JNPs were analyzed using a Hitachi S4800 high resolution 
scanning electron microscopy (SEM). Fluorescence microscope images and darkfield images 
were acquired using a Zeiss Axiovert 200M inverted microscope with an EC Epiplan 50X HD 
objective (NA=0.7) and CCD camera. The digital camera was white–balanced using Zeiss 
Axiovision software before data acquisition. The fluorescence spectra were obtained by using a 
fluorimeter (FluoroMax-P; Horiba Jobin Yvon, Edison, NJ). 
Preparation of DNA Functionalized JNP  
Functionalization of thiolated DNA on 200 nm F-JNP was carried out by following a 
previous published protocol with some modifications.55 Briefly, 3 µL of 1 mM thiolated DNA 
was first mixed with 0.5 µL of 10 mM TCEP solution and 0.4 µL of 500 mM acetate buffer (pH 
5.2) to activate the thiolated DNA. After 1 hour of incubation, the mixture was then transferred 
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into 1 mL of 200 nm F-JNP solution (0.2 nM) followed by incubation overnight. The buffer 
concentration was increased to 5 mM by addition of 500 mM Tris acetate buffer (Tris = 2–
amino–2–hydroxymethyl–1, 3–propanediol, pH 8.2). The solution was left to anneal for another 
24 hours after gradually increase the NaCl concentration to 100 mM over 1 hour. To purify the F-
JNP from the unreacted DNA, excess thiolated DNA strands were removed from the solution by 
washing with 5 mM Tris acetate buffer in Amicon-100K 8 times. 
JNP-DNA Probe Preparation 
Before testing, the Hg-binding strand and Cy3-releasing strand, at a molar ratio of 1:1.2 
were added to 0.2 nM HS-BHQ2 strand modified F-JNP solution. The solution was heated up to 
65°C for 5 min, and slowly cooled down at room temperature for 2 h. The solution was stored at 
4°C overnight to allow full hybridization. After overnight incubation, excess DNA strands were 
removed from the solution by intensive washing with 10 mM MOPS buffer (150 mM NaNO3, 
pH 7.2) in Amicon-100K for 8 times. After purification, JNP-DNA mercury probe solution was 
dispersed in 10 mM MOPS buffer to ~ 0.2 nM for further use. 
Mercury Ion Detection in Buffer 
The mercury nitrate stock solution was freshly prepared using Milli-Q water (18.2 MΩ). 
The 0.2 nM JNP-DNA mercury probe stock solutions were diluted 1:20 with 10 mM MOPS 
buffer and transferred to a 100 μL cuvette. The cuvette was placed in a fluorimeter (FluoroMax-
P; Horiba Jobin Yvon, Edison, NJ) at 25 ˚C. The excitation and emission wavelength was set 
accordingly (440ex / 485em for JNP and 580ex / 610em for Cy3-releasing DNA). After the initial 
reading, the cuvette was taken out, and a small volume of concentrated mercury nitrate stock 
solution was added. After vortexing, the cuvette was put back into the fluorimeter to continue the 
measurement. 
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Cell Culture 
HeLa cells were cultured in Dulbecco’s modified Eagles medium (DMEM), respectively, 
with 10 % heat inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL 
streptomycin, on 25 cm2 culture flasks and maintained at 37°C in a humidified 5% CO2 
incubator. Prior to imaging, cells were plated on 35 mm glass-bottom dishes (MatTek) and grown 
to 70-90% confluence before imaging. 
JNP-DNA Uptake 
JNP-DNA mercury probe solution of 0.2 nM was freshly prepared by 1:20 dilution in 
Opti-MEM medium. After thoroughly washing HeLa cells with PBS, 2 mL of Opti-MEM 
containing the JNP-DNA probe was added to each glass-bottom dish. After incubation for 6 
hours at 37 °C, cells were thoroughly washed with PBS buffer three times and with fresh DMEM 
medium three times.  
Mercury Nitrate Uptake 
The mercury nitrate stock solution was freshly prepared by using Milli-Q water (18.2 
MΩ). After uptake of the JNP-DNA probes, the cell media was supplemented with a small 
volume of concentrated mercury nitrate stock to reach specific mercury concentrations. Cells 
were then incubated in the presence of mercury for 15 min to allow mercury uptake and 
minimize damage to cells. Cells were thoroughly washed with PBS and incubated at 37 °C for 
another 30 min for further experiments. Cell nuclei were stained with Hoechst 33258 at a 
concentration of 2.5 ng/mL for 20 minutes prior to imaging. 
Cell Imaging 
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Images were obtained using a Zeiss LSM 710 NLO confocal microscope at 63x 
magnification equipped with a Mai-Tai Ti-Sapphire laser. Fluorescence emission was measured 
over 450-520 nm and 575-620 nm ranges, with excitation at 401 nm and 561 nm, respectively. 
The pinhole and gain settings were kept constant throughout the whole imaging process. For JNP 
internalization studies, Lysotracker Green (Invitrogen) was added to cells for 30 minutes after 
Hoechst staining, at a final concentration of 50 nM. Cells were fixed with 4% paraformaldehyde 
and the fluorescence emission was measured over 510-570 nm, with excitation at 488 nm. 
Flow Cytometry Study 
Prepared HeLa cells were lifted using 0.05% trypsin-EDTA and collected by 
centrifugation. The suspended cell solution was centrifuged at 2,000 g for 5 min and washed 
with PBS three times. The total number of cells was counted using a hemocytometer. Flow 
cytometry was performed using a BD FACSCanto system using 488 nm excitation with 
detection in different channels. Control cells without any treatment were used to set the gating. 
Each measurement set was performed in triplicate and averaged, and each measurement used 
10,000 cells. 
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3.6. Figures 
 
Figure 3.1. (a) Schematic view of the design and working mechanism of the JNP-DNA 
ratiometric probe for mercury inside live cells. (b) Detailed three-sequence design of the DNA-
based mercury sensor. 
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Figure 3.2. (a) Schematic view of the fabrication process of fluorescent JNPs. (b) SEM images 
of fabricated JNPs with half surface covered by gold. (Inset) high magnification SEM image of a 
single JNP. Scale bar = 100 nm. (c) Fluorescence spectra of original fluorescent PS nanoparticle 
(blue) and fabricated fluorescent JNP (red) with the same concentration. (d) Calibration curve for 
fluorescent JNPs correlating the concentration of JNPs and the corresponding fluorescence 
intensity. 
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Figure 3.3. Dual imaging modalities of the fluorescence-gold JNP. Fluorescence and darkfield 
imaging of single nanoparticles spread between two glass coverslips: (top) 200 nm F-JNP, (mid) 
200 nm F-PS NP, (bottom) 60 nm AuNP. 
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Figure 3.4. Fluorescence confocal images of fluorescent JNP modified with HS-Cy3 DNA 
strand. (Left) FITC fluorescence from JNP. (Mid) Cy3 fluorescence from HS-Cy3 strand. (Right) 
Overlay of JNP and Cy3 DNA fluorescence. 
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Figure 3.5. (a) Combined JNP (left, Ex = 440 nm) and DNA (right, Ex = 580 nm) fluorescence 
emission spectra of the JNP-DNA probe in the presence of various Hg2+ ions concentration. The 
fluorescence spectra were measured first 15 min after addition of Hg2+ ions. (b) Calibration 
curve of JNP-DNA ratiometric mercury probe. (c) Kinetics of the normalized fluorescence ratio 
increase in the presence of varying concentrations of Hg2+ ions. (d) Selectivity of the JNP-DNA 
Hg2+ probe. Black bars represent the normalized fluorescence ratio responses 15 min after the 
addition of 2 µM of different metal ions. From left to right: Hg2+, Mg2+, Ca2+, Mn2+, Zn2+, Cu2+, 
Cd2+, and Pb2+ ions. 
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Figure 3.6. Confocal microscopy images of (a) control HeLa cells without JNP-DNA probes, 
and HeLa cells incubated with JNP-DNA probes for 2 hours (b), 4 hours (c), and 6 hours (d). 
Differential interference contrast (DIC) microscopy images of cells are shown in the first column. 
The red channel is fluorescence from Lysotracker stain and the FITC green channel is JNP 
fluorescence. Scale bar = 20 μm. 
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Figure 3.7. 2D contour plot of the DNA fluorescence and JNP fluorescence measured in flow 
cytometry. Contour lines of cells with JNP-DNA probes (red) shift more to the top than that of 
the control cells (black), indicating the uptake of JNP probes into HeLa cells. 
 
 
 
 
103 
 
 
Figure 3.8. Qualitative analysis of Hg2+ concentration in live HeLa cells using flow cytometry. 
Contour lines of JNP-DNA probe pretreated HeLa cells incubated with cell medium containing 
five different mercury concentrations from 0 to 30 µM. The contour lines of cells shift to the 
right side with the increase of the Hg2+ concentration. 
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Figure 3.9. Quantitative analysis of Hg2+ concentration in live HeLa cells. (a) The cell-
associated fluorescence intensities in control cells and JNP-DNA probe pretreated HeLa cells 
using flow cytometry. Curves were plotted with DNA to JNP fluorescence ratio. Higher 
concentrations of mercury ions lead to higher fluorescence ratio. (b) Calibration curve of 
mercury ion concentrations and normalized DNA to JNP mean fluorescence ratio for JNP-DNA 
probe in HeLa cells. 
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Figure 3.10. Confocal microscopy images of JNP-DNA probe pretreated HeLa cells incubated in 
DMEM medium without Hg2+ ions (a), and with Hg2+ ions at a concentration of 10 µM (b) and 
20 µM (c). Differential interference contrast (DIC) microscopy images of cells are shown in the 
first column. The FITC green channel shows JNP internal standard fluorescence. The Cy3 red 
channel shows the fluorescence from the mercury sensor. Scale bar = 20 μm. 
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  CHAPTER 4 
TARGET-RESPONSIVE LIPOSOME FOR MULTIMODAL DETECTION 
OF SMALL MOLECULE TARGETS 
4.1. Introduction 
Nanomaterials with the ability to load multiple payloads in an inert and protected state 
during transportation have demonstrated their promising applications in nanomedicine and 
biosensors.1-3 Among them, nanomaterials which can respond to external stimuli have attracted 
considerable attention due to their ability to control the timing, dosage, selectivity of the release 
profile of the payloads.4-6 The stimuli-responsive nanomaterials, or smart nanomaterials, are 
specialized nano-sized carriers with “load-and-release” modalities which can be activated by 
external signals.7,8 The operating principle of smart nanomaterials lies in the fact that a speciﬁc 
physical, chemical, and biochemical stimulus can trigger the conformational or chemical changes 
of the nanomaterials, and thereby promoting the release of the payloads.9-11  
In contrast to conventional nanomaterials, one advantage of smart nanomaterials is that 
they can undergo relatively large and abrupt physical and chemical changes in sharp response to 
applied stimuli. Such action can not only facilitate the release of cargo with desirable 
pharmacokinetics, but also guarantee that cargo can be spatiotemporally released at a targeting 
site, which is of great importance in clinical application.12 Another advantage is that stimuli-
responsive nanomaterials allow multimodal detection, because nanomaterials can be engineered 
to combine many features from mono-functional components to generate favorable 
functionalities within a single system.13,14 In the past decade, a variety of smart nanomaterials 
have been reported, including dendrimers,15,16 gold nanomaterials,17,18 nano-emulsions,19 drug-
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polymer conjugates,20 drug-antibody conjugates,21 and quantum dots22. Each of these stimuli-
responsive platforms possesses unique fabrication components and can promote the release of 
loaded imaging agents to external physical or chemical stimuli, such as temperature,23 light,24 
magnetic ﬁeld,25 mechanical force,26 pH,27 redox potential,28 and enzymes.29 
 Among all different kinds of nanomaterials, liposome is considered as one of the most 
promising smart nanomaterials because of the superior biocompatibility, biodegradability, low 
toxicity, and versatility in size and surface.30,31 Smart liposomes have been reported to be 
triggered by a broad ranges of physical external stimuli, including magnetic or electric field,32,33 
temperature,32  light,34 and acoustic waves. Recently, smart liposomes responsive to stimuli of 
chemical and biochemical origins have been reported, including pH-shift, redox, enzymes, host–
guest recognitions, and antigen–antibody interactions.35-41 Despite the achievements, current 
reported smart liposomes can only respond to external physical stimuli and a few chemical 
stimuli but not to various small molecule metabolite and metal ion targets, limiting their 
applications for biological systems. A smart liposome system which can be designed to respond 
to specific small molecule targets is required but remains a challenge, due to the difficulty in 
designing the transduction process between target binding and triggered release. 
Functional DNA (fDNA) has emerged as a promising candidate as the recognition agent 
for small molecule and metal ion targets in past decades. Functional DNAs are single-stranded 
oligonucleotides which can bind to target molecules with high specificity and binding affinity, or 
catalyze certain reactions. First developed in early 1990s, aptamers have recently been reported 
as an excellent alternative to antibodies as agents to specific target cancel cells.42,43 Many 
aptamers are originally obtained through system evolution of ligands by exponential enrichment 
(SELEX), by selecting the active strands from a pool of random DNA or RNA sequences. By 
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combining fDNA with signaling agents, many fDNA sensors have been developed for a wide 
range of targets,42,43 including fluorescence,44-48 colorimetry,49-51 electrochemistry,52-54 and 
magnetic resonance.55 Despite the great advancements, one significant limitation remains. 
Different detection methods require different chemical modifications of fDNA strands in order to 
allow a conversion between recognition and signal output. Therefore, a universal strategy 
compatible to multiple detection modalities is of great demand. 
In this work, we reported a novel smart liposome system which can allow multimodal 
detection of different small molecule targets in a sensitive and selective manner by using DNA-
enzyme conjugates. Specifically, DNA is covalently conjugated to phosphatidylcholine 2-
acetylhydrolase (PLA2), an enzyme that can hydrolyze the 2-acyl bond in lipid molecule. The 
existence of small molecule targets triggers the release of PLA2-modificed DNA strand. Reaction 
between PLA2 with smart liposome breaks the structure of the lipid bilayer and releases the 
containing payloads. Fluorescence, MRI, and photothermal detection of cocaine were 
demonstrated by using the smart liposome system loading with different signaling agents. The 
same strategy was further applied to the 39E DNAzyme for the photothermal detection of UO2
2+ 
to further demonstrate the broad scope of the method. 
4.2. Results and Discussion 
Design and Strategy 
In order develop a smart liposome which is responsive to various small molecule targets, 
we need to establish a link between the rupture of liposome and the target molecule. A class of 
heat-stable, calcium-dependent enzymes phosphatidylcholine 2-acetylhydrolase (PLA2) can 
provide the link. In aqueous solution, PLA2 can catalyze the hydrolysis of 2-acyl bond of 3-n-
phosphoglycerides, a major component of biological membranes including liposome, generating 
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lysolipid and fatty acid as the major products. Therefore, a direct relationship can be established 
between the concentrations of PLA2 and the ruptured liposomes. More importantly, because of 
the efficient enzymatic turnover, PLA2 with nanomolar concentration can lead to the rupture of 
liposome under ambient conditions, making it an ideal catalyst to release the signaling agents 
and amplify ‘turn-on’ signals. 
The next challenge is to establish the relationship between target concentration and PLA2 
concentration. As shown in Figure 4.1, we designed a mechanism of target-induced release of 
DNA-PLA2 conjugate to meet this challenge. DNA–PLA2 conjugate synthesized by the 
maleimide-thiol conjugation reaction hybridizes with the thiolated DNA strand. The fDNA and 
DNA-PLA2 is immobilized onto magnetic beads (MBs) through streptavidin–biotin interactions. 
The binding of the target molecules can induce the release of DNA-PLA2 conjugate from 
functional DNA sequences that are immobilized on magnetic beads. Unreleased PLA2 enzyme 
will be removed together with MBs from solution through magnetic separation. The released 
DNA-PLA2 conjugate can catalyze the hydrolysis of signaling agents-loaded liposomes. The 
rupture of the liposomes results in the releasing of signaling agents into the solution and being 
detected by multiple detecting modalities. Under optimized condition, the concentration of 
released signaling agents is proportional to the concentration of released enzymes, and therefore 
is proportional to the target molecules. This strategy allows a general responsive liposome 
platform which is able to quantitatively detect small molecules with multiple signal outputs. 
Preparation and Characterization of Liposome 
The formulation and hydrolysis reaction of the smart liposome is shown in Figure 4.2a. 
The liposomes are formulated from 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] 
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(DPPE-PEG, ammonium salt) at a molar ratio of 9.5 : 0.5. The usage of DPPE-PEG is critical, 
because the PEG modification on the surface can increase the surface area interacting with PLA2, 
and therefore significantly facilitate the hydrolysis reaction. The smart liposomes were prepared 
using 200 nm polycarbonate membrane supported extruders based on a previous published 
protocol. Different signaling agents, including uranin, gadopentetic acid (Gd-DTPA), and 
indocyanine green (ICG), were encapsulated into liposome through the process. Free signaling 
agents were removed by using size-exclusion chromatography (SEC). 
To elucidate the structure and morphology of aptamer-modified liposomes, Cryo-EM 
experiments were performed. As shown in Figure 4.2b, the obtained liposome samples were 
spherical an average size around ~ 160 nm, which agrees well with the pore size of the 
polycarbonate membrane used in preparation. The smart liposomes were further characterized by 
dynamic light scattering (DLS) measurements. The liposomes showed an average hydrodynamic 
diameter of ~ 155 nm, which is consistent with the Cryo-EM images (Figure 4.2c). If PLA2 was 
added into liposome solution, after 30 min incubation, the average hydrodynamic diameter 
increased to ~ 221 nm, confirming the hydrolysis of liposomes. The concentration of the lipids in 
each sample was measured at the fluorescence emission of 627 nm using Nile Red stained smart 
liposome samples. The prepared liposome sample can be easily centrifuged down and 
concentrated. The standard lipids concentration for prepared liposome solution was tuned to be ~ 
5 mg/mL for further experiments. 
Preparation of DNA-PLA2 Conjugates 
The conjugation of thiolated DNA to PLA2 was carried out by using a heterobifuntional 
linker sulfo-SMCC, which can link the reactive amines of PLA2 with DNA (Figure 4.3a). Since 
the amine groups in PLA2 are not involved in the active sites, the conjugation will still preserve 
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the catalytic activity of the enzyme. In the presence of excess amount of thiolated DNA, the 
conjugation chemistry yielded sufficient amounts of DNA-PLA2 conjugates. To demonstrate the 
successful conjugation chemistry between DNA and PLA2 and purify DNA-PLA2 conjugates, 
SDS-PAGE gel electrophoresis was applied followed by fluorescence and photograph imaging 
(Figure 4.3b). Coomassie brilliant blue was used to stain free PLA2 and DNA-PLA2 conjugates. 
Thiolated DNA was modified with fluorescein, so that free conjugates could be fluorescently 
imaged. As shown in Figure 4.3b, DNA-PLA2 conjugates exhibited multiple bands that migrated 
slowly on both fluorescence and photograph images, while free DNA and free PLA2 migrated 
faster than DNA-PLA2 conjugates. The molecular weight of free PLA2 is 13.9 kDa, which is in 
agreement with the location of the band on the gel. After conjugating with ~ 7 kDa DNA strands, 
the molecular weight of the conjugates showed multiple bands ~ 20 – 50 kDa, suggesting one or 
multiple DNA binding to PLA2. The UV absorption spectra of purified DNA-PLA2 conjugate 
was overlapped well with the sum of its two components, free DNA and PLA2, further 
confirming the successful formation of PLA2-DNA conjugates (Figure 4.3c). 
Measurement of Smart Liposome Releasing Profile 
Before moving toward to small molecule detection, the releasing profile of smart 
liposome was first tested to optimize the experiment conditions in 10 mM pH 7.4 HEPES buffer 
solution containing 150 mM NaCl and 150 µM CaCl2. Uranin-containing smart liposome 
solution was treated with PLA2 of various concentrations (from 0 – 64 nM) at room temperature 
for 15 min and 1 hour respectively. Liposome sample treated with Triton-X and heat was 
completely ruptured and served as positive control group (red dot), while liposome incubated 
without PLA2 was used as negative control (green dot). After the reaction, the liposome solution 
was ultracentrifuged at 16,110 g for 5 min and the supernatant was collected for fluorescence 
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measurement. The fluorescence profile and photograph image were monitored at incubation time 
of 15 min (Figure 4.4a) and 1 hour (Figure 4.4b).   The results suggested that higher 
concentrations of PLA2 resulted in solution with increasing green color and higher fluorescence 
intensity. At the incubation time of 15 min, the liposome hydrolysis reaction is not complete. The 
64 nM PLA2 treated liposome only showing ~ 50% fluorescent intensity of positive control. At 
the incubation time of 1 hour, the fluorescent intensity started reaching plateau at 16 nM PLA2 
with ~ 80% fluorescent intensity of positive control reached for 64 nM PLA2 treated liposome. 
The kinetics of uranin-loaded smart liposome releasing profile was further studied by using 
PLA2 of 16 nM concentration (Figure 4.4c). The results showed that smart liposome began to 
rupture after 15 min and started reaching plateau after 40 min. The releasing profiles suggested 
that even small changes in PLA2 concentration (e.g. 5 nM) can potentially release large enough 
uranin dye to generate detectable fluorescence signal and 1 hour incubation time is the optimum 
condition. 
Fluorescence Detection of Cocaine 
To demonstrate the proof of concept, cocaine was selected as a model target, as the 
sensitive detection of cocaine is very important for law enforcement and clinical diagnostics and 
the cocaine aptamer is one of the most studied fDNA strands. As shown in Figure 4.5a, the 
biotin-DNA is immobilized onto magnetic beads (MBs) by means of streptavidin-biotin binding 
and the DNA-PLA2 conjugates synthesized by the maleimide-thiol reaction hybridizes with the 
cocaine DNA aptamer. The target specific structure switching of the aptamer in the presence of 
cocaine (0 - 1000 µM) release the DNA–PLA2 conjugate to solution and hydrolyze the 
liposomes, resulting in the increase of the fluorescence signal (Figure 4.5b). Upon the addition of 
1000 µM cocaine and subsequent removal of the MBs, the fluorescence spectrum showed about 
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~ 50% higher fluorescence emission intensity than that of a sample containing no cocaine. The 
calibration curve showed the relative fluorescence intensity increased with the increase of 
cocaine concentration and the relative fluorescence intensity reached a plateau when cocaine 
concentration is higher 200 µM (Figure 4.5c). 
MRI Detection of Cocaine 
To demonstrate the compatibility of smart liposome method for other detection 
modalities besides fluorescence, we tested the MRI detection of cocaine by loading Gd-DTPA, a 
widely used T1-weighted MRI imaging contrast agent, into smart liposomes. Different 
concentrations of cocaine samples (0 – 1000 µM) were added to trigger the target specific 
structure switching of the aptamer to release DNA–PLA2 conjugate into solution. The released 
PLA2 was mixed with Gd-liposomes samples and incubated at room temperature for 1 hour. The 
PLA2-treated Gd-liposome samples were ultra-centrifuged at 16,110 g for 5 min and the 
supernatant was collected for MRI imaging. The supernatant solution samples were placed in a 
96-well plate and imaged by using Allegra 3T MRI scanner at a repetition time (TR) of 2000 ms 
and inversion time (TI) from 22 ms to 1600 ms. Figure 4.6 shows a representative photograph 
image and corresponding MRI image of a series of samples of different cocaine concentrations. 
MRI images obtained at different inversion times were used to estimate T1 relaxation 
time for samples of different cocaine concentrations. Quantitative analysis was achieved by 
plotting T1 relaxation time with corresponding cocaine concentration. As shown in Figure 4.7a 
and 7b, the addition of cocaine decreased the T1 from ~ 2430 ms at 50 µM cocaine, to finally ~ 
1970 ms at 1000 µM cocaine, which is about a ~ 20% T1 change. The selectivity of the strategy 
was tested by measuring the response of the smart liposome toward 1000 µM of cocaine, 
adenosine, and glucose (Figure 4.7c and 7d). The addition of cocaine significantly decreased the 
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T1 from ~ 2490 ms to ~ 1970 ms, while the addition of the same concentration of adenosine and 
glucose only changed T1 to ~ 2250 ms and ~ 2300 ms, indicating the high selectivity of this 
approach. Furthermore, at an inversion time of 800 ms and repetition time of 2000 ms, the MRI 
images from left to right changed from dark (left: in the absence of cocaine) to brighter (in the 
presence of 1000 µM) with the increase of the cocaine concentration. The contrast of the MRI 
images increased with the addition of different concentration of cocaine (Figure 4.7e). The 
imaging results are consistent with the T1 decrease demonstrated in Figure 4.7a and 7b, 
suggesting that a ~ 20% T1 change can proved a significant contrast change in an MRI image. 
Detection of Cocaine Using Portable Thermometer (PTM) 
To further demonstrate the broad scope of the liposome-based stimuli-responsive 
platform, we performed the thermal detection of cocaine by using portable thermometer (PTM). 
Smart liposome was loaded with indocyanine green (ICG), the only near-infrared (NIR) 
photosensitizer dye approved by the United States Food and Drug Administration (FDA) for 
clinical usage,  which can effectively convert NIR laser light into heat. Figure 4.8 shows the self-
built photothermal detection system used in the study, including a dark chamber, a NIR laser 
pointer (1 W, ~1.5 mm in diameter for illumination area), a 96-well colorless plate, and a 
portable thermometer (PTM). Upon NIR-laser light irradiation, the released ICG dye in solution 
can convert NIR photon energy into heat, resulting in a temperature increase, which is detectable 
by PTM.  
To test the PTM-based detection of cocaine, smart liposome was loaded with ICG and 
treated with PLA2 from cocaine-induced releasing. Temperature change of the supernatant 
solution was measured before and after NIR laser irradiation. In the absence of cocaine, the 
temperature increase (ΔT) was about 2 °C, which may be due to the ICG leakage during 
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centrifugation. In the presence of cocaine with a concentration as low as 5 μM, the ΔT was 
significantly increased. Under the same incubation condition, the ΔT increased with the increase 
of cocaine concentration and reached a plateau at 300 μM (Figure 4.9a). This observation was 
consistent with the fluorescence and MRI results, indicating the reliability of PTM-based 
detection and the compatibility of smart liposome approach. 
To demonstrate the selectivity of the PTM-based cocaine detection, a control experiment 
was tested by using adenosine and glucose. As shown in Figure 4.9b, the addition of adenosine 
or glucose only increased the temperature for ~ 2 °C, which is similar to the buffer control. In 
contrast, the temperature change of cocaine was ~ 5 °C at 100 μM and ~ 7 °C at 500 μM. The 
result suggests PTM-based detection method maintained the high selectivity to cocaine. 
Detection of UO22+ Using PTM 
Furthermore, because the PLA2 enzyme trigger-releasing mechanism is compatible with 
different fDNA, we extended our method from cocaine aptamers to 39E DNAzyme to test the 
detection of toxic metal ion UO2
2+. The design of the sensor is shown in Figure 4.10a. Similar to 
previous cocaine sensor, the DNA–PLA2 conjugates were connected to biotin-DNA 
immobilized MBs together with the UO2
2+-specific DNAzyme (39E) and its substrate (39S) 
through 12-base-pair hybridization. Upon the addition of UO2
2+, the DNAzyme catalyzed the 
cleavage of its substrate at the 3'-phosphoester bond of the ribonucleotide A (rA) and 
subsequently released the DNA–PLA2 conjugate. The released DNA-PLA2 was incubated with 
smart liposome solution and triggered the releasing of ICG. PTM was then applied for the 
measurement using the photothermal detection system. PTM-based detection of UO2
2+ was 
applied with a dynamic range from 0 to 1000 nM (Figure 4.10b). The detection limit was 
calculated to be 25.7 nM (6.8 µg/L), which is much lower than the US Environmental Protection 
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Agency (EPA) regulated level (30 µg/L) for drinking water. Furthermore, the PTM-based UO2
2+ 
sensor also exhibited highly selectivity over a variety of divalent metal ions (Figure 4.10c). 
4.3. Conclusions 
In conclusion, we have successfully developed a target-responsive liposome system for 
the multimodal detection of small molecule targets by loading different signaling agents. The use 
of DNA-PLA2 conjugate provided a link between the target recognition ability from fDNA and 
the signal production ability from smart liposome. As a proof of concept, fluorescence detection, 
MRI detection, and PTM-based detection were performed by using uranin, Gd-DTPA, and ICG 
as signaling agents respectively.  All detection methods showed good sensitivity as well as high 
selectivity to cocaine, indicating the compatibility to different detection modalities. The broad 
scope of the approach was further demonstrated by 39E DNAzyme for the detection of UO2
2+
. 
The target-responsive liposome system can be easily applied to other imaging agents and 
molecular targets allowing a wide range of diagnostic applications. 
4.4 Experimental Section 
Chemicals and Materials  
Streptavidin-coated magnetic beads (1 µm in average diameter) and Amicon-10K/30K 
centrifugal filters were purchased from Bangs Laboratories Inc. (Fishers, IN) and Millipore Inc. 
(Billerica, MA), respectively. Phospholipase A2 (PLA2, MW = 14.5 kDa) from honey bee 
venom, Indocyanine green (ICG), sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (sulfo-SMCC), Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), 2-(N-
morpholino)ethanesulfonic acid (MES), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), gadopentetic acid (Gd-DTPA) and other chemicals were purchased from Sigma-
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Aldrich, Inc. (St. Louis, MO). Phospholipids including 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-1000] (ammonium salt, DPPE-PEG) were purchased from 
Avanti Polar Lipids.  
The following oligonucleotides were purchased from Integrated DNA Technologies, Inc. 
(Coralville, IA): from left to right: 5' to 3'. 
All oligonucleotides used in this study were purchased from Integrated DNA 
Technologies Inc. (Coralville, IA) with the following sequences (from left to right: 5′ to 3′): 
Biotin-modified DNA (Biotin-DNA) for cocaine, and uranium sensors: 
TCACAGATGAGTAAAAAAAAAAAA-biotin 
Thiol-modified DNA (Thiol-DNA) for cocaine and UO2
2+ sensors: 
HS-AAAAAAAAAAAAGTCTCCCGAGAT 
Cocaine aptamer (Coc-Apt): 
TTTTTTACTCATCTGTGAATCTCGGGAGACAAGGATAAATCCTTCAATGAAGTGGGT
CTCCC 
UO2
2+-dependent DNAzyme (39E): 
CACGTCCATCTCTGCAGTCGGGTAGTTAAACCGACCTTCAGACATAGTGAGT 
Substrate of the UO22+-dependent DNAzyme (39S): 
ACTCATCTGTGAACTCACTATrAGGAAGAGATGGACGTGATCTCGGGAGAC 
Buffers used in this work: 
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PBS Buffer: pH 7.3, 0.1 M sodium phosphate, 0.1 M NaCl, 0.05% Tween-20 
HEPES buffer: pH 7.4, 0.01 M HEPES, 0.1 M KCl, 0.001 M MgCl, 0.05% Tween-20 
MES buffer: pH 5.5, 0.05 M MES, 0.2 M NaCl, 0.05% Tween-20 
Liposome buffer: pH 7.6, 25 mM HEPES, 150 mM NaCl, 5 mM KCl, 1mM MgCl2, 1mM CaCl2 
Formulation of Liposomes 
Smart liposomes were prepared by the film hydration/extrusion method. DPPC and 
DPPE-PEG (95:5 mol %, 3.6 µmol total lipid) were co-dissolved in chloroform. The organic 
solvent was eliminated under nitrogen, and the lipid film was placed under vacuum overnight. 
The dried film was then hydrated with liposome preparation buffer containing different signaling 
agents (0.8 mg/mL, lipid/dye molar ratio of 260). The lipids mixture dispersion was freeze 
thawed 6 times, and incubated at 37 °C overnight. After that, the solution was extruded 10 times 
through double-stacked 200-nm pore size polycarbonate membranes using an extruder (Avanti 
Polar Lipids, Inc.) to yield small unilamellar vesicles. Free molecules were removed by size 
exclusion chromatography on a G-25 column (GE Healthcare) using liposome preparation buffer 
as eluent.  
Preparation of DNA-PLA2 Conjugations 
The DNA−PLA2 conjugate was synthesized by the maleimide-thiol reaction using hetero-
bifunctional linker sulfo-SMCC (Figure S2a). Briefly, 30 µL of 1 mM thiol-DNA, 2 µL of 1 M 
PBS buffer (pH 5.5), and 2 µL of 30 mM TCEP were mixed and incubated at room temperature 
for 1 hour. Then, the thiol-DNA was purified by Amicon-10K using PBS buffer by 8 times. For 
PLA2 conjugation, 200 µL of 5 mg/mL PLA2 in PBS buffer was mixed with 1 mg of sulfo-
SMCC. After vortexing for 5 minutes, the solution was placed on a shaker for 1 hour at room 
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temperature. The mixture was then purified by Amicon-10K using PBS buffer by 8 times. The 
purified solution of sulfo-SMCC-activated PLA2 was mixed with the above solution of thiol-
DNA. The resulting solution was kept at room temperature for 48 hours. To remove unreacted 
thiol-DNA, the solution was purified by Amicon-30K 8 times using PBS buffer. 
Characterization 
Dynamic light scattering (DLS) was performed using a Malvern Zetasizer Nano ZS 
instrument (Malvern Instruments, UK).  
Cryo-TEM samples of liposomes were prepared using a Vitrobot according to a literature 
protocol. Briefly, a drop of liposome solution was applied onto a TEM grid, the grid was then 
blotted and immediately plunge-frozen into ethane slush cooled by liquid nitrogen. The as-
prepared sample onto TEM grid was then transferred onto a cryo holder via Gatan CT3500 
Cryotransfer system, which was pre-cooled with liquid nitrogen. The images were obtained on a 
JEOL 2100 transmission electron microscope at an acceleration voltage of 80 kV.     
Supernatants of Gd-liposomes were placed in a 96-well plate and imaged by using 
Allegra 3T MRI scanner at a repetition time (TR) of 2000 ms and inversion time from 22 ms to 
1600 ms. MRI images obtained at different inversion times were used to fit T1 relaxation time 
corresponding to different cocaine concentrations by  using following equation: 
S(t) = S0 (1 – 2exp(-TI/T1) + exp(-TR/T1)), 
where S0: magnetization, TI: inversion time, TR: repetition interval, S(t): relaxivity (signal from 
amplitude of free induction decay). 
 The self-built photothermal system for PTM-based detection is consist of a dark chamber, 
a NIR laser pointer (1 W, ~1.5 mm in diameter for illumination area), a 96-well colorless plate, 
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and a portable thermometer (PTM). The NIR laser pointer and 96-well colorless plate were 
firmly fixed at the top and the bottom of sample holders in the chamber, respectively. The output 
power of NIR laser pointer was 1 W, and the height of the pointer to the bottom was controlled 
to have an illumination area of ~ 1.5 mm in diameter. All NIR-laser irradiations were carried out 
at room temperature (25 oC) under atmospheric conditions. After 60 s laser irradiation, a super-
fast thermapen with 3-second readings was used to detect the temperature change. The portable 
thermometer (PTM) used for the tests in this work was Super-Fast Thermapen (ThermoWorks, 
UT). The NIR laser pointer (808nm, 1 W) was purchased from BOB LASER Co., LTD (China). 
 
 
 
 
 
 
 
 
 
 
 
 
 
121 
 
4.5. References 
 (1) Shi, J. J.; Votruba, A. R.; Farokhzad, O. C.; Langer, R. Nanotechnology in Drug 
Delivery and Tissue Engineering: From Discovery to Applications. Nano Lett. 2010, 10, 3223-
3230. 
 (2) Fleige, E.; Quadir, M. A.; Haag, R. Stimuli-responsive polymeric nanocarriers for 
the controlled transport of active compounds: Concepts and applications. Adv. Drug Deliv. Rev. 
2012, 64, 866-884. 
 (3) Wang, A. Z.; Langer, R.; Farokhzad, O. C. Nanoparticle Delivery of Cancer 
Drugs. Annu. Rev. Med. 2012, 63, 185-198. 
 (4) Delcea, M.; Mohwald, H.; Skirtach, A. G. Stimuli-responsive LbL capsules and 
nanoshells for drug delivery. Adv. Drug Deliv. Rev. 2011, 63, 730-747. 
 (5) Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-responsive nanocarriers for drug 
delivery. Nature Mater. 2013, 12, 991-1003. 
 (6) Cheng, R.; Meng, F. H.; Deng, C.; Klok, H. A.; Zhong, Z. Y. Dual and multi-
stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. 
Biomaterials 2013, 34, 3647-3657. 
 (7) Motornov, M.; Roiter, Y.; Tokarev, I.; Minko, S. Stimuli-responsive nanoparticles, 
nanogels and capsules for integrated multifunctional intelligent systems. Prog. Polym. Sci. 2010, 
35, 174-211. 
 (8) Barreto, J. A.; O'Malley, W.; Kubeil, M.; Graham, B.; Stephan, H.; Spiccia, L. 
Nanomaterials: Applications in Cancer Imaging and Therapy. Adv. Mater. 2011, 23, H18-H40. 
122 
 
 (9) Lu, Y.; Sun, W.; Gu, Z. Stimuli-responsive nanomaterials for therapeutic protein 
delivery. J. Control. Release 2014, 194C, 1-19. 
 (10) Shim, M. S.; Kwon, Y. J. Stimuli-responsive polymers and nanomaterials for 
gene delivery and imaging applications. Adv. Drug Deliv. Rev. 2012, 64, 1046-1058. 
 (11) Zha, L. S.; Banik, B.; Alexis, F. Stimulus responsive nanogels for drug delivery. 
Soft Matter 2011, 7, 5908-5916. 
 (12) Siegel, R. A. Stimuli sensitive polymers and self regulated drug delivery systems: 
a very partial review. J. Control. Release 2014, 190, 337-351. 
 (13) Sanvicens, N.; Marco, M. P. Multifunctional nanoparticles - properties and 
prospects for their use in human medicine. Trends Biotechnol. 2008, 26, 425-433. 
 (14) Liong, M.; Lu, J.; Kovochich, M.; Xia, T.; Ruehm, S. G.; Nel, A. E.; Tamanoi, F.; 
Zink, J. I. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS 
Nano 2008, 2, 889-896. 
 (15) Majoros, I. J.; Williams, C. R.; Baker, J. R. Current dendrimer applications in 
cancer diagnosis and therapy. Curr. Top. Med. Chem. 2008, 8, 1165-1179. 
 (16) Tomalia, D. A.; Reyna, L. A.; Svenson, S. Dendrimers as multi-purpose 
nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans. 2007, 35, 
61-67. 
 (17) Boisselier, E.; Astruc, D. Gold nanoparticles in nanomedicine: preparations, 
imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev. 2009, 38, 1759-1782. 
 (18) Dykman, L.; Khlebtsov, N. Gold nanoparticles in biomedical applications: recent 
advances and perspectives. Chem. Soc. Rev. 2012, 41, 2256-2282. 
123 
 
 (19) Gutierrez, J. M.; Gonzalez, C.; Maestro, A.; Sole, I.; Pey, C. M.; Nolla, J. Nano-
emulsions: New applications and optimization of their preparation. Curr. Opin. Colloid Interface 
Sci. 2008, 13, 245-251. 
 (20) Du, J. Z.; Du, X. J.; Mao, C. Q.; Wang, J. Tailor-Made Dual pH-Sensitive 
Polymer-Doxorubicin Nanoparticles for Efficient Anticancer Drug Delivery. J. Am. Chem. Soc. 
2011, 133, 17560-17563. 
 (21) Alley, S. C.; Okeley, N. M.; Senter, P. D. Antibody-drug conjugates: targeted 
drug delivery for cancer. Curr. Opin. Chem. Biol. 2010, 14, 529-537. 
 (22) Zrazhevskiy, P.; Sena, M.; Gao, X. H. Designing multifunctional quantum dots 
for bioimaging, detection, and drug delivery. Chem. Soc. Rev. 2010, 39, 4326-4354. 
 (23) Liu, L.; Wang, W.; Ju, X. J.; Xie, R.; Chu, L. Y. Smart thermo-triggered squirting 
capsules for nanoparticle delivery. Soft Matter 2010, 6, 3759-3763. 
 (24) Skirtach, A. G.; Javier, A. M.; Kreft, O.; Kohler, K.; Alberola, A. P.; Mohwald, 
H.; Parak, W. J.; Sukhorukov, G. B. Laser-induced release of encapsulated materials inside 
living cells. Angew. Chem. Int. Ed. 2006, 45, 4612-4617. 
 (25) Veiseh, O.; Gunn, J. W.; Zhang, M. Q. Design and fabrication of magnetic 
nanoparticles for targeted drug delivery and imaging. Adv. Drug Deliv. Rev. 2010, 62, 284-304. 
 (26) Coti, K. K.; Belowich, M. E.; Liong, M.; Ambrogio, M. W.; Lau, Y. A.; Khatib, 
H. A.; Zink, J. I.; Khashab, N. M.; Stoddart, J. F. Mechanised nanoparticles for drug delivery. 
Nanoscale 2009, 1, 16-39. 
 (27) Gao, W. W.; Chan, J. M.; Farokhzad, O. C. pH-Responsive Nanoparticles for 
Drug Delivery. Mol. Pharm. 2010, 7, 1913-1920. 
124 
 
 (28) Jhaveri, A.; Deshpande, P.; Torchilin, V. Stimuli-sensitive nanopreparations for 
combination cancer therapy. J. Control. Release 2014, 190, 352-370. 
 (29) de la Rica, R.; Aili, D.; Stevens, M. M. Enzyme-responsive nanoparticles for drug 
release and diagnostics. Adv. Drug Deliv. Rev. 2012, 64, 967-978. 
 (30) Peer, D.; Karp, J. M.; Hong, S.; FaroKHzad, O. C.; Margalit, R.; Langer, R. 
Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech. 2007, 2, 751-760. 
 (31) Malam, Y.; Loizidou, M.; Seifalian, A. M. Liposomes and nanoparticles: 
nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009, 30, 592-599. 
 (32) Yan, X. J.; An, X. Q. Thermal and photic stimuli-responsive polydiacetylene 
liposomes with reversible fluorescence. Nanoscale 2013, 5, 6280-6283. 
 (33) Amstad, E.; Kohlbrecher, J.; Muller, E.; Schweizer, T.; Textor, M.; Reimhult, E. 
Triggered Release from Liposomes through Magnetic Actuation of Iron Oxide Nanoparticle 
Containing Membranes. Nano Lett. 2011, 11, 1664-1670. 
 (34) Puri, A. Phototriggerable liposomes: current research and future perspectives. 
Pharmaceutics 2013, 6, 1-25. 
 (35) McIntyre, J. O.; Fingleton, B.; Wells, K. S.; Piston, D. W.; Lynch, C. C.; Gautam, 
S.; Matrisian, L. M. Development of a novel fluorogenic proteolytic beacon for in vivo detection 
and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem. J. 2004, 377, 
617-628. 
 (36) Liotta, L. A.; Stetlerstevenson, W. G. Tumor Invasion and Metastasis - an 
Imbalance of Positive and Negative Regulation. Cancer Res. 1991, 51, S5054-S5059. 
125 
 
 (37) Kratz, F.; Muller, I. A.; Ryppa, C.; Warnecke, A. Prodrug strategies in anticancer 
chemotherapy. ChemMedChem 2008, 3, 20-53. 
 (38) Yigit, M. V.; Mishra, A.; Tong, R.; Cheng, J. J.; Wong, G. C. L.; Lu, Y. Inorganic 
Mercury Detection and Controlled Release of Chelating Agents from Ion-Responsive Liposomes. 
Chem. Biol. 2009, 16, 937-942. 
 (39) Chung, M. F.; Chen, K. J.; Liang, H. F.; Liao, Z. X.; Chia, W. T.; Xia, Y. N.; 
Sung, H. W. A Liposomal System Capable of Generating CO2 Bubbles to Induce Transient 
Cavitation, Lysosomal Rupturing, and Cell Necrosis. Angew. Chem. Int. Ed. 2012, 51, 10089-
10093. 
 (40) Dong, R. J.; Zhu, B. S.; Zhou, Y. F.; Yan, D. Y.; Zhu, X. Y. "Breathing" Vesicles 
with Jellyfish-like On-Off Switchable Fluorescence Behavior. Angew. Chem. Int. Ed. 2012, 51, 
11633-11637. 
 (41) Xiang, B.; Dong, D. W.; Shi, N. Q.; Gao, W.; Yang, Z. Z.; Cui, Y.; Cao, D. Y.; Qi, 
X. R. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of 
prostate cancer. Biomaterials 2013, 34, 6976-6991. 
 (42) Farokhzad, O. C.; Cheng, J. J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; 
Richie, J. P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy 
in vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 6315-6320. 
 (43) Liu, J. W.; Cao, Z. H.; Lu, Y. Functional Nucleic Acid Sensors. Chem. Rev. 2009, 
109, 1948-1998. 
 (44) Li, J.; Lu, Y. A highly sensitive and selective catalytic DNA biosensor for lead 
ions. J. Am. Chem. Soc. 2000, 122, 10466-10467. 
126 
 
 (45) Nutiu, R.; Li, Y. F. Structure-switching signaling aptamers. J. Am. Chem. Soc. 
2003, 125, 4771-4778. 
 (46) Yang, C. J.; Jockusch, S.; Vicens, M.; Turro, N. J.; Tan, W. H. Light-switching 
excimer probes for rapid protein monitoring in complex biological fluids. Proc. Natl. Acad. Sci. 
U. S. A. 2005, 102, 17278-17283. 
 (47) Csordas, A.; Gerdon, A. E.; Adams, J. D.; Qian, J. R.; Oh, S. S.; Xiao, Y.; Soh, H. 
T. Detection of Proteins in Serum by Micromagnetic Aptamer PCR (MAP) Technology. Angew. 
Chem. Int. Ed. 2010, 49, 355-358. 
 (48) Oh, S. S.; Plakos, K.; Lou, X. H.; Xiao, Y.; Soh, H. T. In vitro selection of 
structure-switching, self-reporting aptamers. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 14053-
14058. 
 (49) Liu, J. W.; Lu, Y. A colorimetric lead biosensor using DNAzyme-directed 
assembly of gold nanoparticles. J. Am. Chem. Soc. 2003, 125, 6642-6643. 
 (50) Willner, I.; Shlyahovsky, B.; Zayats, M.; Willner, B. DNAzymes for sensing, 
nanobiotechnology and logic gate applications. Chem. Soc. Rev. 2008, 37, 1153-1165. 
 (51) Xue, X. J.; Wang, F.; Liu, X. G. One-step, room temperature, colorimetric 
detection of mercury (Hg2+) using DNA/nanoparticle conjugates. J. Am. Chem. Soc. 2008, 130, 
3244-3245. 
 (52) Willner, I.; Zayats, M. Electronic aptamer-based sensors. Angew. Chem. Int. Ed. 
2007, 46, 6408-6418. 
 (53) Lubin, A. A.; Plaxco, K. W. Folding-Based Electrochemical Biosensors: The 
Case for Responsive Nucleic Acid Architectures. Acc. Chem. Res. 2010, 43, 496-505. 
127 
 
 (54) Swensen, J. S.; Xiao, Y.; Ferguson, B. S.; Lubin, A. A.; Lai, R. Y.; Heeger, A. J.; 
Plaxco, K. W.; Soh, H. T. Continuous, Real-Time Monitoring of Cocaine in Undiluted Blood 
Serum via a Microfluidic, Electrochemical Aptamer-Based Sensor. J. Am. Chem. Soc. 2009, 131, 
4262-4266. 
 (55) Yigit, M. V.; Mazumdar, D.; Lu, Y. MRI detection of thrombin with aptamer 
functionalized superparamagnetic iron oxide nanoparticles. Bioconjugate Chem. 2008, 19, 412-
417. 
 
 
 
 
 
 
 
 
 
 
 
 
 
128 
 
4.6. Figures 
 
Figure 4.1. Schematic of the target-responsive liposomes for the multimodal detection of small 
molecule targets using PLA2 enzyme triggered method. 
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Figure 4.2. (a) Formulation of target-responsive liposome and the hydrolysis reaction of smart 
liposome catalyzed by PLA2 enzyme. (b) Cryo-EM micrograph of smart liposomes. (c) DLS 
results of smart liposome samples diluted in buffer (black) and PLA2-containing buffer (red). 
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Figure 4.3. (a) The conjugation chemistry of DNA and PLA2 by the hetero-bifuntional linker 
sulfo-SMCC. (b) Protein-staining (left) and fluorescence (right) and image of native PAGE gel 
(4-20% gradient) for the DNA-PLA2 conjugation product. (b) UV-Vis absorption spectra of 
DNA, PLA2, and DNA−PLA2 conjugate. 
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Figure 4.4. Enzymatic activity tests of PLA2 with the reaction time of 15 min (a) and 2 hours (b). 
Top: calibration curve of fluorescent intensity from hydrolyzed liposomal uranin to PLA2 of 
different concentration concentrations. Bottom: corresponding photograph images. Sample with 
green label is no PLA2 negative control and sample with red label is fully ruptured positive 
control. (c) Kinetic calibration curve of the fluorescence intensity versus the incubation time with 
16 nM PLA2 concentration. 
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Figure 4.5. Design and performance of fluorescence detection of cocaine. (a) Cocaine-induced 
release of immobilized DNA–PLA2 conjugates. (b) Fluorescence spectra of the supernatants of 
smart liposomes treated with released DNA–PLA2 conjugates upon the addition of cocaine at 
different concentrations. (b)  Calibration curve of the fluorescent detection of cocaine using 
uranin-containing smart liposome. 
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Figure 4.6. Representative photograph (a) and MRI image (b) of a 96-well plate with a series of 
samples corresponding to different cocaine concentrations. 
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Figure 4.7. (a) Calibration curve of the T1 relaxation time respond to the presence of different 
cocaine concentrations. (b) The selectivity of the MRI detection method. The significant T1 
increase can only be observed with the existence of cocaine. (c) MRI images of Gd-liposome 
supernatant solutions after the incubation with cocaine solution of different concentration 
(inversion time of 800 ms and repetition time of 2000 ms). 
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Figure 4.8. (a) Photo image of the self-built photothermal chamber with a NIR laser pointer (1 
W, ~1.5 mm in diameter for illumination area) and a 96-well colorless plate. (b) Photo image of 
the super-fast thermapen with 3-second readings that used to detect the temperature change 
during laser irradiation. (c) Probe tip with minimum immersion of 3.2 mm, which could measure 
the solution temperature in a small volume (180 µL). 
 
 
 
 
 
 
136 
 
 
Figure 4.9. (a) Cocaine detection in buffer using the PTM. Inset: comparison of temperature 
increase at low concentration of cocaine. (b) Selectivity of the PTM-based detection of cocaine 
using adenosine and glucose as control molecules. 
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Figure 4.10. Design and performance of UO2
2+ detection using PTM system. (a) UO2
2+-induced 
release of immobilized DNA–PLA2 conjugates. (b) UO22+ detection in buffer using the PTM. (c) 
Selectivity of UO2
2+ detection using PTM system (UO2
2+, 500 nM; Ca2+, Mg2+, 100 µM; other 
metal ions, 1 µM). 
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CHAPTER 5 
SELECTIVE DELIVERY OF APTAMER-FUNCTIONALIZED 
LIPOSOMES TO BREAST CANCER CELLS IN VITRO AND IN VIVO 
Part of this chapter was published as:  
1. “Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast 
Cancer Cells in vitro and in vivo”, Hang Xing, Li Tang, Xujuan Yang, Kevin Hwang, Wendan 
Wang, Qian Yin, Ngo Yin Wong, Lawrence W. Dobrucki, Norio Yasui, John Katzenellenbogen, 
William Helferich, Jianjun Cheng, Yi Lu, Journal of Material Chemistry B,  2013, 1, 5288-5297.  
5.1. Introduction 
A major challenge in nanomedicine for cancer diagnosis and therapy is the delivery of 
imaging agents or anticancer drugs specifically and efficiently.1-5 To achieve this goal, the use of 
targeting or recognition motifs for active targeting is considered one of the most promising 
approaches.6,7 Small molecules, targeting peptides, as well as antibodies have been widely 
reported as targeting agents.8-10 However, when incorporated with nanomaterials, the properties 
of the resulting constructs are often dictated more by the material used rather than the targeting 
agent,11,12 and consequently developing targeted nanomedicines capable of potential clinical use 
is still challenging.13,14 
To meet these challenges, DNA aptamers have been investigated as a new class of 
targeting agent.15-17 Aptamers are single-stranded oligonucleotides that can bind to target 
molecules with excellent specificity and affinity.18-22 In comparison to antibodies, which suffer 
from problems with instability and immunogenicity, DNA aptamers are stable in harsh 
environments and have been demonstrated to be nonimmunogenic.23 They are easier to prepare 
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and to conjugate to nanomedicine-based platforms.24,25 In addition, the targeting functionality of 
DNA aptamers can be inhibited by complementary DNA sequences, which can thus function as a 
specific antidote to prevent overdosage in drug delivery.26 Moreover, in comparison with various 
previously reported RNA aptamers, DNA aptamers showed reduced susceptibility to 
biodegradation, which makes them more favorable for clinical applications. 
Liposomes are one of the most successful nanomedicine delivery platforms, and have 
been used to deliver a wide variety of small molecules, genes, imaging agents, and even 
nanoparticles.27,28 Compared with other delivery systems, liposomes offer superior 
biocompatibility, biodegradability, reduced toxicity and improved control over size and surface 
functionality.29 Since liposomes have previously been approved by the United States Food and 
Drug Administration (FDA) for a number of clinical therapies, starting from this scaffold and 
incorporating DNA aptamers to incorporate targeting functionality should potentially facilitate 
the translation to clinical practice. Despite this promise, few studies of DNA aptamer-
nanomedicine constructs have shown successful efficacy in vivo, even though the use of DNA 
aptamers for targeted drug delivery in vitro has been reported.26 Demonstrating the efficacy both 
in vitro and in vivo is important to advance nanomedicine. 
In order to investigate this issue, we prepared a nanoscale liposome modified with a 26-
mer guanosine-rich DNA aptamer AS1411. AS141 has strong binding affinity to nucleolin 
(NCL), a bcl2 mRNA-stabilizing protein overexpressed on the plasma membrane of many types 
of cancer cells, including leukemia and breast cancers.30-33 AS1411 has been shown to be 
remarkably stable against nuclease degradation in serum, which is attributed to the formation of 
the G-quartet structure.34 Further pharmacokinetic studies have shown enhanced stability of 
AS1411 in blood in vivo, which overcomes one of the major limitations reported for potential 
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aptamer use in clinical practice.35 In previous work, we have demonstrated that the AS1411 
DNA aptamer (Apt) facilitated the cellular uptake of cisplatin-containing liposomes and showed 
higher cytotoxicity to MCF-7 cells than the same liposome system without the aptamer or with a 
non-aptameric DNA strand (Ctrl).26 While these in vitro results are promising, it is important to 
demonstrate the efficacy of the approach in vivo for future clinical applications.  
In this study, we report the preparation of AS1411 aptamer-functionalized liposomes 
containing an anticancer drug, doxorubicin (Dox). The targeted liposomal doxorubicin (Apt-
Dox-Lip) showed selective internalization and enhanced cytotoxicity to MCF-7 breast cancer 
cells. Athymic nude mice bearing xenograft MCF-7 tumors treated with intratumorally injected 
Apt-Dox-Lip exhibited an earlier onset of tumor inhibition and improved anticancer efficacy 
when compared with non-aptameric DNA modified congeners, which is attributable to enhanced 
tumor penetration and cellular internalization. 
5.2. Results and Discussion 
Preparation and characterization of DNA-functionalized liposomes 
Figure 5.1 illustrates the basic design and formulation of aptamer-functionalized 
liposomes containing different cargos. The sequence of the NCL aptamer used is 5'-GGT GGT 
GGT GGT TGT GGT GGT GGT GGT TTT TTT TTT TT-Cholesterol-3'. The poly-T region in 
the above sequence serves as a spacer to separate the aptamer recognition sequence from the 
hydrophobic cholesterol end. A non-aptameric DNA sequence 5'-GAG AAC CTG AGT CAG 
TAT TGC GGA GAT TTT TTT TTT TT-Cholesterol-3' was used as a control. Doxorubicin 
hydrochloride was chosen as the anticancer agent. The liposomes were formulated from HSPC, 
cholesterol, and mPEG2000–DSPE at a molar ratio of 2:1:0.16.36 The aptamer-modified 
liposome structurally resembles Doxil®, an FDA-approved, doxorubicin-containing liposome, 
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except that the latter has no targeting ligand incorporated.37 This well-established formulatioin 
has been demonstrated to have intriguing features for in vivo applications. The combination of 
HSPC and DSPE possesses relatively high transition temperature at 48 °C, providing liposomes 
with high rigidity and low permeability at 37 °C.36 Free cholesterol molecules serve as 
hydrophobic anchors to increase the hydrophobic-hydrophobic interactions in lipids bilayer as 
well as the rigidity and stability of liposomes.36 The inert, hydrophilic PEG modification reduces 
the nonspecific uptake of liposomes.38 The formulation of liposomes provides an excellent 
system with long-term stability suitable for the in vivo study of aptamer-directed targeted drug 
delivery. 
The NCL aptamer-functionalized liposomes of ~200 nm in diameter were prepared 
according to a previously published protocol, using polycarbonate membrane supported 
extruders.26 In a typical experiment, the overall lipid concentration was controlled at ~8 mg mL-
1 in the presence of 12 µM cholesterol-DNA in a preparation buffer (pH 7.4) containing 25 mM 
HEPES, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, and 1 mM CaCl2. The prepared Dox-
containing Apt-liposomes can be easily concentrated via centrifugation (Figure 5.2a). Under a 
fluorescence microscope, a solution of dye-containing liposomes was observed as separate bright 
dots, confirming the formation of lipid vesicles (Figure 5.2b). To further elucidate the structure 
and morphology of aptamer-modified liposomes, Cryo-EM experiments were performed. As 
shown in Figure 5.3a, the liposomes appeared spherical with a lipid bilayer membrane thickness 
of several nanometers. The average size is around ~200 nm, which agrees well with the pore size 
of the polycarbonate membrane used in preparation. 
To demonstrate the functionalization of liposomes with the DNA aptamer and to achieve 
a quantitative measure of the DNA density on each liposome, we used a commercially available 
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green-fluorescent stain, OliGreen® ssDNA reagent, to measure the DNA concentration. Prior to 
the staining process, Triton-X and heat treatment (80 °C) was used to break the lipid vesicles and 
release DNA strands. The ruptured liposome samples were incubated with the OliGreen® reagent 
for 10 min and excited at 480 nm. As shown in Figure 5.3b, liposomes without the DNA aptamer 
functionalization showed only a low level of background fluorescence. After attachment of DNA 
aptamer, Apt-Lip and Ctrl-Lip samples exhibited a strong fluorescence emission peak at 520 nm 
after staining, demonstrating the presence of ssDNA. Quantitative measurement of DNA 
concentration in the liposome samples was achieved using a calibration curve generated from a 
series of standard DNA solutions (Figure 5.4). The DNA aptamer concentration of Apt-Lip 
sample was calculated to be 9.7 µM, with a corresponding conjugation efficiency of ~34.6%.  
The DNA density per liposome was estimated to be ~1.1 nmol DNA adsorbed on 1.0 mg of 
lipids.  
The DNA-functionalized liposomes were further characterized by Dynamic Light 
Scattering (DLS) and zeta-potential measurements. Liposomes without the DNA aptamer 
functionalization showed an average hydrodynamic diameter of 190 ± 16 nm, which is consistent 
with the Cryo-EM images. After DNA functionalization, an average hydrodynamic diameter of 
210 ± 20 nm was observed for both aptamer and control DNA-modified liposomes (Figure 5.3c). 
In order to further understand the effect of DNA modification on the surface of liposomes, we 
measured the zeta-potential of different liposome samples. In a 5 mM HEPES buffer (pH 7.4) 
containing 10 mM NaCl, liposomes without the DNA aptamer functionalization displayed a zeta-
potential of -4 ± 2 mV, which is consistent with previously reported values for liposomes with 
this composition.25 After conjugation with the DNA strands, the zeta-potential of control and 
aptamer DNA-modified liposome samples decreased to approximately -15 ± 5 mV, further 
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indicating the attachment of negatively charged DNA strands on the surface of the liposomes 
(Figure 5.3d). 
Since the in vivo biological microenvironment is significantly different from the liposome 
preparation buffer, it is critical to evaluate the stability of the liposomes under physiological 
conditions before proceeding to cellular and animal studies. In order to evaluate the stability of 
the DNA-modified liposomes, we monitored the fluorescence intensity of NCL aptamer-
modified, uranin-containing liposome samples (Apt-Urn-Lip) after incubation at 37 °C in 50% 
human serum over a period of 24 hours (Figure 5.5a). Fully ruptured Apt-Urn-Lip samples were 
used as positive control group to illustrate the fluorescent intensity after complete release of 
uranin (black line). As shown in Figure 5.5b, after 24 hours at 37°C in 50% human serum, less 
than ~10% of the maximum possible enhancement of fluorescence intensity was observed, 
suggesting only minimal decomposition of the liposome samples and minimal leakage of 
encapsulated uranin. Similar release profile was observed for doxorubicin-loaded liposome 
samples (Figure 5.6). These results indicate that the aptamer modified liposome samples are 
highly stable in 50% human serum with well-preserved fluorescent properties. 
Towards the goal of achieving an enhanced anticancer therapy in vivo, it is also critical to 
control the drug loading in order to provide sufficient anticancer agent in the aptamer-liposome 
system. The DNA-lipid mixture was incubated with ~25 mg mL-1 Dox solution to achieve high 
Dox loading. The fluorescence of the DNA-Dox-Lip sample was measured by excitation at 480 
nm before and after heat treatment (Figure 5.7a). According to a standard curve of free 
doxorubicin, the equivalent Dox concentration of a typical Apt-Dox-Lip sample was calculated 
to be 0.92 mg mL-1 based on fluorescence emission intensity of fully decomposed liposomes at 
592 nm (Figure 5.7b, S4c). The drug-to-lipid ratio of the Apt-Dox-Lip sample was estimated to 
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be 0.097 (w/w), which is comparable to the 0.125 (w/w) drug-to-lipid ratio of Doxil®,39 
suggesting a sufficient drug loading capacity for in vivo study. 
In vitro targeting capability of aptamer-functionalized liposomes 
To assess the targeting capability of aptamer-functionalized liposomes, uranin-loaded 
liposomes that were modified with control DNA (Ctrl-Urn-Lip, 50 µM) or NCL-Apt (Apt-Urn-
Lip, 50 µM) were incubated with MCF-7 cells separately, and the fluorescence of the treated 
cells was analyzed by flow cytometry (Figure 5.8a and Table 5.1).  The results showed a 6.6-fold 
increase in mean fluorescence intensity in MCF-7 cells treated with Apt-Urn-Lip versus those 
treated with Ctrl-Urn-Lip (Table 5.1). It is also noticeable that 93.6% of cells incubated with 
Apt-Urn-Lip for 4 hours showed a fluorescent response, compared to 57.0% for Ctrl-Urn-Lip 
(Table 5.1). When the concentration of Urn-Lip was increased to 500 µM, a similar trend was 
also observed (Figure 5.9). The results clearly demonstrated the enhanced binding of Apt-Urn-
Lip to the MCF-7 cells compared with Ctrl-Urn-Lip, presumably due to the selective affinity 
between the NCL aptamer and the nucleolin which was overexpressed on the plasma membrane 
of MCF-7 cells. 
We next investigated whether the increased binding of Apt-Urn-Lip to MCF-7 cells 
indeed resulted in enhanced cellular uptake of liposomes by MCF-7 cells. Using confocal 
fluorescence microscopy with fine z-axis resolution, we studied the localization of Urn-Lip in the 
treated cells (Figure 5.8b). The nuclei of MCF-7 cells were stained with 4',6-diamidino-2-
phenylindole (DAPI, shown as blue in Figure 5.8b), and the liposomes were labeled with uranin 
(shown as green in Figure 5.8b). More green fluorescence was observed in the cytoplasm of the 
MCF-7 cells treated with Apt-Urn-Lip than Ctrl-Urn-Lip, demonstrating that Apt-Urn-Lip was 
more efficiently internalized by MCF-7 cells. Furthermore, Apt-Urn-Lip was specifically 
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internalized by cells which overexpress NCL on the cell membrane, i.e. MCF-7 cells (NCL(+)), 
but not by LNCaP cells (NCL(-)) (Figure 5.10). Together, these results showed that the NCL 
aptamer-modified liposomes targeted MCF-7 cells selectively and efficiently due to the specific 
binding of the aptamer to NCL overexpressed on cell membrane. 
To evaluate whether the NCL aptamer-functionalized, Dox-containing liposomes can 
increase the toxicity of the drug to the cancer cells, we further investigated the cytotoxicity of 
doxorubicin-loaded, PEGylated liposomes, modified either with NCL aptamer (Apt-Dox-Lip) or 
a control DNA sequence (Ctrl-Dox-Lip). The MCF-7 cells were first incubated with Dox, Ctrl-
Dox-Lip or Apt-Dox-Lip samples for 6 h to allow specific and efficient cellular internalization of 
the targeted liposomes. The cells were further cultured in fresh medium for a total of 72 h before 
the assessment of cell viability by MTT assay. The results suggested that Apt-Dox-Lip showed 
significantly higher cytotoxicity to MCF-7 cells as compared to Ctrl-Dox-Lip (p< 0.01). As 
shown in Figure 5.8c, the cell viabilities were 57.0 ± 6%, 75.0 ± 4%, and 80.9 ± 4% (mean ± SD) 
for MCF-7 cells treated with Apt-Dox-Lip at equivalent Dox concentration of 500 µM, 100 nM 
and 10 nM, respectively. In contrast, the cell viabilities were 92.4 ± 9%, 107.2 ± 7%, and 109.7 ± 
13% for cells treated with Ctrl-Dox-Lip at the same concentrations, respectively. There was no 
statistical significance when comparing the cytotoxicity of free Dox and Apt-Dox-Lip, 
suggesting that all the Dox loaded in Apt-Dox-Lip was eventually released and available to the 
cancer cells. Although the AS1411 aptamer itself has been reported to be cytotoxic towards 
MCF-7 cells,40 the amount of aptamer used here was much less than that necessary to cause 
significant cell death.41 The cell viability was mainly determined by the amount of Dox delivered 
into the MCF-7 cells. Therefore, Apt-Dox-Lip can strongly bind to and be internalized by MCF-
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7 cells, leading to selective delivery of the encapsulated anticancer drug into cells and improved 
antiproliferative activity in cancer cells in vitro. 
In vivo antitumor efficacy of aptamer-functionalized liposomes 
 We next examined the efficacy of Apt-Dox-Lip on the inhibition of growth of MCF-7 
tumors, which were established by injecting MCF-7 cells subcutaneously into athymic nude 
mice. Human breast cancer MCF-7 cells are hormone-dependent cells, requiring estrogen to 
maintain the growth of primary tumors in mice.42,43 Therefore, the engraftment and growth of 
MCF-7 tumors was supported by estrogen pellets subcutaneously implanted in the interscapular 
region of the mice prior to cell injection. Nude mice were treated with Apt-Dox-Lip or Ctrl-Dox-
Lip (25 μg Dox equivalent per tumor) every 4 days. Tumors were measured every 4 days, and the 
tumor growth curves are displayed in Figure 5.12a. Tumors in the E2 group maintained a high 
growth rate in the presence of exogenous estrogen released by the E2 pellets, and the relative 
average tumor size increased to 166% at the end of the study (day 24) compared to the tumor 
size at the start of treatment (Figure 5.12b). Analysis of relative tumor size using the PROC 
MIXED of SAS showed that the Apt-Dox-Lip significantly inhibited MCF-7 tumor growth 
induced by E2 through the study duration, and is more effective than the Ctrl-Dox-Lip control 
group (p = 0.004, Figure 5.12a). At the end of the study, the observed relative tumor size of 95% 
in the Apt-Dox-Lip group was significantly different from the 120% observed in the Ctrl-Dox-
Lip group (Figure 5.12b). Furthermore, treatment with Apt-Dox-Lip caused an earlier onset of 
tumor inhibition on Day 8 when compared with the onset of Day 16 in Ctrl-Dox-Lip (Table 5.2). 
These results strongly suggested that Apt-Dox-Lip inhibited estrogen-induced MCF-7 tumor 
growth more effectively when compared with Ctrl-Dox-Lip.  
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To examine the toxicity of Apt-Dox-Lip to mice, the body weights of mice were 
monitored weekly to assess their overall health. The SAS PROC MIXED analysis of the 
interaction of time and treatment showed no difference between the E2, Apt-Dox-Lip and Ctrl-
Dox-Lip groups (Figure 5.11a), indicating that the overall health of the animals was not affected 
during the course of the study. The 3 experimental groups also maintained 100% survival rate 
throughout the study. Daily food intake was measured twice, and no significant differences were 
found in food intake among the 3 experimental groups in this study. (Figure 5.11b). 
Tumor penetration study of aptamer-functionalized liposomes 
To investigate the possible reasons for the enhanced efficacy of Apt-Dox-Lip in 
suppressing MCF-7 tumor growth, we compared the tumor penetration behavior of Apt-Dox-Lip 
and Ctrl-Dox-Lip after  they were injected intratumorally into the MCF-7 tumors in mice. The 
tumors were collected 1 h post injection, sectioned and stained with DAPI (Figure 5.13a). The 
fluorescence microscope images of the whole injection area revealed a marked increase of 
penetration depth into surrounding tumor tissues by Apt-Dox-Lip as compared to Ctrl-Dox-Lip 
(Doxorubicin fluorescence shown in red). The fluorescence intensity plot profile was analyzed 
by ImageJ, as shown in Figure 5.14. The center of peak correlates to the initial injection site and 
the half width of the peak is an estimate of the penetration radius from the injection site to the 
surrounding tissues. Tumor sections treated with Apt-Dox-Lip showed not only overall enhanced 
fluorescence intensity (y axis of Figure 5.14), but also a larger area with fluorescence (x axis of 
Figure 5.14). Apt-Dox-Lip penetrated up to ~1000 µm from the injection site at 1 h post injection 
while Ctrl-Dox-Lip exhibited much smaller penetration depth (~500 µm).  
The passive diffusion of the liposomes into tumors was also evaluated in an ex vivo 
experiment to compare their penetration in tumor tissues mimicking the situation of a 
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intratumoral injection of liposomes. MCF-7 tumors collected from athymic nude mice were 
incubated with Apt-Urn-Lip or Ctrl-Urn-Lip in cell medium for 24 h. The tumors were then 
collected, sectioned, stained with DAPI and imaged via confocal microscope. The results shown 
in Figure 5.15 suggest that Apt-Urn-Lip was taken up more in tumor tissues than Ctrl-Urn-Lip 
(Uranin shown in green fluorescence). Together, these results demonstrated that Apt-Dox-Lip 
could better penetrate MCF-7 tumor tissue due to the targeting effect of surface bound NCL-Apt, 
thus facilitating the efficient delivery of anticancer drugs more deeply into tumor tissues than 
Ctrl-Urn-Lip. This could be one of the reasons that Apt-Urn-Lip showed improved efficacy 
against MCF-7 tumors. 
To further determine whether the liposomes were actually internalized by cancer cells 
inside tumor tissue or simply stayed in the interstitial space of tumor tissues, the MCF-7 cells in 
the tumor tissue sections were analyzed with confocal fluorescence microscopy (Figure 5.13b). 
Much more red fluorescence was observed inside MCF-7 cells in the tissue sections from the 
mice treated with Apt-Dox-Lip than Ctrl-Dox-Lip, suggesting that the targeted liposomes also 
enhanced cellular internalization in vivo. This result agreed well with the observed enhancement 
in internalization by MCF-7 cells in vitro as demonstrated above. 
Apt-Dox-Lip are favored for the uptake by MCF-7 cells resulting more efficient delivery 
of anticancer drug, doxorubicin, to the cancer cells in vivo, thus leading to more efficient killing 
of cancer cells. Our observations agree well with previous reports by Kirpotin et al.44 and Choi et 
al.45, where antibody anti-HER2 and transferrin were used as targeting ligands respectively. 
Likely, the active targeting ligand on liposome surface did play a role in sub-organ distribution 
and in vivo cellular internalization. Once the liposomes are inside the tumors, the specific 
binding between Apt-Dox-Lip and nucleolin expressed on MCF-7 cell surface facilitate the 
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enhanced tissue penetration and internalization by cancer cells. Thus, doxorubicin was delivered 
more efficiently in vivo by AS1411 aptamer-functionalized liposomes into MCF-7 cells of the 
tumor, which lead to the improved antitumor efficacy. 
5.3. Conclusions 
In conclusion, we demonstrated the successful formulation of doxorubicin-encapsulated, 
AS1411 aptamer-functionalized liposomes as a drug delivery system that was able to target 
nucleolin. In vitro studies showed the high targeting efficiency of AS1411 aptamer-
functionalized liposomes toward MCF-7 cells with overexpressed nucleolin. Enhanced 
cytotoxicity and antitumor efficacy were observed in MCF-7 cells and in MCF-tumor bearing 
mice with the use of AS1411 aptamer-functionalized liposomes versus control liposomes. 
Aptamer-functionalized liposomes exhibited enhanced tumor penetration ability, which could 
account for the improved antitumor efficacy observed in vivo.  In conjuction with the high 
stability and excellent biocompatibility of liposomes, the AS1411 aptamer-functionalized 
liposome demonstrated here may have potential for development as cancer therapeutic agents. 
5.4. Experimental Section 
Chemicals and materials 
Chemicals and reagents used in this study were obtained from Sigma-Aldrich Inc. (St. 
Louis, MO) and used as received. HSPC, cholesterol, mPEG2000-DSPE, and extruder were 
obtained from Avanti Polar Lipids, Inc (Alabaster, AL). Sephadex G-100 medium was purchased 
from GE Healthcare (Chalfont St. Giles, UK). OliGreen® ssDNA Reagent was obtained from 
Invitrogen (Carlsbad, CA). All oligonucleotides used in this study were purchased from 
Integrated DNA Technologies Inc. (Coralville, IA) with the following sequences: 
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NCL-Aptamer (Apt): 5'-GGT GGT GGT GGT TGT GGT GGT GGT GGT TTT TTT 
TTT TT-Cholesterol-3'. 
Random DNA (Ctrl): 5'-GAG AAC CTG AGT CAG TAT TGC GGA GAT TTT TTT 
TTT TT-Cholesterol-3'. 
Formulation of liposomes 
DNA-functionalized, cargo-loaded liposomes are prepared according to a previously 
published method, 26 with some modifications. Stock solutions of 50 mg mL-1 of HSPC (3.0 mg), 
cholesterol (0.77 mg), and mPEG2000–DSPE (0.89 mg) in chloroform were mixed in a 2:1:0.16 
molar ratio in a scintillation vial. This mixture was blown dry with N2 and further dried under 
vacuum overnight. The liposome preparation buffer contained 25 mM 2-[4-(2-hydroxyethyl)-1-
piperazinyl]-ethane sulfonic acid (HEPES, pH 7.4), 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 
and 1 mM CaCl2. The buffer solution (100 µL) was added to the dry lipids followed by addition 
of 7 nmol of cholesterol-tagged DNA. After the mixture was incubated for 6 h at 37 °C, 400 µL 
of liposome preparation buffer containing 25 mg mL-1 doxorubicin was added. A doxorubicin 
stock solution was prepared by dissolving the drug in 25 mM HEPES preparation buffer at 50 °C 
followed by cooling to 37 °C for incubation with lipids. The overall lipid concentration was 
estimated to be ~4.7 mg mL-1 with a DNA concentration of 14 µM for the mixture. This solution 
was gently stirred and kept at 37 °C for 3 h. After that, the solution was stirred and then 
alternatively flash-frozen in liquid nitrogen and thawed at least 5 times each. The final solution 
was incubated at 37 °C overnight. The lipid mixture was then extruded to form liposomes of 
~200 nm in diameter following the instructions from Avanti Polar Lipids, Inc. The liposomes 
were purified on a column containing Sephadex G-100 medium to remove free DNA and 
doxorubicin. Fluorescence spectra of fully decomposed liposome samples were used to 
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determine the concentration of encapsulated fluorescent cargo by plotting a standard curve of 
fluorescence emission intensity versus concentration. DNA-functionalized liposome samples 
were standardized to the same corresponding cargo concentration before any imaging or therapy 
experiments. For the in vivo tumor efficacy study, the doxorubicin concentration of control and 
aptamer liposome samples was standardized to ~1 mg mL-1 for consistency. In a typical 
experiment, two vials of lipid mixture will generate approximately 500 µL of ~1 mg mL-1 
doxorubicin-loaded liposome samples. 
Typically, liposomes are characterized after extrusion. These characterization methods 
include: loading capacity estimation, stability and release profile test, size measurement by using 
cryo-EM and DLS, surface charge estimation by measuring the ζ-potential. 
Determination of DNA concentration, density and conjugation efficiency 
The OliGreen® ssDNA reagent (Invitrogen, USA) was utilized to measure the 
concentration of DNA strands. DNA-modified liposome samples were treated with Triton-X and 
heated at 80 °C for 20 minutes to rupture liposomes and release DNA strands prior to the 
staining process. A standard curve was obtained from a series of standard DNA solutions 
following manufacturer’s instructions. 
Microscope characterization 
In cell staining and microscope images, in order to focus on the evaluation of pure 
internalization of the aptamer-modified liposome, the fluorescent dye uranin was loaded into 
liposomes instead of Dox to avoid cell death due to the cytotoxicity of Dox. Fluorescence 
microscope images of uranin-loaded liposomes (Urn-Lip) were acquired with a Zeiss Axiovert 
200M inverted microscope equipped with an EC Epiplan 40× objective and CCD camera under 
152 
 
mercury lamps for excitation. The digital camera was white-balanced using Zeiss Axiovision 
software before data acquisition. Measurement of fluorescence spectra of liposome samples was 
carried out in a Fluoromax-P fluorimeter (Horiba Jobin Yvon, Edison, NJ) at room temperature.  
For MTT assay, the absorbance wavelength on a Victor3TM V microplate reader (Perkin-
Elmer, Waltham, MA) was set at 590 nm. Flow cytometric analysis of cells was conducted using 
a BD FACSCanto 6 color flow cytometry analyzer (BD, Franklin Lakes, NJ).  
MCF-7 cells (250,000 per well) were plated in a 4-well chamber slide and treated with 
Ctrl-Urn-Lip or Apt-Urn-Lip with same total fluorescence intensity at 37 ºC for 4 h before 
confocal microscopy study. The confocal microscopy images for cell internalization studies were 
taken on a LSM700 Confocal Microscope (Carl Zeiss, Thornwood, NY) using a 63× / 1.4 oil 
lens with excitation wavelengths set at 405 nm, 488 nm and 555 nm.    
 For the ex vivo tumor penetration study, the flash frozen tumor tissue embedded with 
optimum cutting temperature (O.C.T.) compound (Sakura Finetek, USA) was sectioned (5 µm 
thick) with a Leica CM3050S cryostat and mounted on glass slides. Tissue sections were 
observed on an Axiovert 200M fluorescence microscope (Carl Zeiss, Thornwood, NY). 
Fluorescent images were taken on a Zeiss Axiovert 200M fluorescence microscope. A tiling 
image was taken with fixed exposure time to show the penetration of Urn-Lip in tumor sections. 
For the in vivo tumor penetration study, flash frozen tumor sections measuring 10 µm in 
thickness were imaged on an Axiovert 200M fluorescence microscope and LSM700 confocal 
microscope. The nucleus was stained by DAPI. Fluorescence images were taken on a Zeiss 
Axiovert 200M fluorescence microscope to image the whole injection area. Cellular 
internalization in the selected area of tissue sections were further analysed with a LSM 700 
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confocal microscope. Tissue sections were imaged with a 63× and 0.3 NA lens. Doxorubicin 
fluorescence, representing Dox-Lipo, was visualized with 555 nm laser excitation. 
Cryo-EM characterization  
Cryo-EM samples of liposomes were prepared using a Vitrobot. Briefly, a drop of 
liposome solution was applied onto a TEM grid, the grid was then blotted and immediately 
plunge-frozen into ethane slush cooled by liquid nitrogen. The as-prepared sample, on TEM grid, 
was then transferred onto a cryo holder via a Gatan CT3500 Cryotransfer system, which was pre-
cooled with liquid nitrogen. The images were obtained on a JEOL 2100 transmission electron 
microscope at an acceleration voltage of 80 kV. 
DLS and zeta-potential measurement  
To estimate the size and charge of the liposomes, dynamic light scattering and zeta-
potential experiments were performed using a Malvern Zetasizer Nano ZS (Malvern Instruments, 
UK). Freshly prepared unmodified or DNA-conjugated liposomes were dispersed in a buffer 
containing 10 mM NaCl, 5 mM HEPES at pH 7.4 to a lipid concentration of ~0.1 mg mL-1 for 
size and zeta-potential measurement. The reported hydrodiameter and zeta-potential of liposome 
samples was calculated from the algebraic average of twenty measurements. Errors represent 
standard deviation. 
Cell culture 
MCF-7 and LNCaP cells (ATCC, Manassas, VA) were cultured in DMEM medium 
containing 10% Fetal Bovine Serum (FBS) and supplemented with 1000 units mL-1 aqueous 
Penicillin G, 100 μg mL-1 streptomycin (Invitrogen, Carlsbad, CA).  For the culture of MCF-7 
cells, 1 nM estrogen (Sigma-Aldrich Inc., St. Louis, MO) was added to the cell media. 
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In vitro cellular internalization and cytotoxicity studies 
MCF-7 cells were seeded, washed, and incubated with Opti-MEM containing either Apt-
Urn-Lip or Ctrl-Urn-Lip (50 µM lipid equivalent) samples. The cells were stained, fixed, and 
then subsequently imaged on a confocal laser scanning microscope (LSM700, Carl Zeiss, NY). 
Cells without the addition of Urn-Lip were imaged as control. Both the percentage of the 
fluorescent cells relative to the total analyzed cells and the fluorescence intensity of the 
fluorescence-positive cells were assessed. 
Fresh medium containing Dox, Ctrl-Dox-Lip, or Apt-Dox-Lip in concentrations ranging 
from 10 nM to 500 nM of Dox or equivalent Dox was used for cytotoxicity study. Cell viability 
was determined by the MTT assay. Standard MTT assay protocols were followed thereafter.46 
Cellular internalization  
 MCF-7 cells (250,000) were seeded in a 4-well chamber slide for 24 h (37 °C, 5% CO2). 
Cells were washed once with Opti-MEM and then incubated for 4 h (37 °C) with 1 mL Opti-
MEM containing either Apt-Urn-Lip or Ctrl-Urn-Lip (50 µM lipid equivalent). The cells were 
then washed with PBS (3 x 1 mL), fixed with 4% paraformaldehyde, and subsequently imaged 
on a confocal laser scanning microscope. Nuclei were stained by DAPI. Cells without the 
addition of Urn-Lip were imaged as control.  
 To examine cell uptake of Urn-Lip, MCF-7 cells (200,000) were seeded in a 12-well plate 
for 24 h. Urn-Lip (50 µM or 500 µM lipids in equivalent) were incubated with the cells in opti-
MEM (1 mL) for 2 h (37 °C, 5% CO2). The cells were then washed with PBS (3 x 1 mL) and 
detached via trypsinization. Cells were fixed with 4% paraformaldehyde for flow cytometry 
analysis (10,000 cells analysed, green fluorescence, FITC channel). Both the percentage of the 
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fluorescent cells relative to the total analysed cells and the fluorescence intensity of the 
fluorescence-positive cells were assessed. The marker was set such that 1.0% of non-treated cells 
were fluorescently positive. All experiments were performed in triplicate. 
Cytotoxicity (MTT assay) 
 MCF-7 cells (3,000 per well) were seeded in 96-well plates and grown in DMEM 
medium containing 10% FBS and 1 nM estrogen at 37 °C for 24 h in a humidified 5% CO2 
atmosphere. The medium was then replaced with fresh medium containing Dox, Ctrl-Dox-Lip, or 
Apt-Dox-Lip in concentrations ranging from 10 nM to 500 nM of Dox or equivalent Dox. At 
each concentration six wells per plate were treated. The cells were treated for 6 h and then the 
drug-containing media was replaced with fresh media. The cells were further incubated for 66 h. 
The cells were subsequently washed and incubated in media for a total of 72 h before assessing 
cell viability by MTT assay in each group. The standard MTT assay protocols were followed 
thereafter 46.  
Animals 
Female athymic nude mice were purchased from Charles River (Wilmington, MA) and 
ovariectomized at the age of 21 days by the vendor. After arrival, mice were single-cage housed, 
with free access to food and water. Artificial light was provided in a 12/12 hour cycle. The AIN-
93G semi-purified diet (Dyets, Bethlehem, PA) was selected as it has been established to meet 
the nutritional requirements of mice.47 Animals were maintained under animal protocols 
approved by the Institutional of Animal Care and Use and Committee at the University of Illinois 
at Urbana-Champaign. 
Efficacy study using MCF-7 xenografts 
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A 1 mg estrogen pellet (1 mg : 19 mg estrogen: cholesterol) was subcutaneously 
implanted into the intrascapular region on each mouse. Four days after pellet implantation, 
human breast cancer MCF-7 cells were suspended in MatrigelTM and subcutaneously injected 
into four sites (2×105 cells per site) on the flank of each mouse. Tumors were measured with a 
caliper every four days, and the tumor cross sectional area was calculated using the formula 
(length/2) × (width/2) × 3.14.48 When the average tumor cross sectional area reached 40 mm2, 
the animals were normalized by their tumor size and distributed into 3 groups: estrogen (E2) 
group (animal n = 4, tumor n = 11), Apt-Dox-Lip group (animal n = 5, tumor n = 21), Ctrl-Dox-
Lip group (animal n = 6, tumor n = 22), and the treatment was initiated. Apt-Dox-Lip or Ctrl-
Dox-Lip (25 μg Dox equivalent) was directly injected into each tumor every 4 days for 24 days. 
The mice in the estrogen group received the same volume of PBS per tumor. The cross sectional 
area of each tumor was calculated at each time point, and expressed as a percentage of the tumor 
area at the onset of treatment (100%), as described previously. Daily food intake was measured 
twice, the first time 3 weeks post cell injection (measurement 1, M1) and the second time 3 
weeks post treatment initiation (M2). Body weight was monitored weekly. 
Ex vivo tumor penetration study 
Female athymic nude mice bearing MCF-7 tumors were sacrificed to collect the tumors 
when the average tumor size reached ~4.0 × 4.0 mm. Whole tumors (n = 3) were ex vivo cultured 
with Ctrl-Urn-Lip or Apt-Urn-Lip at concentration of 10 µg equivalent uranin per mL in cell 
medium for 24 h. Tumors without any treatment served as the control. Tumor sections (5 µm) 
were collected by cryostat, mounted on glass slides, and imaged. 
In vivo tumor penetration study 
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Female athymic nude mice bearing MCF-7 tumors were divided randomly into groups of 
three (n = 3) and were treated when the average tumor size reached 5.0 ~ 6.0 mm. Animals in 
each group received a PBS solution, Ctrl-Dox-Lip, or Apt-Dox-Lip (25 L, 1 mg doxorubicin 
equivalent per mL) respectively through intratumoral injection. The animals were euthanized 1 h 
after administration, and tumor sections (10 µm) were collected by cryostat, mounted on glass 
slides, and imaged. 
Statistics 
All statistical data analysis was conducted using either SASTM 9.2 (SAS Institute Inc., 
Cary, NC) or OriginPro® 8.5 (OriginLab Corporation, Northampton, MA) program. Data of food 
intake and tumor size measured on the same time point were analyzed using one-way ANOVA 
(OriginPro) with post hoc Fisher’s LSD test. Continuous data of body weight or tumor size over 
the duration of the study were analyzed using the PROCEDURE MIXED of SAS. P<0.05 was 
considered significantly different between treatment groups.   
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5.6. Figures 
 
Figure 5.1. Schematic illustration of the NCL Aptamer-conjugated liposome with encapsulated 
cargo. HSPC, cholesterol, and mPEG2000–DSPE were mixed in a 2:1:0.16 molar ratio. 
Cholesterol-modified DNA strands were immobilized onto the surface of liposome by 
intercalating the 3' cholesterol modification into the lipid bilayer. 
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Figure 5.2. (a) Photograph of doxorubicin-loaded liposome sample. Liposome sample solution 
was centrifuged at 2000 g for 10 min to precipitate dark red Dox-Lip samples to the bottom of 
centrifuge tube. (b) Fluorescence microscope image of Rhodamine 6G-loaded liposome sample  
(Zeiss, Axiovert 200M). 40X objective lens and 555 nm excitation wavelength were used for 
imaging of liposomes. 
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Figure 5.3. (a) Cryo-EM micrographs of Apt-Dox-Lip samples. The average liposome size is 
around 200 nm. (b) Fluorescent spectra of OliGreen® ssDNA reagent stained Apt-Lip, Ctrl-Lip, 
and No-Lip samples. Sample solution was treated with Triton-X and heated at 80 °C for 20 
minutes to break the lipid bilayer and release DNA strands before staining. λex = 480 nm. λem = 
520 nm. (c) Representative DLS and (d) zeta-potential results of different liposome samples with 
NCL-aptamer (red), control DNA (blue), and lacking DNA modifications (black). The reported 
hydrodiameter and zeta-potential of liposome samples were calculated from the algebraic 
average of twenty measurements. Bars represent standard deviation. 
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Figure 5.4. (a) Fluorescent spectra of OliGreen® ssDNA reagent stained 100-1000 ng mL-1 
standard DNA solutions and Apt-Lip sample. Apt-Lip solution was treated to break the lipid 
bilayer and release DNA strands before staining. λex = 480 nm. λem = 520 nm. (b) Standard curve 
for quantification of DNA aptamer concentration plotted from 100-1000 ng mL-1 standard DNA 
solutions. The NCL aptamer concentration in Apt-Lip sample was calculated to be ~9.7 µM. 
Therefore, in 1 mL Apt-Lip samples, there are approximately 9.7 nmol NCL aptamer strands 
with ~9.3 mg lipids. The conjugation efficiency is estimated to be [9.7 µM / (14 µM × 2)] × 
100% = 34.6%. 
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Figure 5.5. (a) Fluorescent spectra of Apt-Urn-Lip sample solution at 1:500 dilution in 50% 
human serum after incubation at 37 °C for different lengths of time. λex = 490 nm; λem= 515 nm. 
Heat treatment was used to facilitate the rupture of liposomes. (b) Timecourse study of uranin 
release from liposomes at 37 °C in 50% human serum. 
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Figure 5.6. Release profile of doxorubicin-loaded liposome. (a) Fluorescent spectra of Apt-Dox-
Lip sample solution at 1:500 dilution in 25 mM HEPES preparation buffer (pH 7.4) after 
incubation at 37 °C for different lengths of time. λex = 480 nm; λem= 592 nm. Heat treatment 
was used to facilitate the rupture of liposomes. (b) Timecourse study of doxorubicin release from 
liposomes at 37 °C in 25 mM HEPES preparation buffer. 
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Figure 5.7. (a) Fluorescent spectra of Apt-Dox-Lip solutions before and after heat treatment. (b) 
Fluorescent spectra of free Dox solutions from 0.2-1.2 mg mL-1. (c) Standard curve for 
quantification of doxorubicin concentration. The fluorescence emission intensity at 592 nm was 
plotted as a linear function of Dox concentration. The equivalent Dox concentration in Apt-Dox-
Lip sample was determined to be 0.92 mg mL-1 with the drug-to-lipid ratio of 0.097 (wt/wt). 
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Figure 5.8. In vitro study of breast cancer cell targeting. (a) Flow cytometry analysis of MCF-7 
cells treated with Ctrl-Urn-Lip or Apt-Urn-Lip. (b) Confocal microscope images of MCF-7 cells 
treated with Ctrl-Urn-Lip or Apt-Urn-Lip. Nuclei were stained by DAPI (blue). Liposomes were 
labeled with uranin (green). (c) Cytotoxicity study of Ctrl-Dox-Lip and Apt-Dox-Lip samples. 
MCF-7 cells were treated with free Dox, Ctrl-Dox-Lip or Apt-Dox-Lip at various concentrations 
of Dox or Dox equivalent for 6 h at 37 ºC. **p< 0.01, student T-test. 
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Figure 5.9. In vitro cellular targeting study of MCF-7 cells with bare Ctrl-Urn-Lip or Apt-Urn-
Lip by flow cytometry. MCF-7 cells (200,000 per well) were plated in a 12-well plate. The cells 
were treated with liposome (50-500 µM lipids in equivalent) labeled with uranin at 37 ºC for 2 h. 
The cells were then washed, trypsinized and fixed in 4% paraformaldehyde solution for flow 
cytometry analysis. 
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Figure 5.10. Fluorescence microscope images of LNCaP (left) and MCF-7 (right) cells treated 
with NCL aptamer-functionalized liposomes (Apt-Urn-Lip) containing uranin. LNCaP cells 
(200,000 per well) or MCF-7 cells (200,000 per well) were plated in a 12-well plate. The cells 
were treated with liposome (500 µM lipids in equivalent) labeled with uranin at 37 ºC for 2 h. 
The cells were then washed and fixed in 4% paraformaldehyde solution for fluorescence 
microscope imaging analysis. 
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Figure 5.11. (a) Neither Apt-Dox-Lip nor Ctrl-Dox-Lip affected the body weight of mice 
bearing human breast MCF-7 tumors. The animals’ body weight was monitored weekly 
throughout the study. Data were analyzed using the PROC MIXED of SAS, and the results 
showed no significant differences between the experimental groups. (b) Neither Apt-Dox-Lip nor 
Ctrl-Dox-Lip affected food intake (per day) of mice bearing human breast MCF-7 tumors. Food 
intake (per day) was measured twice, the first time at week 3 (M1) and the second time at week 
12 (M2) post cell injection. Data were analyzed using one-way ANOVA with post hoc Fisher’s 
LSD test, and the results showed no significant differences between the experimental groups.  
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Figure 5.12. (a) Apt-Dox-Lip inhibited estrogen-induced human breast MCF-7 tumor growth 
more efficiently when compared to Ctrl-Dox-Lip. Apt-Dox-Lip and Ctrl-Dox-Lip (25 μg 
doxorubicin equivalent per tumor) were directly injected into tumors every 4 days. The cross 
sectional area of each tumor was calculated at each time point, and standardized to be expressed 
as a percentage of the tumor area at the onset of treatment. Data were analyzed using the PROC 
MIXED of SAS, and curves with different letters indicate significant differences at the level of 
0.05. (b) Relative tumor size in each treatment group at the end of the study. Data were analyzed 
using one-way ANOVA with post hoc Fisher’s LSD test. Bars with different letters indicate 
significant difference at the level of p< 0.05.  
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Figure 5.13. In vivo tumor penetration study. (a) Fluorescence microscope images of MCF-7 
tumor sections. Athymic nude mice bearing MCF-7 tumor (~5.0 × 5.0 mm, n=3) were 
administered with Ctrl-Dox-Lip or Apt-Dox-Lip by intra-tumor injection. The mice were 
sacrificed and the tumors were collected 1 h post injection. The tumors were flash frozen in OCT, 
sectioned (10 µm thickness), and stained with DAPI for nucleus. The tumor sections were 
analyzed by confocal fluorescence microscopy. (b) Confocal fluorescence microscope images of 
MCF-7 cells in tumor sections.  
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Figure 5.14. Fluorescence intensity profiles of tumor sections after intratumoral injection of 
Ctrl-Urn-Lip or Apt-Urn-Lip in MCF-7 tumors and the corresponding single-peak fits.  
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Figure 5.15. MCF-7 tumors (size: ~4.0 mm × 4.0 mm) were ex vivo cultured with PBS (as non-
treatment group), Ctrl-Urn-Lip or Apt-Urn-Lip (10 µg uranin in equivalent per mL) in cell 
medium at 37 ºC for 24 h. Tumor sections (5 µm thickness) were collected by cryostat and 
mounted on glass slides. Nuclei were stained by DAPI. A tiling image was taken by fluorescence 
microscope (Zeiss, Apotome) with fixed exposure time to show the penetration of liposomes into 
tumor tissues.  
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Table 5.1. Flow cytometry analysis of MCF-7 cells treated with Ctrl-Urn-Lip or Apt-Urn-Lip. 
MCF-7 cells (200,000 per well) were plated in a 12-well plate. The cells were treated with 
liposome (50 µM lipids in equivalent) labeled with uranin at 37 ºC for 4 h. Percentage of 
fluorescence (FL) positive cells and mean fluorescence intensity are summarized in the table. 
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Table 5.2. Statistical P value between two treatment groups for each measurement. The first 
column lists the two treatment groups to be compared. The first row lists the time point for each 
measurement. Data were analyzed using one-way ANOVA. If the overall F ratio was significant, 
the means of different treatment groups were compared using Fisher’s LSD test.  
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CHAPTER 6 
THE INFLUENCE OF DNA APTAMER AND POLYETHYLENE GLYCOL 
MODIFICATION ON CELL-SPECIFIC TARGETING 
6.1. Introduction 
Delivery vehicles with size in the nanoscale have been widely used for the construction of 
nanomedicine in combination with traditional chemotherapy to boost the efficacy of cancer 
treatment. Compared with the free drug counterpart, combinations of drugs and nanocarriers 
endow the combined system with enhanced stability, specificity, and controllable release kinetics. 
Aiming at enhanced diagnostic sensitivity and therapeutic indices, tremendous research has been 
carried out to study how the physical properties of the delivery system influence its interactions 
with cells, including as size, shape, rigidity, charge, and surface functions.1-6 The ability to 
control the surface properties of nanocarriers is critical to improve the efficiency of delivery to 
diseased tissue, because the biological interactions occur mainly at the interface between the 
delivery vehicle and biological components during the delivery process.6-10 One of the most 
important strategies is to functionalize nanocarrier surface with active biorecognition agents, 
which can recognize specific receptors on the cell surface, to allow the selective accumulation of 
nanomedicine into diseased tissues but not normal tissues.11,12 Various biorecognition agents 
have been intensively studied, including small molecules, antibodies, peptides, and aptamers 
(Apt).11-16 Among these, DNA aptamers, which are single-stranded oligonucleotides that can 
bind to target molecules selectively, have been considered as a promising class of targeting 
ligands due to their specificity, non-immunogenicity, ease of preparation and functionalization, 
and even higher stability than RNA congeners.17-21 Moreover, aptamers against different targets 
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of interest can be selected through the Systematic Evolution of Ligands by Exponential 
Amplification (SELEX) process, allowing the development of nanomedicine for specific cells 
and tissues.22-24 It has been reported that the successful delivery and release of drugs at diseased 
samples can be achieved using DNA aptamer-functionalized nanocarriers for a variety of in vitro 
and in vivo models.17,25-27  
In spite of the enhanced efficiency stemming from the specific surface interactions 
between membrane receptors and biorecognition molecules, the idealized scenario of the targeted 
delivery process are greatly complicated by other biological components under physiological 
conditions.28-31 A number of literature reports have demonstrated that serum proteins can absorb 
onto nanoparticle surfaces to form a protein corona.32,33 Nonspecifically adsorbed serum proteins 
affect the physiological properties of nanocarriers and can mask their targeting capabilities to 
cell receptors, thereby leading to a loss of recognition specificity and fast clearance via the 
reticuloendothelial system (RES).34,35 To suppress nonspecific serum protein adsorption, 
researchers have grafted the surface of nanocarriers with protection molecules, such as the 
antifouling polymer polyethylene glycol (PEG), allowing a much longer circulation time in 
blood.36,37 Some recent studies also reveal that PEG modification can prevent nonspecific 
masking of the recognition agent on a nanocarrier surface, therefore retaining the targeting 
capabilities of the nanocarrier.6,7   
To further develop mechanistic insight into cell-specific targeting, it is important to 
investigate not only the interactions at the interface of the nanocarrier under physiological 
conditions but also the interactions among different molecules on the nanocarrier surface. 
Although the use of PEG modifications to inhibit protein adsorption and recover binding 
specificity has been previously reported, the interaction between PEG molecules and neighboring 
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recognition molecules on the same surface is much less studied.17,27 The PEG shield on the 
surface may not only block the nonspecific binding of proteins but also sterically hinder the 
binding of recognition molecules to the receptor target. 
In order to investigate this issue, a PEGylated liposomal doxorubicin (PEG-Dox-Lip) 
with DNA aptamer modifications was used as the model system. Liposomes are one of the most 
successful delivery systems due to inherent advantages like high loading efficiency and 
biocompatibility,17,27,38,39 and the first nanomedicine formulation approved by the United States 
Food and Drug Administration (FDA) was Doxil, a PEGylated liposomal doxorubicin 
formulation used for the treatment of a variety of cancers.40,41 The use of PEGylated liposomal 
doxorubicin can provide a practical scope to the field of nanomedicine, and knowledge obtained 
can be easily translated to clinical application. 
In previous work, we have demonstrated that liposomal doxorubicin can be effectively 
functionalized with DNA aptamer AS1411, which has strong binding affinity to nucleolin (NCL), 
a mRNA-stabilizing protein overexpressed on the plasma membrane of many types of breast 
cancer cells.17 We further showed that targeted liposomal doxorubicin facilitated cellular uptake 
to breast cancers and exhibited enhanced tumor penetration ability and antitumor efficacy in in 
vivo MCF-7 tumor models.27 While these results are promising, it remains unclear how the PEG 
coating would affect the binding ability of the DNA aptamers, which might affect the overall 
targeting efficiency. Therefore, it is critical to systematically investigate the interactions between 
PEG and the DNA aptamer in order to properly design the DNA aptamer targeted delivery 
system with optimal performance. In this study, we prepared a series of liposomal doxorubicin 
fomulations with different DNA aptamer and PEG modifications to investigate how the spatial 
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size of the recognition and protection molecules on the surface affects the targeting ability of the 
liposome delivery system to breast cancer cells. 
6.2. Results and Discussion 
Design and Approach 
The formulation of the model system, liposomal doxorubicin with PEG and aptamer 
modifications, is designed to structurally mimic Doxil®, an FDA-approved, doxorubicin-
containing liposome, with no targeting ligand incorporated.42 The liposome was formulated from 
hydrogenated soy phosphatidylcholine (HSPC) and cholesterol (chole) at a molar ratio of 2:1.43 
Free cholesterol molecules significantly increase the hydrophobic-hydrophobic interactions 
within lipid bilayer as hydrophobic anchors, and therefore improve the rigidity and stability of 
liposomes.43 Lipid distearoyl phosphatidyl-ethanolamine (DSPE)-modified methoxy-PEG with a 
molecular weight (MW) of 5000 Da or 2000 Da (mPEG5000, mPEG2000) was applied as a 
protecting element with a molar ratio of ~ 6% of total lipid content (Figure 6.1). The 
combination of HSPC and cholesterol provides liposomes with a high transition temperature of 
48 °C, as well as high rigidity and low permeability under physiological conditions.43 
Doxorubicin, an anticancer drug as well as a fluorescent probe, was encapsulated into the 
liposome through pH-ion gradient loading method.44 This well-established formulation of 
PEGylated liposomes has been used in clinical practice for cancer treatment for decades. 
To introduce the targeting ability of PEG-Dox-Lip, AS1411, a 26-mer NCL aptamer 
(Apt) with the sequence 5ʹ-GGT GGT GGT GGT TGT GGT GGT GGT GG-3ʹ, is used as 
targeting agent for breast cancer cells and a scrambled strand of the same length (Ctrl) with the 
sequence of 5ʹ-GAG AAC CTG AGT CAG TAT TGC GGA GA-3ʹ was applied as the non-
targeting control agent. DNA strands were functionalized with cholesterol at the 3ʹ end, serving 
185 
 
as an anchor to the lipid bilayer, to immobilize the sequences to the surface of the liposome 
(Figure 6.1). 
To study the PEG-aptamer interaction, we first hypothesize that the PEG coating on 
liposome surface could sterically interfere with the binding of DNA aptamer. Therefore, the 
aptamer sequence should be fully exposed from surrounding PEG molecules in order to maintain 
the targeting ability. To expose the DNA aptamer, a spacer group should be introduced between 
liposome and aptamer to extend the recognition sequence from the surface; the length of the 
spacer group would have significant impact on the targeting ability of PEG-Dox-Lip and should 
be properly designed in order to overcome the PEG shielding effect. 
To control length of aptamer sequence from the liposome surface, poly-thymine (poly-T) 
sequence was used as spacer group for AS1411 aptamer and the length of the spacer will be 
controlled by the number of T bases (Apt-Tn, n represents the length of the poly-thymine spacer) 
(Figure 6.1). To help carry out the experiment, molecular dynamics (MD) simulations were 
applied to estimate the length of PEG5000 and help us design poly-T spacer groups with 
appropriate lengths at a room temperature of 298K, an atmospheric pressure of 0.1 GPa, and 
aqueous environment, using the Discover module in Material Studio 7.0. As shown in Figure 6.2, 
the length of PEG5000 is estimated to be ~ 58 Å. Three poly-T spacers of T1, T6, and T20 with 
different lengths were designed to extend the aptamer sequence to different extents. The length 
of T1 is estimated to be ~ 17 Å with T6 of ~ 32 Å and T20 of ~ 58 Å. Thus, AS1411 sequences 
with different lengths of spacers on PEG-Dox-Lip surface represent three levels of PEG 
shielding effect, roughly described as mostly shielded (T1), partially exposed (T6), and mostly 
exposed (T20). 
Preparation and Characterization of DNA-Modified PEG-Dox-Lip Sample 
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The DNA-Tn modified PEG-Lip samples were prepared in pH 5.5 130 mM (NH4)2SO4 
buffer with 10 % w/v sucrose based on previously published protocols using 100 nm 
polycarbonate membrane supported extruders.17,27 Doxorubicin was then loaded into the 
liposome through pH-ion gradient loading method after the formation of liposome in pH 6.5 10 
mM histidine with 300 mM sucrose to reach a high loading efficiency. Size exclusion 
chromatography was applied to remove free doxorubicin. The prepared liposome sample can be 
easily concentrated via centrifugation. To elucidate the morphology of the liposome sample, 
cryo-TEM experiments were performed. The resulting liposomal Dox samples exhibited a 
“coffee bean” shape with rod-shaped Dox solids in the middle of the liposomes. The length of 
the liposomal Dox is ~ 170 nm with the width of ~ 120 nm, which is consistent with the 
morphology of commercial samples, indicating the successful and efficient loading (Figure 
6.3).45,46  
The Dox concentration in the DNA modified PEG-Dox-Lip sample was quantified by 
UV-Vis absorption at 480 nm after treatment with a solution of 90% isopropanol and 10% 0.075 
mol/L HCl to fully rupture the liposome. Using a standard UV-Vis absorption curve of free 
doxorubicin, the equivalent Dox concentration of a DNA modified PEG-Dox-Lip sample can 
reach a high Dox loading of ~ 2 mg/mL after tuning the concentration (Figure 6.4a). To evaluate 
the stability of the DNA modified PEG-Dox-Lip formulation, the fluorescence emission at 592 
nm with excitation at 480 nm was monitored after incubation at 37 °C in 50% human serum over 
a period of 24 hours. As shown in Figure 6.4b, only ~ 5% of the maximum possible enhancement 
of fluorescence intensity was observed after 10 hours of incubation, and lower than 15% of 
maximum leakage can be detected after 24 hours of incubation, suggesting low levels of 
decomposition of the liposome samples and corresponding minimal leakage of encapsulated Dox. 
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These results indicate that the DNA modified PEG-Dox-Lip samples are highly stable in 50% 
human serum with well-preserved fluorescent properties. 
Effect of the Poly-Thymine Spacer Length 
To systematically investigate the effect of the length of the poly-T spacer, PEG-5000 
protected liposomal doxorubicin functionalized with AS1411 aptamer or control DNA sequences 
using T1, T6, and T20 as spacers were prepared. Dynamic light scattering (DLS) and zeta-
potential measurements were performed to investigate the effect of DNA modification on 
hydrodynamic radius and surface charge of the liposome sample in Apt-PEG-Lip samples with 
different Tn spacers prior to loading Dox. PEGylated liposome samples showed a hydrodiameter 
of 157.7 ± 15.4 nm with surface zeta-potential of –3.4 ± 2.2 mV. After DNA modification, 
PEGylated liposome samples had a ∼ 20 nm increase in diameter and a ~ 10 mV decrease in 
surface zeta-potential (Figure 6.5), which can be attribute to the modification of negatively-
charged DNA strands on surface.47 Variation of the Tn spacer also does not affect the physical 
properties of the liposome samples, as evidenced by the similar hydrodynamic radius and surface 
zeta-potentials for T1, T6, and T20 samples (Figure 6.5).   
The concentration of the lipids in each sample was measured at the fluorescence emission 
of 627 nm using Nile Red stained DNA-Lip samples without loaded Dox (Figure 6.6). The DNA 
density on each liposome sample was measured using the SYBR Green II dye without loaded 
Dox (Figure 6.7). The results showed that the lipids and DNA concentration are similar for all 
the samples even with different spacer length, and the DNA concentration can reach a final 
concentration of ~ 5 µM (Figure 6.8). 
To investigate the targeting capability of liposomes, the as-prepared doxorubicin-loaded 
liposomes functionalized with Apt-Tn (for Apt-Tn-Dox-Lip) or Ctrl-Tn (Ctrl-Tn-Dox-Lip) 
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diluted to the same equivalent Dox concentrations (20 µM) were incubated with MDA-MB-231 
cells for 2 hours. The treated cells were then washed, trypsinized, and fixed in 4% 
paraformaldehyde solution for flow cytometry analysis to measure the fluorescence intensity. It 
was clearly shown that the geometric mean fluorescence intensity (MFI) in cells treated with 
Apt-Tn-Dox-Lip was significantly higher than that of cells treated with corresponding Ctrl-Tn-
Dox-Lip (Figure 6.9a), indicating the targeting effect of the AS1411 sequence to MDA-MB-231 
cells. When comparing the MFI of all the Apt-Tn samples with different length of spacer groups, 
the results suggested that Apt-T20 showed higher MFI in treated cells than Apt-T6 (*p < 0.05) 
with Apt-T1 exhibiting the lowest MFI as compared to T20 and T6 samples (**p < 0.01). 
According to the estimated lengths of PEG5000, T1, T6, and T20 from MD simulation, the 
degree of AS1411 exposure in a PEG backfilled surface increases as the length of the polyT 
sequence increases. Therefore, the observation of the enhancement of targeting capability with 
the increase of length from T1 to T6 to T20 is possibly due to the increased exposure of aptamer 
sequence on the surface of liposomes, suggesting the biorecognition ability of aptamer could be 
affected by steric hindrance from the PEG layer.48-51 In order to obtain a quantitative estimation 
of the targeting ability of Apt-Lip samples, we define the targeting ability index (TAI), which is 
calculated as follows: 
Targeting Ability Index (TAI) = MFI (Apt) / MFI (Ctrl) 
Theoretically, the TAI for non-targeting sample is 1 when the sample MFI is equal to 
control MFI. Higher TAI indicates improved targeting effects of the Apt-Tn-Dox-Lip sample to 
MDA-MB-231 cells. It was shown that the average TAI increases from T1 to T6 and T20 from 
1.30 to 1.86 to 2.15, suggesting increased targeting ability (Figure 6.9c) for longer spacers, 
which is consistent with our hypothesis.  
189 
 
To further confirm our hypothesis, we investigated the cytotoxicity of Apt/Ctrl-Dox-Lip 
samples modified with different Tn spacers. In order to give MDA-MB-231 cells enough time to 
take up Dox-Lip samples, cells were incubated with Apt-Tn-Dox-Lip or Ctrl-Tn-Dox-Lip 
samples (equivalent Dox concentration of 10 µM) for 12 hours followed by 24 hours of cell 
growth time before measuring cell viability study by MTT assay. The results showed that Apt-Tn 
sample exhibited significantly higher cytotoxicity than corresponding Ctrl-Tn sample (p < 0.01). 
When we compared the cytotoxicity of different Apt-Tn samples, decreased cell viability was 
observed with the increase in Tn spacer length. As shown in Figure 6.10, the cell viabilities were 
71 ± 6%, 48 ± 5%, and 38 ± 8% for cells treated with Apt-Dox-Lip samples with the same 
Dox concentration but different Tn spacers. Since the cell viability depends mainly on the 
amount of Dox delivered into the MDA-MB-231, the Apt-T20 modified Dox-Lip can be best 
internalized by MDA-MB-231 cells, leading to the highest antiproliferative activity in cancer 
cells in vitro. In comparison, Apt-T1 sample was internalized least by MDA-MB-231 cells, 
indicating lowest binding affinity to surface nucleolin biomarkers, further confirming the PEG 
steric hindrance due to the length difference. 
Different Types of Spacers and PEG Groups 
After demonstrating that the length of the poly-T spacer is critical to the targeting ability 
of AS1411 aptamer, it is also important to investigate whether the type of spacer will affect the 
targeting ability. To compare different types of spacers, we designed a conjugated spacer that 
consists of Tn and PEG2000 molecules for comparison to the fully exposed T20 spacer. 
Specifically, MD simulations were applied to design the formulation of the conjugated spacer to 
be T11-PEG2000 in order to mimic the length of T20 spacer. To synthesize the conjugated 
spacer, which has a predicted overall length comparable to that of T20 (according to MD 
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simulation), we used PEG2000-DSPE with a maleimide modification to conjugate to thiolated 
AS1411-T11 (Figure 6.11). The AS1411-T11-PEG2000 conjugate was prepared via thiol-
maleimide coupling at room temperature. The successful coupling of DNA-lipid conjugates was 
confirmed by MALDI-MS and SDS-PAGE (Figure 6.12). DNA-lipid conjugates were then 
introduced to liposomes (Apt-Conj-Dox-Lip or Ctrl-Conj-Dox-Lip) by incubating the conjugates 
together with other lipids during the mixing process. The PEGylated liposome modified with 
Apt-T11-PEG2000 conjugate showed a hydrodiameter of –170 ± 28 nm with surface zeta-
potential of – 15.3 ± 0.6 mV, comparable to the Apt-T20 modified liposome (Figure 6.13). 
By using T11-PEG2000 conjugate as the spacer, the nucleolin recognition motif is 
supported from the liposome surface with a spacer of similar length as T20 while the chemical 
composition and charge varies. The targeting abilities of Apt-Conj-Dox-Lip and Ctrl-Conj-Dox-
Lip were analyzed by flow cytometry using the same conditions as before. As shown in Figure 
6.14, the mean fluorescence intensity of MDA-MB-231 cells treated with Apt-Conj-Dox-Lip 
sample is significantly higher compared with those treated with Ctrl-Conj-Dox-Lip, suggesting 
the new conjugated spacer can also maintain AS1411 targeting ability. Comparing Apt-Conj-
Dox-Lip sample with Apt-T20-Dox-Lip sample shows that the MDA-MB-231 cells treated with 
both samples exhibited similar MFI, indicating similar cell internalization property. To further 
study targeting ability of the conjugation sample, the TAI for T20 and Conj sample groups was 
calculated. Again, no significant difference was observed in TAI value for Apt-Conj-Dox-Lip 
sample and Apt-T20-Dox-Lip sample, confirming the similar binding affinity (Figure 6.14c). It 
can be shown that for different types of spacers, it is important to fully expose the recognition 
motif from the PEG backfilling on the surface of liposomes to achieve the best targeting effect. 
These results further suggest that length of the spacer may have higher priority than other factors 
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like charge and composition in determining the targeting ability and must therefore be carefully 
designed for any targeted delivery system. 
We have thus demonstrated the length of the spacer groups is a critical factor in 
preserving the targeting ability of DNA aptamer sequence on the PEG protected nanocarrier 
surface. In order to further confirm that the surface interactions between PEG and aptamer are 
mainly due to steric effects, we would like to investigate the targeting effects of liposome 
samples with fixed spacer on targeting agent but with varying PEG molecular weights (MW). T6 
is chosen as the spacer as it was partially shielded by PEG5000. Two widely used mPEG lengths, 
with molecular weight 5000 kDa and 2000 kDa, were selected as the protection groups. 
According to MD simulation results, although the MW of mPEG2000 and mPEG has a ~ 2.5 
times difference in mass, the length of a single PEG2000 molecule (~ 55 Å) is estimated to be 
roughly equal to that of PEG5000 (~ 58 Å), as PEG2000 showed a less folded formation than 
PEG5000 (Figure 6.15), which is consistent with results reported in previous studies.52,53 Apt-
T6-Dox-Lip samples modified with PEG5000 and PEG2000 protection groups were prepared 
and tested for DLS and zeta-potential respectively. The results suggested that the hydrodiameter 
and surface charge of PEG2000 and PEG5000 are roughly the same, demonstrating the similar 
physical properties of both samples (Figure 6.16). Flow cytometry studies were applied to study 
the targeting effect of PEG2000 and PEG5000 samples using the same MDA-MB-231 cell 
modal. Cells treated with aptamer samples showed higher MFI than control samples for both 
PEG2000 and PEG5000 protection, indicating AS1411 recognition group is exposed and 
functional (Figure 6.17a, b). Furthermore, cells treated with Apt-T6-PEG2000 sample showed 
similar MFI and TAI as cells treated with Apt-T6-PEG5000, indicating similar binding affinity 
and cell internalization property (Figure 6.17b, c). The results suggest that although the MW is 
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very different for PEG2000 and PEG5000, the shielding effect of PEG is mainly based on the 
length of the PEG rather than molecular weight, and the targeting ability of aptamer is mainly 
determined by the exposure degree resulting from the relative length of the spacer compared with 
the surrounding PEG. The conclusion is consistent with the result of previous studies on spacer 
composition, in which the length of spacer was demonstrated to be a primary factor in 
determining the targeting ability of the whole system. 
6.3. Conclusions 
In conclusion, we have systematically investigated the interactions between the AS1411 
DNA aptamer and PEG protection group on the cellular uptake ability for MDA-MB-231 cells 
using liposomal doxorubicin as a model system. Besides reducing non-specific serum protein 
absorption, backfilled PEG groups can also interact with biorecognition molecules on the surface. 
We demonstrated that the AS1411 aptamer on liposome surface should be fully exposed by 
having a Tn spacer of appropriate length to overcome the shielding from surrounding PEG5000 
in order to achieve the best targeting effect. By testing different types of spacers and PEG with 
different MWs, we further showed that physical spacer length is a critical factor in determining 
the targeting ability of the system, as the length of the spacer groups should be longer than the 
length of the backfilled PEG in order to allow the binding of the biorecognition molecule to the 
target receptor. Although it is well known that PEG is an effective antifouling polymer for 
nanomedicine, the mechanism is not as simple as putting PEG on the surface. Our studies here to 
understand the interaction between PEG and aptamers will help reveal the surface chemistry at 
the nano-bio-interface and offer important guidelines for the design of targeted drug delivery 
system with better performance. 
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6.4. Experimental Section 
Materials 
The oligonucleotides were purchased from Integrated DNA Technologies Inc. (Coralville, 
IA). HSPC, cholesterol, mPEG2000-DSPE, mPEG5000-DSPE, maleimide-PEG2000-DSPE, and 
extruder were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). SYBR Green II stain 
was obtained from Thermo Fisher Scientific Inc. (Grand Island, NY). Sephadex G-100 medium 
was obtained from GE Healthcare (Chalfont St. Giles, UK). MDA-MB-231 and MCF-7 cells 
were obtained from ATCC (Manassas, VA). Streptomycin was obtained from Invitrogen 
(Carlsbad, CA). Other reagents of analytical grade were obtained from Sigma-Aldrich Inc. (St. 
Louis, MO) and used without further purification. 
Molecular Dynamics  
Molecular dynamics simulation was performed using the Discover module in Material 
Studio 7.0. The polymer consistent force field (PCFF) was selected. The NPT ensemble was 
used, and simulations were run at a room temperature of 298 K, and an atmospheric pressure of 
0.1 GPa, with Berendsen thermostat and barostat respectively. A large periodic cell was 
constructed including each long molecule under study, as well as randomly filled water 
molecules, to a final density of the system of 0.997 g/cm3, the experimental density of liquid 
water at the temperature and pressure used. Configurations were calculated at 5 fm time steps, 
with data outputted every 100 steps, with a total duration of 100 pm was lasted to ensure 
equilibration of each system. Data were recorded after the first 10000 steps. 
Preparation of DNA-Lipid Conjugate 
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Lipids were activated by adding 300 nM DSPE-PEG2000-Maleimide in 1 mL of PBS 
buffer and heating to 50 °C for 15 min. DNA-lipid conjugate was prepared by mixing 300 nM 
activated lipids and 100 nM activated thiol-modified DNA into 1 mL of PBS buffer (pH 7.2) and 
shaking the reaction solution in room temperature for 48 h. The reaction mixture was purified 
using 4-20% gradient polyacrylamide gel electrophoresis. The purified DNA-lipid conjugate can 
be extracted from the gel by soaking in extraction buffer (0.5 M ammonium acetate; 10 mM 
magnesium acetate; 1 mM EDTA; pH 8.0; 0.1% SDS) at 50 °C for 30 minutes, twice. The 
resulting solution was desalted using PD-10 column, lyophilized overnight and dispersed in 
Millipore water for mass spectrometry and later usage.   
Preparation of Liposomes 
DNA-functionalized and cargo-loaded liposomes are prepared on the basis of our 
previously reported method with some modifications. 5 mg of HSPC, 1.67 mg of cholesterol, and 
1.67 mg of mPEG2000-DSPE (or 3.46 mg of mPEG5000-DSPE) were dissolved in 300 μL of 
chloroform with a molar ratio of 1.5:1:0.14 in a scintillation vial. The mixture was blown dry 
with N2 gas and further lyophilized overnight. 4 nmol of DNA was then added; the solution was 
frozen in liquid nitrogen and lyophilized for 1 h. 300 μL of chloroform was added and blown dry 
with N2 gas, followed by overnight lyophilization. After addition of 300 μL hydration buffer 
(130 mM (NH4)2SO4, 10 % w/v sucrose, pH 5.5), the mixture was incubated at 50 °C for 30 min, 
followed by being incubated at 37 °C for 2 h. Five freeze-thaw cycles were applied using liquid 
nitrogen and a 50 °C water bath. The mixture was incubated at 37 °C for 6 h. The obtained 
liposomal suspension was sized by extruding the lipid mixture through a filter of pore size 0.1 
μm 11 times. The sized liposomes were dialyzed against external buffer (10 mM histidine, 300 
mM sucrose, pH 6.5) to remove hydration buffer outside liposomes using a column containing 
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Sephadex G-100 medium to obtain ~ 1 mL of liposomes. 150 μL of doxorubicin solution (10 
mg/mL doxorubicin in external buffer) was then added to the sized and dialyzed liposomes and 
incubated at 60 °C for 1 h. The doxorubicin-loaded liposome was separated from the free 
doxorubicin over a Sephadex G100 column eluted with external buffer and was cooled down to 
room temperature and stored at 4 °C 
Characterization of Liposomes 
After dialysis, liposome samples were characterized using cryo-EM, DLS, and zeta-
potential measurements. 
A Vitrobot was used to prepare the cryo-EM samples of liposomes. Briefly, the TEM grid 
covered with a drop of liposome solution was blotted and rapidly frozen into liquid ethane 
cooled by liquid nitrogen. A Gatan CT3500 Cryotransfer system, which was pre-cooled with 
liquid nitrogen, was used to transfer the as-prepared liposome sample, on a TEM grid, onto a 
cryo holder. The cryo-EM images were taken on a JEOL 2100 transmission electron microscope 
at an acceleration voltage of 80 kV. 
For estimation of size and surface charge of the liposomes, DLS and zeta-potential were 
measured by using a Malvern Zetasizer Nano ZS (Malvern Instruments, UK). Freshly prepared 
liposomes without drug loading were used for size and zeta-potential measurements. Error bars 
are obtained from three parallel experiments. 
The concentrations of encapsulated doxorubicin were determined from UV-Vis spectra 
by comparison to a calibration curve of free doxorubicin. Liposome samples were standardized 
to the same corresponding encapsulated cargo concentration before any cell experiments. 
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The stability of the Dox-loaded liposomes can be characterized by monitoring the 
fluorescence of Dox at the emission wavelength of 556 nm. As the fluorescence of intact Dox-
loaded liposomes can be significantly lower than released Dox due to self-quenching effects 
while encapsulated, the extent of fluorescence increase can indicate the stability of the liposomes. 
60 μL liposomes were incubated with 90 μL of liposome elution buffer and 150 μL of human 
serum at 37 °C. The fluorescence can be monitored by taking an aliquot of the solution in 
different time points.       
Estimation of Lipids and DNA Concentration 
Nile Red-stained liposomes without loaded cargo were prepared to measure lipid 
concentrations. The concentrations were analyzed by measuring the fluorescence of the prepared 
samples to determine whether the lipid concentrations were the same.  
DNA-functionalized liposomes without cargo loading were prepared to measure the DNA 
concentration and density on the surface of liposomes. The SYBR Green II stain was utilized to 
measure the concentration and density of DNA. DNA-functionalized liposome samples were 
treated with Triton-X and heated at 80 °C for 30 min to rupture liposomes and release DNA 
strands prior to the staining process. A calibration curve was obtained from a series of standard 
DNA solutions following manufacturer’s instructions. 
Cell Culture 
MDA-MB-231 cells were cultured in Dulbecco’s Modification of Eagle Medium 
(DMEM) medium containing 10% fetal bovine serum (FBS), 100 units/mL Penicillin G, 100 
μg/mL streptomycin, and 1 nM estrogen. 
197 
 
MDA-MB-231 cells were seeded in a 4-well chamber slide at 37 °C with 5% CO2 for 24 
h. Cells were washed once with Opti-MEM, followed by being incubated at 37 °C for 4 h with 1 
mL Opti-MEM containing prepared liposomes (50 nM lipid equivalent). The cells were then 
washed with PBS buffer (3 × 1 mL), fixed with 4 % paraformaldehyde, and imaged on a 
confocal laser scanning microscope. Cells without added liposomes were imaged as control. 
To examine cell uptake of doxorubicin-loaded liposomes, MDA-MB-231 cells were 
seeded in a 12-well plate for 24 h. 10 μL of doxorubicin-loaded liposomes were incubated with 
cells in 1 mL of Opti-MEM at 37 °C with 5% CO2 for 24 h. The cells were washed with PBS 
buffer (3 × 1 mL) and then detached by trypsinization. Cells were fixed with 4% 
paraformaldehyde for flow cytometry analysis (10000 cells analyzed, λex = 480 nm, λem = 593 
nm). The fluorescence intensity of the fluorescence-positive cells and the percentage of the 
fluorescent cells relative to the total analyzed cells were analyzed. The marker was set such that 
1.0% of non-treated cells were fluorescently positive. All experiments were performed in 
triplicate. 
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6.6. Figures 
 
Figure 6.1. Schematic of the targeting ability of PEGylated liposomal doxorubicin modified with 
DNA aptamer AS1411 using poly-T sequences of different lengths as spacers towards breast 
cancer cells through specific binding of AS1411 to nucleolin on cell membranes. HSPC, 
cholesterol, and mPEG-DSPE (mPEG2000-DSPE or mPEG5000-DSPE) were mixed in a 
2:1:0.16 molar ratio. Cholesterol-modified DNA strands were immobilized onto the surface of 
liposome by intercalating the 3ʹ cholesterol modification into the lipid bilayer. 
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Figure 6.2. Molecular dynamics simulation of PEG5000 and three poly-T spacers of T1, T6, and 
T20 using the Discover module in Material Studio 7.0. The length of mPEG5000 is estimated to 
be ~ 58 Å with T1 of ~ 17 Å, T6 of ~ 32 Å and T20 of ~ 58 Å. 
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Figure 6.3. Cryo-EM micrographs of DNA modified PEG-Dox-Lip sample. The length of the 
liposomal Dox is ~ 170 nm with the width of ~ 120 nm. 
 
 
Figure 6.4. (a). Standard curve for the quantification of doxorubicin. Absorbance at 480 nm vs. 
concentrations of free doxorubicin. (b) Timecourse study of doxorubicin release from liposomes 
at 37 °C in 50% human serum. 
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Figure 6.5. Representative DLS and zeta-potential of different liposome samples (No-DNA-
PEG5000, Apt-T1-PEG5000, Apt-T6-PEG5000, and Apt-T20-PEG5000). The reported 
hydrodynamic diameter and zeta-potential of liposome samples were calculated from the average 
of three measurements. Error bars represent the standard deviation. 
 
Figure 6.6. (a) Fluorescent spectra of Nile Red stained DNA-Lip samples in ethanol. λex = 552 
nm. λem = 627 nm. (b) Fluorescent intensities at 627 nm of different DNA-Lip samples. Bars 
show no significant difference at the level of p > 0.05 under one-way ANOVA with post hoc 
Fisher’s LSD test, indicating that there is no significant difference between concentrations of 
prepared liposome samples. 
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Figure 6.7. (a) Fluorescent spectra of SYBR Green II stained DNA-Lip samples. DNA-Lip 
solutions were treated to break lipid bilayers and release DNA strands before staining. λex = 497 
nm. λem = 538 nm. (b) Standard curves for quantification of DNA concentrations plotted from 
0.8-50 nm standard DNA solutions. 
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Figure 6.8. The amounts of DNAs in ~200 μL liposome samples measured by SYBR Green II. 
Bars show no significant difference at the level of p > 0.05 under one-way ANOVA with post 
hoc Fisher’s LSD test. 
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Figure 6.9. (a) Flow cytometry analysis of MDA-MB-231 cells treated with Apt- or Ctrl-linked 
T1-Dox-Lip, T6-Dox-Lip, and T20-Dox-Lip samples. MDA-MB-231 cells (200 000 per well) 
were plated in a 12-well plate. The cells were treated with liposomal doxorubicin samples (20 
µM doxorubicin in equivalent) at 37 °C for 2 hours. (b) Geometric mean fluorescence intensity 
(MFI) of MDA-MB-231 cells treated with liposomal doxorubicin. (c) Targeting ability index 
(TAI) of liposomal doxorubicin. TAI = MFI (Apt) / MFI (Ctrl). Error bars represent the standard 
deviation. *p < 0.05, **p < 0.01. 
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Figure 6.10. Cytotoxicity study of Ctrl-Dox-Lip and Apt-Dox-Lip samples. MDA-MB-231 cells 
(3000 per well) were plated in a 96 well plate 24 h before study. MDA-MB-231 cells were 
treated with DNA-modified liposomal doxorubicin samples at concentration of 10 µM 
doxorubicin in equivalent of at 37 °C for 6 h. The cells were then washed and incubated in media 
for a total of 72 h before assessing cell viability by MTT assay in each group. *p < 0.05, **p < 
0.01, Student T-test. 
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Figure 6.11. Molecular dynamics simulation of mPEG5000, T20, and T11-PEG2000 conjugate. 
The length of mPEG5000 is estimated to be ~ 58 Å with T20 ~ 58 Å and T20 of ~ 60 Å. 
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Figure 6.12. (a) SDS-PAGE characterization of Apt-T11-PEG2000 conjugate. Protein ladder 
(lane 1), Apt-T11 control (lane 2), and Apt-T11-PEG2000 conjugate (lane 3) were run on a 5-
20% SDS-PAGE gradient gel. (b) MALDI-MS characterization of Apt-T11-PEG2000 conjugate. 
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Figure 6.13. DLS and zeta-potential of liposome samples (No-DNA-PEG5000, Apt-T20-
PEG5000, and Apt-Conj-PEG5000). The reported hydrodynamic radius and zeta-potential of 
liposome samples were calculated from the average of three measurements. Bars represent 
standard deviation. 
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Figure 6.14. (a) Flow cytometry analysis of MDA-MB-231 cells treated with Apt- or Ctrl-linked 
T20-Dox-Lip, and Conj-Dox-Lip samples. MDA-MB-231 cells (200 000 per well) were plated in 
a 12-well plate. The cells were treated with liposomal doxorubicin samples (20 µM doxorubicin 
in equivalent) at 37 °C for 2h. (b) Geometric mean fluorescence intensity (MFI) of MDA-MB-
231 cells treated with liposomal doxorubicin. (c) Targeting ability index (TAI) of liposomal 
doxorubicin. Error bars represent the standard deviation. 
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Figure 6.15. Molecular dynamics simulation of mPEG5000 (~ 58 Å), mPEG2000 (~ 55 Å), and 
T6 spacer (~ 32 Å). 
 
Figure 6.16. DLS and zeta-potential of liposome samples (Apt-T6-PEG5000 and Apt-T6-
PEG2000). The reported hydrodynamic diameter and zeta-potential of liposome samples were 
calculated from the algebraic average of three measurements. Bars represent standard deviation. 
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Figure 6.17. (a) Flow cytometry analysis of MDA-MB-231 cells treated with Apt- or Ctrl-linked 
Dox-Lip-PEG5000, or Dox-Lip-PEG2000 samples. MDA-MB-231 cells (200 000 per well) were 
plated in a 12-well plate. The cells were treated with liposomal doxorubicin samples (20 µM 
doxorubicin in equivalent) at 37 °C for 2h. Each group received liposomal doxorubicin with 
same total fluorescence intensity. (b) Geometric mean fluorescence intensity (MFI) of MDA-
MB-231 cells treated with liposomal doxorubicin. (c) Targeting ability index (TAI) of liposomal 
doxorubicin. Error bars represent the standard deviation. 
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CHAPTER 7 
PRACTICAL SYNTHESIS OF WATER-SOLUBLE ORGANIC 
NANOPARTICLES WITH A SINGLE REACTIVE GROUP AND A 
FUNCTIONAL CARRIER SCAFFOLD 
Part of this chapter was published as:  
1. “Practical Synthesis of Water-soluble Organic Nano-particles with a Single Reactive Group 
and a Functional Carrier Scaffold”, Yugang Bai, Hang Xing, Gretchen A. Vincil, Jennifer Lee, 
Essence Henderson, Yi Lu, Gabriel Lemcoff, Steve Zimmerman, Chemical Science, 2014, 5, 
2862-2868.  
7.1. Introduction 
Organic nanoparticles (ONPs), although a concept without a strict definition, could be 
recognized as any nanoscale structures having relatively fixed architectures and shapes, and 
consisting majorly carbon and hydrogen atoms. Dendrimers, hyperbranched polymers, as well as 
organic nanocrystals, are typically classified as ONPs, although the broadest definition of ONPs 
could include biomacromolecules such as enzymes, proteins, and chromosomes, which play 
essential roles in all life forms and suggest possible artificial functional structures for multiple 
applications. Actually, the usefulness of ONPs has been revealed in many cases of recent years.1-
3 The ONPs have been synthesized in various strategies, majorly as dendrimers or hyperbranched 
polymers, and have been utilized in different ways, such as drug delivery, gene delivery,4 
catalysis5 and bioimaging.6 However, the repetitive steps and long time in the synthesis of 
monodisperse dendrimers is universally acknowledged, especially for large ONPs; while 
hyperbranched polymerization, although convenient, usually gives polymer with high 
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polydispersity (PDI) and unpredictable molecular weight.7,8 Consequently, great efforts had been 
devoted in reducing the labor of dendrimer synthesis9-11 and improving the controllability of 
multibranching polymerization12-14A minor strategy, on the other hand, involves intramolecular 
crosslinking of linear polymers.15-19 The strategy does provide a fast and controlled route for 
ONPs of different sizes, but it lacks efficient pathways for functionalization, therefore effective 
application of such materials have been limited. 
As illustrated schematically in Figure 7.1, the most useful synthetic approach would 
allow control over the ONP: (1) size, (2) hardness (i.e., flexibility), (3) solubility, (4) external 
functionality, (5) internal functionality, and (6) density/porosity, as well as being (7) scalable and 
(8) producing ONPs of low toxicity and high biocompatibility for bio-applications and low 
environmental impact. Finally, having a single reactive functional group on the ONP surface is 
very useful for controlled nanoscale assembly and two orthogonally reactive functional groups 
would provide access to an even broader set of applications.20,21 Obtaining ONPs with a limited 
number of reactive groups is a particular challenge because nanoparticles are invariably prepared 
with a large number of identical groups on their surface. It may be possible to borrow strategies 
developed for preparing monovalent metal nanoparticles, although these do have some 
limitations, particularly with regard to scalability. The successful strategies for generating 
monovalent metal NPs involve statistical surface functionalization followed by fractionation or 
separation steps, or reaction of the NP with a reactive surface.22-24 A very specialized approach 
for gold nanoparticles involves placing two reactive groups on polar opposite positions of the 
surface coated with a mixed monolayer.11 
With regard to the list above, most of the reported approaches to ONPs offer control over 
just a few of these properties. Dendrimers are an exception, offering readily tunable sizes and the 
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ability to place a wide range of functionality at the periphery and within the branching units. 
However, dendrimers require multi-step syntheses making scalablity an issue, and the elegant 
syntheses of mono- and bivalent dendrimers are by necessity even longer.25 The strategy of 
cross-linking linear polymers appears particularly attractive because it can produce ONPs with 
readily controlled molecular weight, cross-link density, polydispersity, and functionality. Indeed, 
the main limitation in these ONPs reported to date is a lack of water solubility and functionality 
for further manipulation. 
Herein we describe a new synthetic approach to ONPs. The key to the strategy is the use 
of the ring-opening metathesis polymerization (ROMP) of functionalized norbornene 
dicarboximides 1, catalysed by pyridine-modified Grubbs catalyst 2 (commonly referred as 
Grubbs 3rd Generation catalyst).26,27 This catalyst is highly functional group tolerant allowing a 
range of functionality to be placed on the ONP scaffold.  At the same time, precise control over 
chain length and polydispersity is provided, as well as straight-forward chain-end 
functionalization using chain-transfer agents (CTAs). Importantly, ROMP is the only living 
polymerization technique that generates unsaturated polymers whose high alkene content allows 
dihydroxylation, yielding non-ionic, hydrophilic back-bones with high aqueous solubility. The 
ROMP was paired with a ring-closing metathesis (RCM) reaction, allowing cross-linking under 
mild conditions, as well as producing an additional set of alkenes. Using these metathesis 
reactions in sequence followed by dihydroxylation has led to an ONP synthesis that possesses 
nearly all of the attributes illustrated in Figure 7.1.  
7.2. Results and Discussions 
Synthesis and Characterization of ONP 
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 Our initial approach examined a tandem ROMP-RCM process using monomer 1 with 
pendant alkene moieties.  This single step approach to ONPs is appealing; however, despite 
investigating multiple monomers with different types of alkene groups, either the ROMP or 
RCM step proved to be problematic due to cross-reactivity. As outlined in Figure 7.2, a 
sequential process, wherein the alkene groups for RCM are added in a second step, was 
developed to bypass the possibility of cross-reactivity.  Thus, each ROMP was carried out with 
monomer 1a carrying an activated ester and a co-monomer, initially 1b.  The ROMP proceeded 
smoothly to give the corresponding poly(endo-norbornenes) 3 with low poly-dispersity indices 
(PDIs) and a range of molecular weights that could be readily controlled by setting the initiator 
to monomer ratio (Table 7.1). Treatment of 3 with tri-O-allyl-TRIS (4) afforded polymer 5 
displaying a large number of allyl groups along its backbone.  The 1H NMR of 5 showed a 
complete absence of the succinimidyl group indicating that within the detection limit of NMR, 
the activated esters were fully converted to the amide. Nitrobenzene was used as a cosolvent in 
the amidation reaction to suppress radical mediated cross-linking of the allyl groups, which was 
previously observed with allylated polyglycerol dendrimers.6 The intramolecular crosslinking 
(RCM) of 5 was effected using 6 (Grubbs 1st Generation catalyst), whose lower reactivity 
avoided intermolecular metathesis during work-up.4,5 Performing the RCM reaction under dilute 
conditions allowed formation of the ONPs with little or no dimeric material observed. Evidence 
for fully cross-linked ONPs was readily observed in the 1H NMR. Thus, the terminal alkene CH 
groups that appear between δ 5.0-5.5 ppm in 5 are replaced by a broad peak at 5.7 ppm in the 
spectrum of 7, consistent with the formation of 1,2-disubstituted alkene groups (Figure 7.3a).  
 The GPC analysis was also consistent with extensive intra-molecular cross-linking.  Thus, 
whereas the conversion of 3 to 5 gave a small shift to a shorter retention time consistent with an 
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increase in size, the RCM product 7 gave a single peak that eluted significantly later (Figure 
7.3b). The molecular weight of 7 determined by conventional calibration gave much smaller 
values than expected for loss of ethylene units from 5, reflecting its collapsed, cross-linked 
structure. In contrast, multi-angle laser light scattering (MALLS) detection gave a more accurate 
assessment of the true molecular weight of the polymers; thus the Mn value for 7 was found 
typically only about 1-4% lower than the Mn obtained for 5 (Table 7.1). 
 ONP 7 was very soluble in common organic solvents.  In an effort to render these 
particles water-soluble, monomers 1c and 1d were synthesized and used in the copolymerization 
with 1a. These two new monomers formed polymer 5 and ONP 7 in the same manner as 1b did, 
showing the versatility of the synthetic strategy. The large number of alkene groups in 7, arising 
from both the ROMP and RCM steps, allowed use of dihydroxylation chemistry to prepare 
water-soluble ONP. Using the Upjohn conditions, 25,28 i.e., N-methylmorpholine N-oxide (NMO) 
and K2OsO4 in acetone-water at room temperature, led to ONP that were fully soluble in water 
but not in organic solvents, even DMF (Figure 7.4a). The ONP containing monomer 1d were 
hydrolysed in aqueous hydrochloric acid to provide additional diol units. In each case the 1H 
NMR spectrum in D2O revealed complete disappearance of the alkene peaks, indicating 
complete oxidation of the double bonds (see Experimental Section). We also proved that this 
synthetic approach, outlined in Scheme 1 and Figure 7.3a, was sufficiently versatile to allow 
gram quantities of ONPs 8 to be prepared (Figure 7.4b). 
 To determine the shape of the ONPs prepared in this study and provide direct information 
about their sizes, transmission electron microscopy (TEM) was performed on three separate 
batches of ONPs 8 with different sizes.  The polymers were prepared using monomer to initiator 
ratio for 1a:1d:2 = 100:200:1, 50:100:1, and 10:20:1, giving water-soluble ONPs with molecular 
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weights of 102, 53, and 12 kDa respectively, according to GPC-MALLS determined molecular 
weights of their corresponding parent polymers after dihydroxylation (Figure 7.5).  As seen in 
Figure 7.6, the ONP are roughly spherical with diameters ranging from ca. 5-10 nm up to ca. 50 
nm. 
 The copolymerization approach described above with functional monomers such as 1e 
and 1f and subsequent cross-linking and dihydroxylation smoothly produces a wide range of 
ONPs with multiple hydroxyl groups on their surfaces and interiors. This same "bottom-up" 
approach appeared to offer a special opportunity to integrate in a single, uniquely reactive 
functional moiety into the nanoparticle. The general strategy used is shown in the preparation of 
ONPs 7 and 8. Thus, the living nature of the ROMP process allows the use of a CTA to cap the 
end of the polymer chain directly, producing a monovalent ONP (Figure 7.7).27,29-31  Toward this 
end, three CTAs, 9a-c, were prepared and added to the reaction mixture at the end of the ROMP.  
The mono-functionalization was confirmed by 1H NMR analysis prior to the RCM-mediated 
cross-linking. 
Demonstration of the Functional Amine Group on ONP 
 To demonstrate the reactivity and accessibility of the functional group of the monovalent 
ONP, a 21.8 kDa ONP, 7 (entry 4, Table 7.1) prepared using CTA-2 (9b) was conjugated to a 10 
kDa thiol-functionalized mPEG as outlined in Figure 7.7.  Thus, the NHBoc-containing polymer 
was treated by trifluoroacetic acid in dichloromethane and the resulting amine reacted with sulfo-
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carb-oxylate (sulfo-SMCC), followed by 
mPEG-SH addition in a DMF-water mixture. Unreacted ONPs were removed by filtration, and 
unreacted mPEG molecules were removed by successive washing and filtering through a 30 kDa 
cutoff Amicon membrane. The mPEG conjugation was immediately apparent given that the 
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functionalized ONPs became soluble in water. To further demonstrate the compatibility of 
monovalent ONP with biological molecules, a thiolated DNA strand with Alexa Fluor® 594 
(Alexa 594) dye modified on the 5' end was conjugated to ONP. The obtained DNA-ONP 
conjugate is water soluble because of the hydrophilicity of DNA strands. Under fluorescence 
microscope, the DNA-ONP conjugate exhibited two fluorescence emissions from Alexa 594 on 
DNA and fluorescein in ONP respectively. The fluorescence images of DNA (red channel) and 
ONP (green channel) overlapped well with each other, confirming the successful 
functionalization of DNA to ONP (Figure 7.8). 
Photostability of ONP 
 Beyond effecting RCM reactions, Grubbs catalyst 6 is able to mediate olefin cross-
metathesis. Because a common catalyst is used for these two processes, it suggested the 
possibility of integrating in new functionality during the cross-linking process (i.e., RCM of 5 to 
7).  To test this possibility, perylenediimide 10 was prepared from allylamine and 1,6,7,12-
tetrachloroperylene-3,4,9,10-tetracarboxylic acid dianhydride. Perylenediimide 10 was added to 
the reaction mixture at the beginning of the RCM process, otherwise the overall ONP preparation 
was identical to that previously described. The resultant perylenedimide-containing polymer 7 
(entry 5, Table 7.1) was fluorescent and exhibited a low PDI. The GPC trace from the UV 
detector showed a peak with an identical shape and elution time to that from the RI detector. 
Fluorescent polymer 7 underwent dihydroxylation, yielding water-soluble, fluorescent ONP 8 
after purification via dialysis. The preparation of fluorescent nanoparticles containing the 
perylenediimide unit is one application of the chemistry described herein. There was particular 
interest in the ability of the ONP to reduce the photobleaching that plagues nearly all organic 
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fluorophores. Indeed, a continuing challenge is to prepare bright and stable fluorescent probes,18 
especially useful being those that are monovalent for specific biolabeling.19   
 To test the possibility that that the polymeric framework of 8 might increase fluorophore 
stability, ONP 8 containing fluorescein units were prepared using monomer 1g. Fluorescein was 
chosen as a widely used fluorophore that is especially prone to photobleaching.20 A fully water-
soluble 28 kD ONP 8 was prepared with CTA-2 (9b) as the end-cap and containing an average 
of four fluorescein units. As seen in Figure 7.9a, the ONP is visibly brighter than fluorescein at a 
similar concentration.  More importantly, its performance over time is significantly improved 
indicating the protective effect of the ONP (Figure 7.9a and 9b). Furthermore, because the 
loading of the fluorescein groups within the ONP is readily controlled simply by tuning the 
equivalents of 1g used in the ROMP, brighter ONPs could be prepared as shown in Figure 7.9c. 
Indeed, as we increase the equivalents of the fluorescein monomer linearly during 
polymerization, we observed a linear increase in ONP fluorescence intensity when the dye 
loading was not too high. This experiment also proved that the loading of a moiety of interest 
could be quite facilely and accurately controlled by tuning M/I ratio. The origin of the protection 
effects is under investigation as are efforts to optimise the performance of these types of 
fluorescent ONP, including understanding the relationship between the different tunable aspects 
of the ONP: its size, number of fluorophores, degree of cross-linking, etc. 
Cell Uptake of ONP 
 Having demonstrated the exceptional photostability of the fluorescein ONPs, we then 
investigated their ability to enter live HeLa cells (human cervical canceras) as a nanoscale 
delivery and imaging system for potential intracellular theranostic applications (Figure 7.10a). 
Fluorescein ONPs (1a:1d:1g ratio = 10:20:4, ca. 12 kDa) were synthesized and incubated with 
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HeLa cells for 6 h before further characterizations. As shown in Figure 7.10b-f, HeLa cells 
treated with ONPs exhibited bright green fluorescence inside cells under confocal microscope, 
indicating the great internalization of ONPs. To study the intracellular distribution of ONPs, 
LysoTracker red was used to stain the lysosomes of HeLa cells. The good co-localization of 
fluorescence from ONPs and LysoTracker demonstrate that the ONPs are mainly transported to 
the lysosomes of HeLa cells, suggesting a receptor-mediated endocytosis process. To further 
ensure that the observations through confocal microscope apply to whole cell population, 
quantitative fluorescence analysis for whole cell population was examined using flow cytometry 
for HeLa cell samples with or without ONPs treatment. The result shows that HeLa cells treated 
with green fluorescence ONPs had more than two-fold higher level of ﬂuorescence than 
untreated cells (Figure 7.10g), which is consistent with the observations under confocal 
microscope, confirming the uptake of ONPs. The demonstrated excellent photostability and 
cellular uptake features of these ONPs have exhibit great potential for future applications of 
long-term bioimaging and continuous tracking of living cells. One potential concern given the 
heavy metal-containing reagents used in the synthesis of ONP 8 is the presence of residual 
osmium and ruthenium.  Indeed, the ICP analyses showed significant levels of both.  Preliminary 
studies showed that treating solutions of 8 with a polyvinylpyridine-based resin such as Smopex-
105 reduced the metal ion contamination to parts per million levels.  Even before treatment with 
the coordinating resin, ONP 8 ranging from ca. 10-100 kDa exhibited MTT HeLa cell viabilities 
of ≥ 80% at a concentration of 10 μM (approximately 1 mg/mL) (Figure 7.11).  
Growth of Gold Nanoparticle (AuNP) in ONP Template 
Since ONP is a highly porous nanosphere with hundreds of hydroxyl groups in the 
framework, it is possible to utilize ONP as template for the synthesis of metal nanoparticle. To 
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validate this concept, chloraurate is used as gold source for the synthesis of gold nanoparticles 
(AuNPs). Due to the electrostatic attraction between partially protonated hydroxyl groups and 
chloroauric acid under low pH, the condensation of metallic atoms on the ONP templates can be 
achieved. First, chloraurate was incubated with 52 kDa ONPs solution for 5-10 min in 5 mM 
citrate buffer (pH = 3) at room temperature. Reducing agent of ascorbic acid or sucrose was then 
added to reduce chloraurate on the ONPs to form AuNPs. 
As shown in Figure 7.12, the obtained AuNPs showed similar size to ONPs, suggesting 
the template-assisted metallization process. To further confirm that the AuNPs were grown in 
ONP templates, kinetics study of AuNP growth process was carried out. With the growth of 
AuNPs, the fluorescence emission from ONPs will decrease due to the strong quenching effects 
of gold, while the UV-vis absorption around 520 nm will increase due to the plasmonic property 
of the newly-formed AuNPs (Figure 7.13a, b). As shown in Figure 7.13c, after adding sucrose to 
ONP-gold source solution for 30 min, a steep increase in UV-vis absorption spectrum was 
observed accompanied by a significant decrease in fluorescence spectrum, indicating the start of 
the formation of AuNP. Two spectra precisely correlate with each other throughout the whole 
reaction process, suggesting the formation of AuNPs is in the ONP templates. 
Because the size of ONPs can be easily controlled by controlling the molecular weight 
during polymerization, AuNPs with different sizes can also be prepared by using ONPs of 
different molecular weights. As shown in Figure 7.14, different sized AuNPs were obtained from 
the ONP templates with different molecular weights of 12 kDa, 50 kDa, and 100kDa. The size of 
AuNPs matched well with the size of ONPs, further confirming that the metallization process 
was confined by the ONP template. In addition, the metallization process can also be applied to 
DNA-functionalized ONP. To demonstrate that the DNA strands on surface remain functional 
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after the formation of AuNP, 5 nm AuNPs with complementary DNA strands were applied to 
assemble with DNA-AuNPs synthesized from ONPs (Figure 7.15a). The preliminary results 
indicated that after adding 5 nm AuNP with complementary DNA modification, homogeneous 
and heterogeneous dimers were observed (Figure 7.15b, c). 
7.3. Conclusions 
We have described a new route to ONPs using sequential living ROMP and RCM 
reactions. By adjusting parameters of the living ROMP, the molecular weight and size of the 
ONP could be precisely controlled with excellent PDI values in each case. The overall synthetic 
strategy is capable of producing gram quantities of product quite flexibly and under mild 
conditions, allowing a range of functional groups to be integrated controllably and covalently 
into the ONP during the ROMP, RCM, or post-functionalization step. Indeed, one application 
demonstrated was the ability of the ONPs to carry multiple fluorescent probes and significantly 
increase their photostability. A major advantage of this approach is the ability to produce mono- 
or poly-functional ONPs that are either organic or water-soluble. The capability of embedding a 
wide range of groups into the poly(norbornene) backbone suggest that numerous additional 
applications including light harvesting, multiplexed bioimaging and drug delivery might be 
possible using the single-chain particle approach described herein. Moreover, the hydroxyl-rich 
ONP can serve as template for the synthesis of gold nanoparticles with the preserve of surface 
functions. 
7.4. Experimental Section 
Chemicals and Materials 
All reagents were purchased from Acros Organics, Fisher Scientific, AK Scientific, TCI 
America, or Sigma-Aldrich, and used without further purification unless otherwise noted. 
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Dichloromethane (DCM), pyridine, THF, toluene, DMSO and DMF were stored over activated 4 
Å molecular sieves. Pyridine-modified Grubbs 2nd Generation catalyst for ROMP 
polymerization,[1] N-glycine cis-5-norbornene-endo-2,3-dicarboximide,[2] N-benzyl cis-5-
norbornene-endo-2,3-dicarboximide (M2),[3] and N-methyl cis-5-norbornene-endo-2,3-
dicarboximide (M3)[4] were each prepared according to literature procedures. The preparation of 
N-(6-amino)hexyl cis-5-norbornene-endo-2,3-dicarboximide was similar to that reported by 
Hanson and coworkers[5], but replacing the diamine (ethylenediamine) with 
hexamethylenediamine and further purifying the crude product with flash chromatography 
(DCM-MeOH, 10:1 to 5:1). N,N’-DiBoc cis-1,4-di(4-aminoethylphenoxyl)-2-butene (CTA2)[6] 
and tris(allyloxymethyl)aminomethane (triallyl-Tris)[7] were synthesized according to procedures 
in literature. Thiolated mPEG-10,000 was purchased from Laysan Bio Inc. and used as received. 
All Olignucleotides used in this study were purchased from Integrated DNA Technologies Inc. 
(Coralville, IA), with following sequence: 
A594_DNA1_SH: A594-TTGCTGAGTATAATTGTTTTTTTTTTTT-SH 
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Instrumentation  
NMR spectra were recorded using a Varian U400, UI400, U500 or VXR500 spectrometer 
in the NMR Laboratory, School of Chemical Science, University of Illinois. The data was 
processed in MestReC v4.8.1.1. Some spectra were treated with the smoothing function of the 
software to obtain better baseline. NMR images were screenshots taken from MestReC and 
aligned/commented in Adobe Photoshop CS4 (Figure 7.2a) or Microsoft Paint of Windows 7. 
Mass spectral analyses were provided by the Mass Spectrometry Laboratory, School of Chemical 
Science, University of Illinois, using ESI on a Waters Micromass Q-Tof spectrometer, FD on a 
Waters 70-VSE spectrometer. Analytical gel permeation chromatography (GPC) experiments 
were performed on a Waters system equipped with an Waters 1515 isocratic pump, a Waters 
2414 refractive index detector, and a Waters 2998 photodiode array detector. Separations were 
performed at 50 °C using DMF containing 0.1 M LiBr as the mobile phase. Relative molecular 
weights and PDIs were calculated by Breeze 2 software from Waters Corporation, based on 
conventional calibration method. Absolute molecular weights were collected on a GPC system 
equipped with an isocratic pump (Model 1100, Agilent Technology, Santa Clara, CA, USA), a 
DAWN HELEOS 18-angle laser light scattering detector, a multi-angle laser light scattering 
(MALLS) detector, (Wyatt Technology) and an Optilab rEX refractive index detector (Wyatt 
Technology). The detection wavelength of HELEOS was set at 658 nm. Separations were 
performed at 60 °C using DMF containing 0.1 M LiBr as the mobile phase. The MALLS 
detector was calibrated using pure toluene and used for the determination of the absolute 
molecular weights. The molecular weights of all polymers were determined based on the dn/dc 
value of each sample calculated offline by using the internal calibration system processed by the 
ASTRA V software (version 5.1.7.3, Wyatt Technology).  GPC data points were exported as 
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ASCII files, re-imported into OriginPro 8, plotted, saved as vector image files (*.ai) and 
colored/commented in Adobe Illustrator CS6. TEM experiments were conducted with a JEOL 
2100 Cryo transmission electron microscope. Negative staining of polymer nanoparticles with 
ammonium molybdate was applied when preparing TEM samples in order to achieve better 
contrast. Samples were prepared by drop casting polymer nanoparticle and ammonium 
molybdate mixture solutions onto a carbon-coated copper TEM grid or a silicon wafer (Ted 
Pella), followed by removing excess solution with filter paper after 10 min. TEM grids were then 
left dried for another 15 min before imaging. DLS analysis was performed on a Brookhaven Zeta 
PALS instrument. 
Synthetic Procedures 
N-Glycine cis-5-norbornene-endo-2,3-dicarboximide NHS ester (M1). N-Glycine cis-
5-norbornene-endo-2,3-dicarboximide (2.21 g, 10 mmol) was dissolved in anhydrous 
dichloromethane (40 mL) in an ice bath. Oxalyl chloride (0.93 mL, 11 mmol, 1.1 eq) and one 
drop of DMF as catalyst was added to the solution. The reaction was stirred for 3 h with the 
temperature gradually increased to 25 oC. Volatiles were removed under reduced pressure to 
yield a white powder. The solid was dissolved in 40 mL of dry dichloromethane, and N-
hydroxysuccinimide (1.27 g, 11 mmol, 1.1 eq) and K2CO3 (2.07 g, 15 mmol, 1.5 eq) were added. 
The suspension was stirred overnight. To the suspension was added 100 mL of dichloromethane 
and the organic solution washed with water twice and dried over Na2SO4. The solvent was 
removed under reduced pressure and a white solid was obtained. The crude product was 
dissolved in anhydrous acetone  and crystallized by adding a layer of hexane which afforded M1 
as a fluffy white solid. Yield: 2.4 g. 1H NMR (400 MHz, CDCl3): δ 6.11 (s, 2H), 4.40 (s, 2H), 
3.41 (m, 2H), 3.35 (m, 2H), 2.81 (s, 4H), 1.73 (d, J = 8.8 Hz, 1H), 1.53 (d, J = 8.8 Hz, 1H). 13C 
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NMR (500 MHz, CDCl3): δ 176.2, 168.4, 162.8, 134.8, 52.4, 46.4, 45.3, 37.0, 25.7. ESI-MS: 
calculated 318.1, found 319.1 [M+H+]. 
N-(2,2-Dimethoxy)ethyl cis-5-norbornene-endo-2,3-dicarboximide (M4). To 2-amino-
acetaldehyde dimethyl acetal (3.15 g, 30 mmol) was slowly added a solution of carbic anhydride 
(4.92 g, 30 mmol) in 40 mL of warm toluene. The suspension was heated to reflux on a heating 
mantle overnight. Solvent was removed under reduced pressure. The crude product was purified 
by column chromatography (silica, EtOAc-hexanes, 1:1 v/v) followed by recrystallization in 
EtOAc-hexanes to yield a colorless crystal. Yield: 4.2 g (55%). 1H NMR (400 MHz, CDCl3) δ 
6.09 (s, 2H), 4.54 (t, J = 5.8 Hz, 1H), 3.47 (d, J = 5.8 Hz, 2H), 3.39 (m, 2H), 3.30 (s, 6H), 3.26 
(m, 2H), 1.73 (d, J = 8.7 Hz, 1H), 1.53 (d, J = 8.7 Hz, 1H). 13C NMR (500 MHz, CDCl3): δ 
177.7, 134.6, 99.5, 53.1, 52.4, 46.0, 54.2, 39.2. ESI-MS: calculated 251.1, found 274.1 [M+Na+]. 
N-(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl cis-5-norbornene-endo-2,3-dicarboximide 
(M5). 3-Amino-1,2-propanediol (1.92 g, 21 mmol, 1.05 eq) was dissolved in warm toluene-
dioxane mixture (50 mL, 10:1 v/v) and cis-5-norbornene-endo-2,3-dicarboxylic anhydride (3.28 
g, 20 mmol, 1 eq) was added. The mixture was heated at reflux overnight. The solution was 
decanted while hot to remove insoluble residue (if present) and cooled to 50 oC. To the solution 
was added p-toluenesulfonic acid monohydrate (0.38 g, 2 mmol, 0.1 eq) and 2,2-
dimethoxypropane (10 mL, excess). The reaction was monitored by TLC, and the volatiles were 
removed under reduced pressure once the protection was complete. The residue was dissolved in 
40 mL of EtOAc, and washed by saturated aqueous NaHCO3, water, and brine. The organic 
phase was collected, dried over Na2SO4, and the solvent removed under reduced pressure to give 
the crude product, which could be further purified by flash column chromatography (silica, 
EtOAc-hexanes, 1:3 v/v) to give a white solid. Yield: 5.3 g (96%). 1H NMR (400 MHz, CDCl3): 
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δ 6.08 (s, 2H), 4.16 (m, 1H), 3.93 (dd, J = 8.5, 6.1 Hz, 1H), 3.57-3.67 (m, 2H), 3.33-3.40 (m, 3H), 
3.27 (m, 2H), 1.72 (d, J = 8.8 Hz, 1H), 1.53 (d, J = 8.8 Hz, 1H), 1.40 (s, 3H), 1.28 (s, 3H). 13C 
NMR (500 MHz, CDCl3): δ 177.7, 134.7, 109.8, 72.8, 67.8, 52.4, 46.0, 45.2, 41.3, 27.0, 25.7. 
ESI-MS: calculated 277.1, found 300.1 [M+Na+]. 
5(6)-Carboxyfluorescein monomer (M6). Commercially available 5(6)-
carboxyfluorescein (0.92 g, 2.4 mmol, 1.0 eq) was dissolved in DMF (10 mL). EDC 
hydrochloride (0.50 g, 2.6 mmol, 1.1 eq) and N-hydroxysuccinimide (0.30 g, 2.6 mmol, 1.1 eq) 
were added and the mixture was stirred for 10 min and N-(6-amino)hexyl cis-5-norbornene-
endo-2,3-dicarboximide (0.68 g, 2.6 mmol, 1.1 eq) was added. The solution was stirred at room 
temperature overnight. The resulting solution was diluted with 50 mL of EtOAc and washed 
three time with water and once each with aqueous HCl (0.1 M) and brine. The organic solution 
was dried over Na2SO4 and evaporated to a residue, which was purified by column 
chromatography (silica, DCM-MeOH, 10:1) to give approximately 1.0 g of product as a yellow 
solid. Note: due to the lactone-acid equilibrium of fluorescein moiety, it is difficult to obtain this 
intermediate in very high purity, but the subsequent acetyl protection locks the fluorescein in its 
lactone form and greatly reduces the polarity of the compound, facilitating its purification. The 
solid was suspended in 5 mL of acetic anhydride and heated at 50 oC overnight to give a 
homogeneous, dark red solution. Acetic anhydride was removed under reduced pressure. The 
residue was purified by column chromatography using silica that was dried in a vacuum oven at 
150 oC for 48 h and pre-treated with EtOAc-hexanes (3:2 v/v) to give a white, non-fluorescent 
solid, which was approximately a 4:3 mixture of 5-isomer and 6-isomers. Yield: 0.7 g (50%). 1H 
NMR (400 MHz, CDCl3): 5-isomer: δ 8.42 (s, 1H), 8.21 (dd, J = 8.1 Hz, J = 1.5 Hz, 1H), 7.27 (d, 
J = 8.1 Hz), 7.09 (m, 2H), 6.81 (m, 4H), 6.61 (t, J = 5.4 Hz), 6.10 (s, 2H), 3.16-3.51 (m, 8H), 
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2.30 (s, 6H), 1.16-1.74 (m, 10H). 6-isomer: δ8.05-8.12 (m, 2H), 7.52 (s, 1H), 7.08 (m, 2H), 6.80 
(m, 4H), 6.42 (t, J = 5.5 Hz, 1H), 6.04 (s, 2H), 3.16-3.51 (m, 8H), 2.30 (s, 6H), 1.16-1.74 (m, 
10H). 13C NMR was not attempted as the product was a mixture. High resolution ESI-MS: 
calculated for [M+H+]: 705.2673; found: 705.2672. Elemental analysis: calculated for 
C40H36N2O10: 68.17% C, 5.15% H, 3.98% N; found: 68.03% C, 5.07% H, 3.96% N. 
Cis-2-Butene-1,4-diol bis(5-azidovaleric acid) ester (CTA1). A solution of 5-
bromovaleric acid (3.7 g, 20 mmol) and oxalyl chloride (1.8 mL, 21 mmol, 1.05 eq) in 30 mL of 
dichloromethane was cooled in an ice bath and one drop of DMF added. The ice bath was 
removed and the solution stirred for 3 h. Solvent was removed under reduced pressure, and the 
resulting residue was dissolved in 5 mL of dry dichloromethane and added to a mixture of cis-
1,4-dihydroxy-2-butene (0.80 g, 9.1 mmol, 0.91 eq) and K2CO3 (4.0 g, 29 mmol, 1.45 eq) in 
THF (25 mL). The mixture was stirred at room temperature overnight. Volatiles were removed 
under reduced pressure and the residue was partitioned between EtOAc and water. The organic 
layer was washed with water and brine, then dried over Na2SO4. The solvent was removed under 
reduced pressure and the crude product purified by column (silica, EtOAc-hexanes, 1:5 v/v) to 
give a olorless oil. The oil was dissolved in 20 mL of DMF, added NaN3 (1.3 g, 20 mmol), and 
stirred at 50 oC for 24 h. The mixture was partitioned between EtOAc and water. Organic phase 
was collected and washed further by water and brine. Crude product was obtained after 
evaporation, and was further purified by column (silica, EtOAc-hexanes, v/v 1:5) to give a 
colorless oil. Overall yield: 1.6 g (52%, relative to the diol). 1H NMR (500 MHz, CDCl3): δ 5.75 
(t, J = 4.3 Hz, 2H), 4.70 (d, J = 4.3 Hz, 4H), 3.30 (t, J = 6.6 Hz, 4H), 2.37 (t, J = 7.2 Hz, 4H), 
1.73 (m, 4H), 1.64 (m, 4H). 13C NMR (500 MHz, CDCl3): δ 173.0, 128.3, 60.2, 51.3, 33.8, 28.5, 
22.3. ESI-MS: calculated 338.2, found 339.2 [M+H+]. 
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Cis-1,4-Bis(4-(2-azidoethyl)phenoxy)-2-butene (CTA3). To a suspension formed from 
2-(4-hydroxyphenyl)ethanol (2.8 g, 20 mmol), K2CO3 (4.0 g, 29 mmol) and cis-1,4-dichloro-2-
butene (1.0 mL, 9.5 mmol) in anhydrous DMF (10 mL), was added tetrabutylammonium iodide 
(10 mg, catalytic) and the mixture stirred at 40 oC for 24 h. The resulting mixture was partitioned 
between diethyl ether and water, separated, and the organic phase was washed with water and 
brine. The solution was dried over Na2SO4 and filtered, then cooled in a -20 
oC freezer. The 
crystalline white solid was collected by filtration and dried under vacuum to get the pure 
intermediate compound cis-1,4-bis(4-(2-hydroxyethyl)phenoxy)-2-butene.  
The intermediate cis-1,4-bis(4-(2-hydroxyethyl)phenoxy)-2-butene (1.7 g, 5.2 mmol) was 
dissolved in 40 mL of DMF-CCl4 (4:1 v/v). To the solution was added NaN3 (0.9 g, 14 mmol) 
and PPh3 (2.7g, 10.3 mmol) and the mixture was heated to 90 
oC for 5 h and cooled to room 
temperature. The mixture was poured into 350 mL of water and extracted by diethyl ether. The 
organic layer was collected and washed with water and brine, dried over Na2SO4, and the solvent 
removed under reduced pressure to give a crude oil. The crude product was purified by column 
chromatography (EtOAc-hexanes, 1:4 v/v) to give the pure product as a colorless or light-yellow 
oil (0.7 g, 19% from cis-1,4-dichloro-2-butene). 1H NMR (400 MHz, CDCl3): δ 7.11 (d, J = 8.5 
Hz, 4H), 6.84 (d, J = 8.5 Hz, 4H), 5.91 (t, J = 3.6 Hz, 2H), 4.64 (d, J = 3.6 Hz, 4H), 3.44 (dd, J = 
7.2 Hz, 4H), 2.81 (t, J = 7.2 Hz, 4H). 13C NMR (500 MHz, CDCl3): δ 157.5, 130.7, 130.1, 128.8, 
115.1, 64.5, 52.9, 34.7. ESI-MS: calculated 378.2, found 401.2 [M+Na+]. 
N,N’-Diallyl-1,6,7,12-tetrachloroperylenediimide (PDI-allyl). To a suspension of 
1,6,7,12-tetrachloroperylene tetracarboxylic acid dianhydride (0.3 g, 0.56 mmol) in 8 mL of 
pyridine was added allylamine (0.2 mL, 2.7 mmol, 4.8 eq), and the suspension heated to reflux 
under nitrogen for 16 h. Solvent was removed under reduced pressure and the residue was 
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purified by column (silica, DCM-hexanes, 4:1 to 5:1 v/v) to yield a dark orange-red powder. 
Yield: 0.11 g (31%). 1H NMR (500 MHz, CDCl3): δ 8.71 (s, 4H), 6.00 (ddt, J = 10.2 Hz, J = 
17.1 Hz, J = 5.9 Hz, 2H), 5.41 (dd, J = 1.3 Hz, J = 17.1 Hz, 2H), 5.38 (dd, J = 1.3 Hz, J = 10.2 
Hz, 2H), 4.85 (d, J = 5.9 Hz, 4H). 13C NMR (500 MHz, CDCl3): δ 162.2, 135.7, 133.3, 133.3, 
131.7, 128.9, 123.6, 123.4, 118.8, 43.0. MALDI-TOF: calculated 610.0, found 610.1 [M+]. 
Typical procedure of polymerization without a CTA. M1 (95 mg, 0.3 mmol, 50 eq) 
and M4 (151 mg, 0.6 mmol, 100 eq) wre dissolved in anhydrous DCM (10 mL). The solution 
was degassed with three freeze-pump-thaw cycles to remove oxygen. Under nitrogen protection, 
pyridine-modified Grubbs 2nd Generation catalyst (0.04 M in DCM, 0.15mL, 0.006 mmol, 1 eq) 
was added. The solution was stirred at room temperature for 4 h before butyl vinyl ether (1 mL) 
was added to quench the catalyst. Solvent was removed under reduced pressure. The solid 
residue was sonicated in ether and centrifuged for 3 times before it was dried under reduced 
pressure to give an off-white solid. Yield: 213 mg (86%). 
Typical procedure of polymerization with a CTA. M1 (95 mg, 0.3 mmol, 50 eq) and 
M3 (106 mg, 0.6 mmol, 100 eq) were dissolved in anhydrous dichloromethane (10 mL). The 
solution was degassed with three freeze-pump-thaw cycles to remove oxygen. Under a nitrogen 
atmosphere, pyridine-modified Grubbs 2nd Generation catalyst (0.04 M in DCM, 0.15 mL, 0.006 
mmol, 1 eq) was added. The solution was stirred at room temperature for 2.5 h and CTA2 (0.2 M 
in DCM, 0.15 mL, 5 eq) was added. The solution was stirred for 3 h and butyl vinyl ether (1 mL) 
was added to quench the catalyst. Solvent was removed under reduced pressure. The solid 
residue was sonicated in ether, centrifuged, and the supernatant discarded 3 times before the 
solid was dried under reduced pressure to give an off-white solid. Yield: 187 mg (93%). 
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Typical procedure for functionalization with triallyl-TRIS. The poly(activated ester) 
(180 mg) was dissolved in a mixture of DCM (8 mL) and nitrobenzene (1 mL) in a 20-mL vial. 
Triallyl-TRIS (0.2 mL) was added. The vial was capped and sealed by parafilm, and the solution 
was stirred in a 40 oC oil bath overnight. Most of the solvent was removed under reduced 
pressure, and the viscous residue was precipitated in 15 mL of a 2:1 (v/v) mixture of ether-
hexanes and centrifuged. The precipitate was sonicated two times in ether (12 mL) and two times 
in methanol (10 mL) each time centrifuging and discarding the supernatant to remove triallyl-
TRIS, NHS and nitrobenzene. The remaining solid was dried under reduced pressure to give the 
product as an off-white powder. Yield: 160 mg. 
Typical procedure for intramolecular crosslinking with or without PDI-allyl. In a 1 
L round-bottom flask, 50 mg of polymer P5-b and 3.3 mg of PDI-allyl (if needed, 5 eq relative to 
the amount of polymer chains) was dissolved in 600 mL of anhydrous DCM under a nitrogen 
atmosphere, and the solution was stirred at room temperature for 15 min. To the solution was 
added 12 mg of 1st Generation Grubbs catalyst in 1 mL of DCM and the lower 1/3 of the flask 
immersed in a 35 oC oil bath. The solution was stirred for 6 h and 6 mg catalyst added and stirred 
18 h and 6 mg catalyst added. The mixture was stirred for a total of 48 h after the first catalyst 
addition and 3 mL of butyl vinyl ether was added to quench the catalyst.  The solution was 
stirred 30 min and evaporated under reduced pressure. The solid residue was dissolved in DCM 
and purified by passing through silica gel eluted by DCM. Solvent was evaporated and the 
residue was sonicated and triturated in diethyl ether. Decantation gave a grey (or reddish if PDI 
was added) powder after vacuum drying. 
Typical procedure for dihydroxylation of the alkene ONPs. In a 20 mL glass vial, 40 
mg of polymer P3-c was suspended in a mixture of water (3 mL) and acetone (7 mL). NMO (50% 
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wt in H2O, 0.4 mL) and K2OsO4 (catalytic amount) was added to the mixture. The vial was 
loosely capped and heated in a 40 oC oil bath for several hours, before the cap was removed and 
the vial was covered by a piece of chemical paper wipe. Acetone was allowed to evaporate over 
time and 4 mL of water was added when the mixture became almost homogeneous. Heating and 
stirring was continued for 5-6 h and the solution decanted to remove any insoluble residue. The 
supernatant was stirred with Smopex-105 metal scavenger at 50 oC. The solution could be further 
purified by dialysis against water using a 1 kDa cutoff membrane and the solution lyophilized to 
yield a grayish-white solid. Yield: 32 mg. 
Typical procedure for dihydroxylation and hydrolysis of acetal groups in one pot. 
The crosslinked polymer (40 mg, from the linear polymer in which M1:M5:M6 = 25:50:4) was 
suspended in a mixture of acetone and water (10 mL, 7:3 v/v) in a 20-mL vial. NMO (0.4 mL, 50% 
w/w in water) was added, followed by K2OsO4 (catalytic amount). The vial was loosely capped 
and heated in a 40 oC oil bath for several hours, before the cap was removed and the vial was 
covered by a piece of chemical paper wipe. Acetone was allowed to evaporate over time and 4 
mL of water was added when the mixture became almost homogeneous. Heating and stirring was 
continued for 5-6 h and the solution was cooled to room temperature and quenched by adding 
NaHSO3 (200 mg) and stirring for 30 min. Concentrated HCl was added dropwise to the fast-
stirring solution until the pH of the solution dropped below 1 as measured by pH test paper. 
Precipitates formed during this process because the polymer before hydrolysis was not soluble in 
aqueous solution with high ionic strength. The reaction was stirred at 35 oC for several hours 
until the solution became almost clear, then filtered or centrifuged to remove any insoluble 
residue and purified by dialysis using dilute aqueous NaHCO3 once and water once. The purified 
solution was lyophilized to give a yellow solid (29 mg). 
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Example of Large Scale ONP Preparation 
(1) ROMP polymerization. M1 (1.7 g, 6 mmol, 100 eq), M5 (958 mg, 3.01 mmol, 50 
eq.) and M6 (165 mg, 0.244 mmol, 4 eq.) were dissolved in 100 mL of chloroform in a 500 mL 
round bottom flask.  The solution and flask were purged with argon for 5 min.  A solution of 
pyridine-modified Grubbs 2nd Generation catalyst (43.6 mg, 59.9 μmol, 1 eq. in 4 mL 
deoxygenated DCM) was added and the mixture stirred at room temperature for 20 min.  CTA2 
(1.097 g, 2.08 mmol, 35 eq.) was added and the solution stirred 4 h.  Butyl vinyl ether (15 mL, 
116 mmol) was added and the mixture stirred for 45 min. The solvent was removed under 
reduced pressure and the residue dissolved in 30 mL of DCM.  The solution was transferred to 
two 50 mL tubes and polymer precipitated with 30 mL diethyl ether and centrifuged (10 min x 
4000 rpm).  The brown supernatant was removed and the polymer dissolved and combined (total 
vol. 28 mL) and precipitated with 22 mL of diethyl ether.  The polymer was pulsed for 30 s in 
the centrifuge and the supernatant poured off.  The polymer was dried under high vacuum to 
yield an off-white solid. Yield: 2.48 g, 94 %. 
(2) Attachment of TriallylTris. The ROMP polymer (2.48 g, 50.5 μmol, 2.54 mmol 
activated ester) was dissolved in 200 mL chloroform:nitrobenzene (19:1 v/v) in a 500 mL round 
bottom flask.  Triallyltris (2.9 g, 12 mmol, 4.7 eq.) was added and the flask sealed with a septum.  
The reaction was heated to 55 °C for 12 h.  The solvent was removed under reduced pressure and 
the residue transferred with DCM to a 50 mL tube (total volume 22 mL).  The polymer was 
precipitated with 25 mL diethylether:hexane (2:1 v/v) and centrifuged (10 min x 4000 rpm).  The 
supernatant was removed and the precipitate dissolved with 10 mL DCM and precipitated with 
40 mL diethyl ether.  The polymer was pulse centrifuged and the supernatant removed.  The 
polymer was dissolved in 20 mL DCM precipitated with 30 mL MeOH, sonicated for 5 min then 
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centrifuged and the supernatant decanted.  The polymer was then dried on high vacuum to yield 
an off-white solid. Yield: 1.76 g, 62 %.   
(3) RCM. The above polymer (1.76 g, 35 μmol) was dissolved in 5 L of DCM in a 3-
neck RBF.  A solution of Grubbs Generation 1 catalyst (445 mg, 0.54 mmol) in 5 mL DCM was 
added.  The reaction was performed under a nitrogen atmosphere and the internal temperature 
monitored to maintain 30 °C via heating mantle.  Additional catalyst was added (223 mg, 0.27 
mmol in 4 mL DCM) at 20 h and the mixture heated for a total time of 68 h. The reaction was 
quenched with 25 mL butyl vinyl ether (193 mmol) and stirred for 45 min.  The solvent was 
removed under reduced pressure and the crude polymer purified by silica gel plug eluting with 
DCM to remove the bulk of the catalyst.  The solvent was removed and the dark brown polymer 
carried forward 
(4) Dihydroxylation and Hydrolysis. To the RCM polymer product in a 300 mL round 
bottom flask was added 200 mL acetone:water (7:3 v/v), K2OsO4 dihydrate (26 mg, 70.6 μmol) 
and NMO (50% w/w in water, 16 mL, 77.2 mmol).  The flask opening was covered by a 
chemical paper wipe and allowed to stir with the bottom half of the flask heated in an oil bath at 
50 °C.  After 12 h most of the polymer dissolved off the sides of the flask. The temperature was 
increased to 65 °C and the mixture stirred for a total of 40 h. Sodium bisulfite (sold as mixture 
with sodium metabisulfite, 8.0 g) was added to the greenish mixture and stirred for 1 h.  Several 
large black clumps were present. The reaction was then carefully acidified to pH 1 by drop-wise 
addition of 5 mL of concentrated HCl.  The solution was stirred for 3 h, basified to pH 12 with 4 
M NaOH momentarily, and neutralized with 2 M HCl.  The black clumps dissolved with the 
addition of ~150 mL DI water.  The reaction was vacuum filtered and most of the solvent 
removed under reduced pressure.  When ~50 mL water remains solid starts to form on the sides 
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of the evaporation flask and the contents were transferred to dialysis tubing.  The polymer was 
dialyzed using a Spectra/Por dialysis membrane with a molecular weight cut-off of 1000 kDa 
against 4 L water for 14 h, and three times for 2 h. The volume of solvent was decreased via 
rotary evaporation then dried via lyophilization. Yield: 1.51 g  (88% for three steps). 
mPEG DNA Conjugation  
To demonstrate the function of amine group on ONP surface, a 10 kDa thiolated 
polyethylene glycol (mPEG-SH) was conjugated with non-water-soluble amine-ONP. Amine-
ONPs (5 mg) were dispersed with 0.1 M sodium phosphate buffer (with 0.1 M NaCl, pH 7.3) 
and DMF to form a 0.2 mM suspension. Sulfo-SMCC (1 mg) was added into 500 µL of the 
amine-ONP suspension, and then placed on a shaker for 2 h at room temperature. The excess 
sulfo-SMCC was removed and the sulfo-SMCC-activated amine-ONPs were purified by 
Amicon-30K passing 0.1 M sodium phosphate buffer (with 0.1 M NaCl, pH 7.3) through 8 times. 
Thiolated mPEG-10,000 (2 mg) was activated by using tris(2-carboxyethyl) phosphine (TCEP) 
in sodium acetate buffer (pH 5.2). The purified sulfo-SMCC-activated ONPs solution and the 
activated thiolated mPEG-10,000 solution were mixed together and vortexed for 1 min. The 
mixture was then incubated at room temperature under shaking for 48 h. After incubation, non-
reacted ONPs were not water-soluble and can be centrifuged down as precipitates and removed 
by filtration. The reacted PNPs formed water-soluble PNP-mPEG conjugates and stayed in 
supernatant. The conjugate was purified by 8 passes through an Amicon-30K centrifugal filter 
using 0.1 M sodium phosphate buffer (with 0.1 M NaCl, pH 7.3) to remove any un-reacted 
thiolated mPEG-10,000. The conjugation of DNA to ONP follows the same procedure. 
Fluorescent ONP Photobleaching experiment 
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Free fluorescein and fluorescent nanoparticle(s) were dissolved in 0.1 M phosphate buffer 
(pH = 7.4) to give 1 µM solutions in 7 mL vials. The vials were placed in a black box equipped 
with a power-adjustable 470 nm LED. The distance between the vials and LED was set at 20 cm. 
After the LED was turned on (t = 0), the fluorescence intensity of the solutions were examined 
every 2 h by a fluorospectrometer until enough data points were obtained. 
Cell Culture  
HeLa cells used for ONP uptake experiments were cultured in Dulbecco’s modification 
of Eagle’s medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 100 U/mL 
penicillin, and 100 µg/mL streptomycin, on 25 cm2 culture flasks in a humidified 5% CO2 
incubator at 37°C. Hela cells were plated onto 35 mm glass-bottom dishes (MatTek) and grown 
to 70-90% confluence before confocal microscopy imaging. 
ONP uptake, imaging and flow cytometry study  
HeLa cells were incubated with 2 mL of Opti-MEM containing 5 µM ONPs in glass-
bottom dish. After 6 hours, cells were washed with PBS 3 times and fresh DMEM was added. 
ONPs treated cells were then stained with Hoechst 33258 (Invitrogen) of 2.5 ng/mL for 20 
minutes. After Hoechst staining, Lysotracker Red (Invitrogen) of 50 nM was added to cells and 
incubated for 30 minutes. 
Confocal images were obtained using a Zeiss LSM 710 NLO confocal microscope at 63x 
magnification equipped with a Mai-Tai Ti-Sapphire laser. Fluorescence emission was obtained 
over 450-520 nm (DAPI), 510-570 nm (ONP), and 575-620 nm (LysoTracker Red) ranges, with 
excitation at 401 nm, 488 nm, and 561 nm, respectively. The pinhole and gain settings were kept 
constant throughout the whole imaging process. 
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For flow cytometry study, after 6-hour incubation with ONPs, Hela cells were washed 
with PBS and detached by 0.05% trypsin. The suspended cell solution was collected by 
centrifugation at 2,000 g for 5 min and further washed with PBS three times. Flow cytometry 
was performed using a BD FACSCanto system under 488 nm excitation. Control cells without 
any treatment were used to set the gating. Each measurement set was performed using 10,000 
cells. 
MTT Cell Viability Assay 
Cellular toxicity of the organic nanoparticles (ONPs) was examined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay.  HeLa cells 
were seeded into 96-well plates at a density of 2,000 cells/well in DMEM media with 10 % fetal 
bovine serum (200 µL) and grown in a humidified 5 % CO2 atmosphere at 37 
oC for 24 h.  The 
media was removed, cells were rinsed with 200 µL of PBS, and incubated for 24 hrs in the 
presence of ONP (60 µL/well).  Next, 25 mg of MTT in 5 mL of PBS was added to each well (20 
µL/well) and incubated for an additional 1.5 h protected from light.  The solution was removed 
and the reduced formazan was solubilize with the addition of DMSO (200 µL/well) producing a 
purple color and mixed for 15 min.  The absorbance of each well was read with a fluorescence 
plate reader at 590 nm. For each experiment, a control of cells that were not incubated with 
ONPs was also analyzed. All samples were run in quadruplet. The average absorbance for each 
sample was calculated and percent viability was determined using the following equation: % cell 
viability = A590 treated cells/A590 untreated cells × 100. 
Growth of Gold Nanoparticle in ONP Template 
Gold nanoparticles were prepared by sucrose and ascorbic acid with a typical protocol as 
following: For gold nanoparticles prepared by sucrose, 10 μL polymer template (50 μM) was 
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added in 940 μL citrate buffer (5 mM, pH =3.01). Then, 25 μL HAuCl4 (10 mM) was added. 
After mixing, incubate the solution at room temperature for 10 min. Then, add 25 μL 1 M 
sucrose to reduce chloroaurate. For control samples, the volume of polymer template solution 
were filled by buffer. All of the SEM and TEM samples reacted overnight. For gold 
nanoparticles reduced by ascorbic acid, 5 μL polymer template (50 μM) was added in 445 μL 
citrate buffer (5 mM, pH =3.01). Then, 25 μL HAuCl4 (10 mM) was added. After mixing, 
incubate the solution at room temperature for 10 min. Then, add 25 μL 100 mM ascorbic acid to 
reduce chloroaurate. 
 Kinetics studies of gold nanoparticles was carried out by UV-Vis spectrophotometer 
(Hewlett–Packard 8453) and fluorometer. 
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7.6. Figures 
 
Table 7.1. Representative characterization data for polymers synthesized in this work. [a] Molar 
ratio of 1a/comonomer (1x, x can be b-g)/2. [b] Absolute number-average molecular weight 
determined by a GPC with a multi-angle laser light scattering (MALLS) detector. [c] Not 
determined. [d] Interference of fluorescence in MALLS detection prevented absolute molecular 
weight determination, but polystyrene calibration gave similar “molecular weight shrinking” 
compared to other entries. [e] Polydispersity was calculated by Breeze 2 software from Waters 
Corporation based on RI data and traditional polystyrene calibration method. 
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Figure 7.1. Illustration of ideal organic nanoparticles with desired features for applications. 
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Figure 7.2. Synthesis of organic nanoparticles (ONPs) using a sequential ROMP and RCM 
process.  Py = pyridine, Mes = 2,4,6-trimethylphenyl, OSu = N-hydroxysuccinimidyl ester. 
 
Figure 7.3. (a) Partial 
1
H NMR spectra of 4 (top) and 7 (bottom) showing loss of terminal alkene; (b) 
Overlaid GPC curves of polymers 3, 5, and 7 (DMF, 0.1 M LiBr, eluent).  Both (a) and (b) are of 
polymers prepared in entry 1, Table 7.1. 
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Figure 7.4. (a) Dihydroxylation protocol to generate water-soluble ONPs;  (b) Example of gram-
scale preparation of ONP 8. Sample in the picture contains a M/I ratio of 1a:1d:1f:2 = 
100:50:4:1. Note: exo-norbornene monomers used. 
 
 
Figure 7.5. GPC curve overlay of polymers prepared with different M/I ratio. 
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Figure 7.6. (a) Selected TEM images of water-soluble ONPs of different sizes.  The polymer Mn 
values are 102 kDa (left), 53 kDa (mid), and 12 kDa (right). (b) A broad selection of TEM 
images of ONPs of different sizes.  These ONPs were end-functionalized with CTA 9b. 
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Figure 7.7. Schematic illustration of the synthesis of monovalent ONPs using CTAs, and further 
functionalization pathways using RCM or facile bioconjugation reactions. 
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Figure 7.8. Colocalization study of DNA-ONP conjugate using fluorescence microscopy. (a) 
Cy3 channel image of DNA-ONP conjugate, showing the fluorescence emission of Alexa Fluor® 
594 dye on DNA strands. (b) FITC channel image of DNA-ONP conjugate, showing the 
fluorescence emission of fluorescein in ONPs.  
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Figure 7.9. (a) Photobleaching study using 470 nm LED with fluorescein (1 µM, left vial) and 
ONP 8 (1 µM, right vial) before and after irradiation in pH 7.4 phosphate buffer; (b) Relative 
fluorescence of fluorescein and ONP 8 over time during the photobleaching experiment; (c) 
accurate tuning of ONP fluorescence intensity by adjusting the equivalents of fluorescein 
monomer 1g during ROMP. 
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Figure 7.10. (a) Schematic view of the 12 kDa green fluorescent ONPs entering HeLa cells. (b-f) 
Confocal microscopy images of HeLa cells treated with 12 kDa green fluorescent ONPs: (b) 
brightfield image of cells; (c) blue channel image showing nucleus staining with DAPI; (d) red 
channel image showing LysoTracker red staining; (e) fluorescein ﬂuorescence from ONPs; (f) 
overlay of nucleus, LysoTracker red and ONP ﬂuorescence; (g) the cell-associated fluorescence 
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intensities of HeLa cells (grey) and fluorescent ONPs (green) treated HeLa cells using flow 
cytometry. 
 
Figure 7.11. Preliminary results of MTT toxicity study of the organic nanoparticles of different 
molecular weights.  The Y-axis shows % cell viability. 
 
 
 
Figure 7.12. TEM images of 50 kDa ONPs (a) and AuNPs synthesized from 50 kDa ONPs using 
sucrose as the reducing agents. 
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Figure 7.13. (a) Time-dependent UV-vis absorption spectra, indicating the growth of AuNPs 
through the reduction process. (b) Time-depend fluorescence emission spectra of ONPs, showing 
the quenching of the fluorescence intensity. (c) Kinetic study showing the correlation between 
UV-vis absorption and the fluorescence emission during the ONP-templated AuNP synthesis. 
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Figure 7.14. Different sized AuNPs synthesized from ONPs with different MWs of 12 kDa (a), 
50 kDa (b), and 100 kDa (c) by ascorbic acid reduction. The size of the obtained AuNPs matches 
well with the size of the template. 
 
Figure 7.15. (a) Schematic view of the DNA-directed assembly of AuNPs dimers. (b) Formation 
of homogeneous AuNP dimers by 5 nm AuNPs and AuNPs synthesized from 12 kDa ONPs. (c) 
Formation of heterogeneous AuNP dimers by 5 nm AuNPs and AuNPs synthesized from 50 kDa 
ONPs. 
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CHAPTER 8 
CONTROL OVER CELLULAR UPTAKE OF ORGANIC 
NANOPARTICLES BY FINE TUNING SURFACE FUNCTIONAL 
GROUPS 
8.1. Introduction 
 Nanoparticles (NPs) are important vectors for transporting desired cargo into cells, 
and thus are widely used in different areas of biological researches, such as drug delivery 
and gene therapy.1-7 To achieve more efficient delivery and targeting, as well as better 
biocompatibility of the particles, the surface functional groups of the particles need to be 
tuned. A wide range of surface coating methods, such as ligand-exchange,8-10 
PEGylation10-12 and targeting-moiety conjugation10,11,13 can be adopted to functionalize 
the particles. These simple methods can greatly change the properties of the nanoparticles, 
providing additional features like surface charges, increased circulation time, bio-derived 
recognition, and etc. Appropriate and clever use of such strategies has become one of the 
most important parts of nanoparticle design. 
 The mechanism of nanoparticle internalization is explicitly important, yet it is far 
from being well understood. One of the reasons that limits this mechanistic study is the 
limited precise chemical control over nanoparticle surfaces. Common inorganic 
nanoparticles, such as metal nanoparticles (MNPs), silica nanoparticles (SiO2-NPs) and 
quantum dots (QDs), all have homogeneous surfaces and the available chemical 
modifications are inherently limited. Surface deposition and ligand exchange are 
commonly employed for the modification of these types of nanoparticles. For systems 
263 
 
working in aqueous media, highly-charged or PEGylated surfaces are needed. Such 
featured surfaces are also applied to organic nanoparticles (ONPs) synthesized from 
polymers via different ways,14-16 as these ONPs are also lack of reactive functional groups 
on their homogeneous surfaces. On the other hand, single-molecule ONPs, such as 
dendrimers17,18 and intramolecular cross-linked polymers19-22 from bottom-up synthesis, 
both potentially provide more ways of functionalization. These macromolecules can bear 
controlled number of specific functional groups, designed internal structures, and narrow 
size distributions. However, the limitations are also apparent: the multi-step synthesis of 
dendrimers restricts the synthesis of particles with different functionalities or larger sizes, 
while most of the reported ONPs synthesized from single-chain crosslinking are insoluble 
in water, limiting on their potential applications in biological field. 
 Our group has recently reported a new strategy to synthesize water-soluble, 
biocompatible ONPs from a consecutive ring-opening metathesis polymerization and 
ring-closing metathesis (ROMP-RCM) process.23 The strategy allows facile and diverse 
incorporation of functionalities, good size control and large-scale synthesis. From 
investigations using this new material, we found that the monomer used in the linear 
polymerization had a profound effect on cell internalization of the final ONPs. This 
phenomenon has attracted our interests in adopting this new material as a great platform 
for studying nanoparticle-cell interaction. As the synthetic route offers very fine control 
over ONP surface properties (Figure 8.1), the ONP is excellent for determining the role of 
surface functionalities on ONP in ONP-cell interactions. While this work was in progress, 
Rotello and co-workers reported the synthesis of corona-free, zwitterionic gold 
nanoparticles with tuneable hydrophobicity and correlated it with cell uptake kinetics.24 
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However, to our knowledge, similar research on non-ionic, water-soluble organic 
nanoparticles is absent because of the challenges in synthesizing neutral, highly 
functionalized, water soluble ONPs. The bottom-up ONP synthesis also offers more 
controlled and tunable degree of functionalization. We hope that such fundamental 
research would complement the published work and offer a complete story on surface-
controlled NP internalization. The finding would potentially serve as useful references in 
future design of NPs for biological applications. In addition, such research may contribute 
to the studies of unveiling the mechanism of NP cell uptake. 
8.2. Results and Discussions 
Synthesis and Characterization of ONPs 
 The 11 ONPs (ONP1-ONP11) with different functional groups were synthesized 
from 9 exo-norbornyl derivatives (M1-M9, Figure 8.2), with two of them as common 
monomers (M1 and M2), which provided crosslinking sites and fluorescence. The 
synthesis was straightforward as described in Chapter 7 and our previous paper.23 All of 
the ten ONPs had approximately the same degree of polymerization (DP) and 
crosslinking density, and were therefore similar in size (ONP175-ONP1175). Another 
group of ONPs with same composition and crosslinking density, but different DP, were 
synthesized in order to determine the size effect of the nanoparticles (ONP230, ONP275, 
ONP2150, ONP2300). All of the ONPs in this study contained same number of fluorescein 
moieties (2 per ONP), and have fluorescence intensities approximately the same in 
aqueous solution at the same molar concentration. To semi-quantitatively determine the 
relative lipophilicity of the variable repeating units in the ONPs, the variable monomers 
(M3-M9) were dihydroxylated under Upjohn conditions and deprotected when necessary, 
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yielding a total of 11 “imaginative monomers” (IM1-IM11, obtained and characterized as 
mixed stereoisomers, Figure 8.2), corresponding to the 11 ONPs that were synthesized. 
These “imaginative monomers” were tested on a LC-MS system under the same eluting 
condition, and the retention times were recorded as a relative scale for repeating units’ 
lipophilicity. 
 ROMP of norbornenyl derivatives mediated by Grubbs 3rd generation catalyst 
offers precise control over polymer composition, length and dispersity, based only on 
feed ratio of monomers and catalyst. Similar to our previous work, careful weighing of all 
monomers and catalyst yield all the linear polymers with molecular weights very close to 
expected weights (Table 8.1), as well as low polydispersity indices (PDIs), based on 
GPC-MALLS characterization. A representative GPC curve is shown in Figure 8.3. These 
linear poly(activated esters) with different co-monomers were then functionalized by 
tris(allyloxymethyl)aminomethane (Triallyl-Tris), crosslinked intramolecularly, and 
finally dihydroxylated (also deprotected in some cases) to give well-defined ONPs. 
Unfortunately, four ONPs (ONP175, ONP375, ONP475 and ONP575) were not quite 
soluble in pH 7.4 phosphate buffer, and were not used in the cell studies. 
The Effect of Surface Functional Groups of ONPs on Cellular Uptake 
 To investigate the ability of different ONPs to enter live cells, we chose the seven 
co-monomers carefully so that they can cover a wide range from lipophilic to hydrophilic, 
and provide several different series for easy comparison. HeLa cells (human cervical 
canceras) were selected as the model system. The uptake of the ONPs with different 
surface functional groups was examined using flow cytometry technique and confocal 
microscope imaging. Because of the well-controlled ONP synthesis process, all of the 
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ONPs prepared in this study contained on average two fluorescein units per particle, 
giving comparable fluorescence intensity at the same molar concentration. As a result, the 
fluorescent intensity measured in flow cytometry experiments was proportional to the 
uptake efficiency of these nanoparticles.  
 We start our investigation from the most obvious set among all structures 
consisting of ONP675, ONP775 and ONP875. These polymers all had a single hydroxyl 
group on the side chains, and one can easily judge the lipophilicity of these three ONPs: 
ONP875 > ONP775 > ONP675, because of the decrease in their aliphatic linker length 
(Figure 8.4a). The ONPs of 2 µM concentration were incubated with HeLa cells for 3 
hours in DMEM at 37 °C. The ONP-treated HeLa cells were then carefully washed and 
lifted for flow cytometry study. As shown in Figure 8.4, with the increase of the carbon 
chain length of the linker, the mean fluorescence peak shifted towards positive direction, 
indicating higher efficiency of cell uptake for more lipophilic nanoparticles (Figure 8.4b). 
The trend can also be explicitly seen on Figure 8.4c, where the If value of the ONP-loaded 
cells was apparently elevated by longer carbon chains. ONP875 had as high as 7-fold 
higher uptake compared to ONP675 in this experiment. 
 The study on the carbon chain length suggests that the hydrophobic domains on the 
nanoparticle would be related to the cell uptake process. To further confirm the effect of 
hydrophobicity of ONP on cell uptake, a second set of ONPs of ONP275, ONP775 and 
ONP975 with different number of hydroxyl groups were used to incubate with HeLa cells 
in DMEM (Figure 8.5a). As shown in Figure 8.5, the flow cytometry results clearly 
showed that the increased number of hydroxyl groups hindered the amount of ONP 
getting into HeLa cells, suggesting the hydroxyl group may participate in the cell uptake 
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process. The three peaks on Figure 8.5b, from left to right, correspond to ONP275, 
ONP775 and ONP975, respectively. The If of the cells treated with ONP975 (no hydroxyl 
group on side chains) was approximately 100% higher than that with ONP775 (one 
hydroxyl group per side chain), which was roughly 50% higher than the case with 
ONP275 (two hydroxyl groups per side chain) (Figure 8.5c). The results suggested the 
same conclusion that particles with more hydrophobic domains facilitates cellular uptake.  
 The method of the single-chain polymer particle can not only synthesize same 
sized ONPs with different surface functions but also can achieve different sized ONPs 
with same surface functionalities. To study the size effect of ONP on cell uptake, we used 
the co-monomer IM2 to prepare ONPs of different sizes. ONP2 with calculated molecular 
weight of 12, 25, 50, and 100 kDa were applied for the cell uptake experiments (Figure 
8.6a). Flow cytometry study showed that HeLa cells treated with smaller ONPs showed 
much higher fluorescence intensity compared to larger ONPs with the same monomer 
composition, indicating the enhanced cell internalization ability (Figure 8.6b and 6c). The 
If of the cells treated by the smallest particle was about 3 times of the If of the cells 
incubated with largest particles. This confirmed that apart from lipophilicity, the size of 
ONPs also played a key role in cell uptake. It is worth noting that all the previous 
experiments were conducted with carefully prepared ONPs with very close DP, hence the 
influence of their size difference was negligible when we were investigating the co-
monomer effect. 
 Although we have demonstrated that the cell uptake ability of ONPs in serum-free 
medium can be tuned by surface functional groups and sizes, the mechanism for ONP 
uptake is still unclear. Previous studies reported that protein corona on nanoparticle 
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surface from non-specific absorption plays very important role in determining 
nanoparticle behaviour in biological environment.25-29 The formation of protein corona on 
nanoparticle surfaces can be reversible or irreversible.24,25,30 For NP uptake studies in 
serum-free conditions (thus no corona formation), similar results were reported where 
lipophilic NPs led to higher cellular uptake.31,32 However, the trend could be completely 
reversed with the presence of serum, as higher hydrophobicity leads to greater protein 
absorption, resulting in reduced NP internalization.33-35 In a very recent report, Rotello 
and co-workers proved that, as opposed to earlier cases, zwitterionic AuNPs that do not 
form irreversible coronas in serum media could show the same uptake efficiency as the 
NPs that do in serum-free conditions.24 This important finding confirmed the possibility 
of direct interaction of the surface ligands (i.e. effect of the chemical properties) with 
cells and in physiological condition. 
 Based on previous nanoparticle cell uptake studies, it is highly possible that the 
interactions between ONP surface functional groups and cell membrane proteins would 
also play a key factor in influencing ONP cell uptake property. Considering that it might 
be extremely difficult to verify the absence of hard corona with direct characterizations 
arising from the extremely low density of such NPs with organic nature,23 we adopted a 
method from Rotello’s research to investigate the cell uptake trend in serum-containing 
media as a good indirect evidence to confirm the formation of protein corona on ONP 
surface. Considering the hydroxyl-rich, charge-free nature of the ONPs, we expected the 
NPs not to form irreversible coronas with serum treatment. To study the surface protein 
absorption of ONP, we repeated all the above-mentioned studies in 10% FBS-containing 
DMEM medium. The flow cytometry results showed that HeLa cells treated with ONP8 
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with the longest carbon chain and ONP9 with no hydroxyl group exhibited highest 
fluorescent intensity among each group, which follows the same trend as the results in 
serum-free medium (Figure 8.7a, b). The overall uptake efficiency in 10% FBS DMEM 
medium was significantly lower than the studies of “naked” NPs under serum-free 
conditions, which is consistent with previously reported results.24,36-38 Moreover, we also 
observed that in 10% FBS environment, all the different sized ONPs with same surface 
functions exhibited approximately the same cell internalization ability, with only the 
smallest ONP internalized slightly more than others (Figure 8.7c). The result suggested 
that after forming the protein corona, the size of ONP is not a dominant factor for ONP 
internalization, further confirming the critical role of surface functions. More importantly, 
the effects of functional groups indicate that the ONPs only have relatively weak 
interactions with serum proteins, and do form coronas reversibly. As a result, the cell 
uptake ability of ONPs can also be tuned under physiological conditions. It is important to 
note that, due to the profound effect of tuning lipophilicity, some ONPs in serum media 
even showed much higher efficiency in uptake, compared to some “naked” ONPs. 
 To further investigate the quantitative analysis for the relationship between ONP 
surface functions and cell uptake ability, we used lipophilicity as a parameter to predict 
the cellular uptake efficiency of corresponding monomers. As a way of measuring 
lipophilicity, we synthesized all “imaginative monomers” from M3 to M9 to mimic the 
repeating units’ properties in the final ONPs. The LC-MS retention times were shown in 
Table 8.2. Because all the synthesized “imaginative monomers” were mixed isomers, the 
peaks were relatively broad. However, it was still apparent that these repeating units 
covered a wide range of lipophilicity, with IM2 being the most hydrophilic and IM5 being 
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the most lipophilic. It is worth noting that IM2, IM6, IM7 and IM8 are unmasked 
products of IM1, IM3, IM4 and IM5, as we hope they can potentially be used to alter the 
ONP’s cell uptake properties in a tunable manner. Unfortunately, all the ONPs with IMs 
more hydrophobic than IM8 were not soluble in pH 7.4 phosphate buffer, as mentioned 
previously, although they were soluble in slightly more basic buffers. This tunable 
behaviour could still be achieved by using mixed monomers, as exemplified in the 
synthesis of ONP1275. 
 The cell uptake results from 6 ONPs synthesized from different co-monomers were 
shown in Figure 8.8. In general, the cell uptake efficiency followed the estimated trend: 
ONPs with more lipophilic repeating units gave better uptake results, and the efficiency 
increased dramatically when the retention time was more than 4 minutes. The only 
exception was from ONP275, which showed slightly higher uptake than ONP675. Possible 
explanation for this phenomenon is that the longer carbon chain on ONP275 may have 
played a more important role. In addition, IM7 and IM9 had extremely close retention 
time, while ONP775 showed an obvious decrease in uptake compared to ONP975, 
suggesting the negative effect of hydroxyl groups. However, it was important that the 
ONPs should have enough hydrophilic functional groups to maintain good solubility in 
water. Surfaces that were too hydrophobic led to particle aggregation and precipitation, as 
in the case of ONP175, ONP375, ONP475 and ONP575. However, water-soluble ONPs at 
extreme lipophilicity did show critical behaviours, as the internalization efficiency of 
ONP875 was exceptionally high compared to other ONPs, in both serum and serum-free 
conditions. 
 
271 
 
8.3. Conclusions 
 In summary, we have demonstrated that the lipophilicity of ONPs from ROMP-
RCM strategy could be fine-tuned by changing the surface functions, which in turn 
changed the cell uptake profile of the yielded ONPs. With the increase of the lipophilicity 
of the monomer and the decrease of the ONP size, cell internalization ability of the 
corresponding ONP increases. In the serum-containing biological environment, ONPs did 
not form hard coronas, and showed improved uptake efficiency as particle lipophilicity 
increased, which was similar to the trend observed for many “naked” NPs. In addition, 
these findings further indicate that the ROMP-RCM strategy provides promising scaffolds 
as a functional, tuneable, and biocompatible delivery vehicle. 
8.4. Experimental Section 
Materials 
All reagents were purchased from Acros Organics, Fisher Scientific, AK Scientific, TCI 
America, or Sigma-Aldrich, and used without further purification unless otherwise noted. 
Dichloromethane (DCM), pyridine, THF, benzene, toluene, nitrobenzene, DMSO and DMF were 
stored over activated 4Å molecular sieves. Other solvents were used as received. Triethylamine 
was dried over KOH pallets. Diisopropylethylamine was dried over 4Å molecular sieves. cis-5-
norbornene-exo-2,3-dicarboxylic anhydride,39 N,N’-DiBoc cis-1,4-di(4-aminoethylphenoxyl)-2-
butene (NHBoc-CTA)23 and tris(allyloxymethyl)-aminomethane (Triallyl-Tris)40 were 
synthesized according to procedures in literature. Pyridine-modified Grubbs 2nd Generation 
catalyst (usually referred as Grubbs 3rd Generation catalyst) for ROMP polymerization was 
synthesized using a modified literature protocol41 from Grubbs 2nd Generation catalyst and 
pyridine (instead of bromopyridine). 
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Instrumentation 
NMR spectra were recorded using a Varian U400, UI400, U500 or VXR500 spectrometer 
in the NMR Laboratory, School of Chemical Science, University of Illinois at Urbana-
Champaign. The data was processed in MestReC v4.8.1.1. Some spectra were treated with the 
smoothing function of the software to obtain better baseline. NMR images were screenshots 
taken from MestReC directly. Mass spectral analyses were provided by the Mass Spectrometry 
Laboratory, School of Chemical Science, University of Illinois, using ESI on a Waters 
Micromass Q-Tof spectrometer, FD on a Waters 70-VSE spectrometer. Analytical LC-MS 
experiments were conducted on an Agilent 1100 LC/MSD Trap XCT Plus in the Metabolomics 
Lab, Roy J. Carver Biotechnology Center, University of Illinois. Analytical gel permeation 
chromatography (GPC) experiments were performed on a Waters system equipped with an 
Waters 1515 isocratic pump, a Waters 2414 refractive index detector, and a Waters 2998 
photodiode array detector. Separations were performed at 50 °C using DMF containing 0.1 M 
LiBr as the mobile phase. Relative molecular weights and PDIs were calculated by Breeze 2 
software from Waters Corporation, based on conventional calibration method using polystyrene 
as standards. Absolute molecular weights were collected on the above GPC system equipped 
with an additional miniDAWN TREOS 3-angle laser light scattering detector (MALLS, Wyatt 
Technology, CA). The detection wavelength of TREOS was set at 658 nm. The MALLS detector 
was calibrated using pure toluene and used for the determination of the absolute molecular 
weights. The molecular weights of all polymers were determined based on the dn/dc value of 
each sample calculated offline by using the internal calibration system processed by the ASTRA 
software (Wyatt Technology CA).  GPC data points were exported as ASCII files, re-imported 
into OriginPro 8, plotted, saved as vector image files (*.ai) and colored/commented in Adobe 
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Illustrator CS6. TEM experiments were conducted with a JEOL 2100 Cryo transmission electron 
microscope. Negative staining of polymer nanoparticles with ammonium molybdate was applied 
when preparing TEM samples in order to achieve better contrast. Samples were prepared by drop 
casting polymer nanoparticle and ammonium molybdate mixture solutions onto a carbon-coated 
copper TEM grid or a silicon wafer (Ted Pella), followed by removing excess solution with filter 
paper after 10 min. TEM grids were then left dried for another 15 min before imaging.  
ONP Cell Uptake Study  
HeLa cells used for ONP uptake experiments were cultured in Dulbecco’s modification 
of Eagle’s medium (DMEM) supplemented with or without 10% Fetal Bovine Serum (FBS), 100 
U/mL penicillin, and 100 µg/mL streptomycin, on 25 cm2 culture flasks in a humidified 5% CO2 
incubator at 37 °C. Hela cells were plated onto 35 mm glass-bottom dishes (MatTek) and grown 
to 70 - 90% confluence before confocal microscopy imaging. HeLa cells were then incubated 
with 2 mL of DMEM (w/o 10% FBS) containing 2 µM ONPs in glass-bottom dish. After 3 hours, 
cells were washed with PBS 3 times and fresh DMEM (w/o 10% FBS) was added. For flow 
cytometry study, after 3-hour incubation with ONPs, Hela cells were washed with PBS and 
detached by 0.05% trypsin. The suspended cell solution was collected by centrifugation at 2,000 
g for 5 min and further washed with PBS three times. Flow cytometry was performed using a BD 
FACSCanto system under 488 nm excitation. Control cells without any treatment were used to 
set the gating. Each measurement set was performed using 10,000 cells. 
Synthesis of Monomers 
 Note: The proton coupling on the norbornene structure was complicated and the coupling 
constants are generally small. Thus, sometimes the splitting of the corresponding peaks is not 
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discernible and these peaks are seen as slightly broad singlets. NMR results were shown from 
Figure 8.9 to Figure 8.26. 
M1. N-carboxymethyl cis-5-norbornene-exo-2,3-dicarboximide was first synthesized 
according to literature procedure.42 In a 100-mL round bottom flask, N-carboxymethyl cis-5-
norbornene-exo-2,3-dicarboximide (2.21 g, 10 mmol) was mixed with N-hydroxysuccimide 
(1.27 g, 11 mmol) and EDC·HCl (2.29 g, 12 mmol) in 15 mL of anhydrous DMF. The reaction 
was stirred at room temperature overnight. The resulting solution was diluted with EtOAc (150 
mL), and washed first with 0.1 M phosphate buffer (pH 7.4, 100 mL), then with water (50 mL x 
2) and brine (50 mL). The organic layer was dried over Na2SO4, evaporated, and the residue was 
purified by flash column chromatography (100% EtOAc, silica was dried in a vacuum oven at 
150 oC for 48 h) to give a white solid. Yield: 2.1 g. 1H NMR (400 MHz, CDCl3): δ 6.32 (s, 2H), 
4.58 (s, 2H), 3.34 (s, 2H), 2.85 (s, 4H), 2.79 (s, 2H), 1.53-1.59 (m, 2H). 13C NMR (500 MHz, 
CDCl3): δ 176.5, 168.3, 163.3, 138.2, 48.2, 45.7, 43.1, 37.3, 25.7. ESI-MS: calculated for 
[M+Na+]: 341.0750, found 341.0750. 
M2. The synthesis of M2 was following the protocol in our previous work,23 using N-(4-
aminobutyl)-cis-5-norbornene-exo-2,3-dicarboximide (synthesized from cis-5-norbornene-exo-
2,3-dicarboxylic anhydride and 1,4-diaminobutane) and 5(6)-carboxyfluorescein. Briefly, 5(6)-
carboxyfluorescein (0.75 g, 2.0 mmol) was mixed with EDC·HCl (0.42 g, 2.2 mmol) and NHS 
(0.25 g, 2.2 mmol) in 15 mL of DMF and stirred for 20 min. N-(4-aminobutyl)-cis-5-norbornene-
exo-2,3-dicarboximide (0.47 g, 2.0 mmol) was added, and the reaction was stirred at room 
temperature overnight. The resulting solution was diluted by EtOAc and extracted with water, 
0.1 M HCl, water and finally brine. The EtOAc solution was dried and evaporated to a residue, 
which was purified by column (DCM/MeOH, 10:1). Yield: 0.86 g. 
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The above product (0.80 g) was suspended in 5mL of acetic anhydride. The suspension was 
heated at 50 Celsius overnight to give a homogeneous dark red solution. The solvent was 
evaporated and the residue was purified by column (3:2 EtOAc/Hexanes, silica was pre-dried in 
vacuum oven at 150 oC for 48 h). After the column, the product was dried under high vac at 
room temperature for several days to remove the trace amount of acetic acid/anhydride, making 
the product turn into a foam-like solid. The product was stored in a -20 oC freezer with drying 
agents. Note: the two isomers could possibly be separated by careful column chromatography, 
but the separation was not needed and attempted. Yield (as a mixture of 5- and 6-isomer): 0.75 g. 
5-isomer 1H NMR (500 MHz; DMSO-d6): δ  8.85 (t, J = 5.8 Hz, 1H), 8.51 (dd, J1 = 1.6 Hz, J2 = 
0.7 Hz, 1H), 8.26 (dd,  J1 = 8.1 Hz, J2 = 1.6 Hz, 1H), 7.53 (dd, J1 = 8.1 Hz, J2 = 0.7 Hz, 1H), 
7.30 (dd, J1 = 2.1 Hz, J2 = 0.6 Hz, 2H), 6.95 (dd,  J1 = 8.7 Hz, J2 = 2.1 Hz, 2H), 6.93 (dd, J1 = 8.7 
Hz, J2 = 0.6 Hz, 2H), 6.30 (t, J = 1.7 Hz, 2H), 3.39 (t,  J = 6.5 Hz, 2H), 3.32 (m, 2H), 3.09 
(quintet,  J = 1.6 Hz, 2H), 2.69 (d, J = 0.8 Hz, 2H), 2.29 (s, 6H), 1.53 (m, 2H), 1.51 (m, 2H), 
1.36 (dt, J1 = 9.7 Hz, J2 = 1.4 Hz, 1H), 1.13 (d,  J = 9.7 Hz, 1H). 6-isomer 
1H NMR (500 MHz; 
DMSO-d6): δ 8.69 (t, J = 5.7 Hz, 1H), 8.21 (dd, J1 = 8.1 Hz, J2 = 1.4 Hz, 1H), 8.16 (dd,  J1 = 8.1 
Hz, J2 = 0.7 Hz, 1H), 7.79 (dd, J1 = 1.4 Hz, J2 = 0.7 Hz, 1H), 7.31 (dt, J1 = 2.1 Hz, J2 = 0.6 Hz, 
2H), 6.97 (dd,  J1 = 8.7 Hz, J2 = 2.1 Hz, 2H), 6.95 (dd, J1 = 8.7 Hz, J2 = 0.6 Hz, 2H), 6.28 (q, J = 
1.7 Hz, 2H), 3.32 (m, 2H), 3.20 (q, J = 6.1 Hz, 2H), 3.04 (quintet, J = 1.8 Hz, 2H), 2.64 (d,  J = 
1.3 Hz, 2H), 2.29 (s, 6H), 1.44 (m, 2H), 1.42 (m, 2H), 1.30 (dt,  J1 = 9.7 Hz, J2 = 1.5 Hz, 1H), 
1.07 (d, J = 9.7 Hz, 1H).  13C NMR was not attempted as the product was a mixture. ESI-MS (5- 
and 6- mixture): calculated for [M+H+]: 677.2135, found 677.2134. 
M3. The synthesis of M3 was following the protocol in our previous work,23 using exo-
anhydride instead but keeping all other reagents and steps same as previously reported. Similar 
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yield was obtained. 1H NMR (400 MHz, CDCl3): δ 6.30 (s, 2H), 4.39 (m, 1H), 4.03 (dd, J1 = 8.5 
Hz, J2 = 6.3 Hz, 1H), 3.77 (m, 2H), 3.48 (dd, J1 = 13.4 Hz, J2 = 4.9 Hz, 1H), 3.30 (s, 2H), 2.71 (s, 
2H), 1.51 (d, J = 9.9 Hz, 1H), 1.44 (s, 3H), 1.36 (d, J = 9.9 Hz, 1H), 1.31 (s, 3H). 13C NMR (500 
MHz, CDCl3): δ 178.2, 138.1, 110.0, 72.6, 67.5, 48.1, 45.5, 43.0, 41.8, 27.0, 25.6. ESI-MS: 
calculated for [M+Na+]: 300.1212, found 300.1225. 
M4. In a 200-mL round bottom flask, cis-5-norbornene-exo-2,3-dicarboxylic anhydride 
(1.64 g, 10 mmol) was suspended in 30 mL of toluene. Ethanolamine (0.61 g, 10 mmol) was 
added into the mixture, and the mixture was stirred and refluxed overnight to give a clear 
solution. The solution was transferred to another  200-mL round bottom flask while hot, to 
remove minor dark insoluble stuff sticking on the flask’s inner surface, if there was any. The 
solution was added acetic anhydride (1.9 mL, 20 mmol), and heated to reflux again. The reaction 
was monitored by TLC. Upon completion, the solution was cooled to 0 oC, and aqueous 
methylamine solution (40 % wt. in water, 5 mL, excess) was dropwisely added to the solution to 
react with excess acetic anhydride, forming water-soluble salt and N-methylacetamide. The 
mixture was then partitioned between extra EtOAc (50 mL) and water (80 mL). The organic 
layer was isolated and further washed by aq. NaHCO3 (80 mL) then brine (50 mL), dried over 
Na2SO4, and evaporated to afford the product as a yellow oil. The purity of the product was 
usually enough for successful ROMP, but it can be further purified by flash chromatography to 
yield a colorless oil, which could sometimes turn to a crystalline solid upon thorough drying and 
cooling to low temperature (-20 oC). Yield: 2.27 g. 1H NMR (500 MHz, CDCl3): δ 6.28 (t, J = 
1.6 Hz, 2H), 4.22 (t, J = 5.4 Hz, 2H), 3.75 (t, J = 5.4 Hz, 2H), 3.27 (t, J = 1.5 Hz, 2H), 2.70 (d, J 
= 1.1 Hz, 2H), 1.99 (s, 3H), 1.51 (dt, J1 = 9.8 Hz, J2 = 1.4 Hz, 1H), 1.30 (d, J = 9.8 Hz, 1H). 
13C 
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NMR (500 MHz, CDCl3): δ 178.1, 171.1, 138.0, 61.9, 48.0, 45.3, 43.0, 35.9, 27.1, 21.1. ESI-MS: 
calculated for [M+Na+]: 272.0899, found 272.0898. 
M5. The synthesis of M5 was following the protocol for M4, using 3-amino-1-propanol 
instead but keeping all other reagents and steps as same as previously described. The pure 
product was a colorless oil with similar yield as M4. 1H NMR (500 MHz, CDCl3): δ 6.26 (t, J = 
1.7 Hz, 2H), 4.03 (t, J = 6.2 Hz, 2H), 3.54 (t, J = 7.1 Hz, 2H), 3.24 (t, J = 1.5 Hz, 2H), 2.66 (d, J 
= 1.0 Hz, 2H), 2.03 (s, 3H), 1.88 (m, 2H), 1.49 (dt, J1 = 9.8 Hz, J2 = 1.4 Hz, 1H), 1.19 (d, J = 9.8 
Hz, 1H). 13C NMR (500 MHz, CDCl3): δ 178.1, 171.1, 138.0, 61.9, 48.0, 45.4, 43.0, 35.9, 27.1, 
21.1. ESI-MS: calculated for [M+Na+]: 286.1055, found 286.1057. 
M6. The synthesis of M6 was following the protocol for M4, using 4-amino-1-butanol 
instead but keeping all other reagents and steps as same as previously described. The pure 
product was colorless oil with similar yield as M4. 1H NMR (500 MHz, CDCl3): δ 6.26 (t, J = 
1.7 Hz, 2H), 4.03 (m, 2H), 3.46 (m, 2H), 3.24 (t, J = 1.5 Hz, 2H), 2.65 (d, J = 1.1 Hz, 2H), 2.00 
(s, 3H), 1.57-1.63 (m, 4H), 1.48 (dt, J1 = 9.8 Hz, J2 = 1.4 Hz, 1H), 1.18 (d, J = 9.8 Hz, 1H). 
13C 
NMR (500 MHz, CDCl3): δ 178.2, 171.2, 138.0, 63.9, 48.0, 45.4, 42.9, 38.4, 26.3, 24.7, 21.2. 
ESI-MS: calculated for [M+Na+]: 300.1212, found 300.1212. 
M7. In a 200-mL round bottom flask, cis-5-norbornene-exo-2,3-dicarboxylic anhydride 
(3.28 g, 20 mmol) was suspended in 40 mL of toluene. Aqueous methylamine (40 % by weight, 
1.90 mL, 22 mmol) was added into the mixture, and the mixture was stirred for 1 hour before it 
was heated to reflux overnight. No water removal apparatus was needed for this reaction. The 
resulting solution was concentrated, and the residue was diluted by ethyl acetate (60 mL) and 
washed with 0.1 M HCl (50 mL), water (50 mL) and brine (50 mL), dried over Na2SO4, and 
evaporated to give a crystalline product. The product can be purified by recrystallization in 
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EtOAc/hexanes to give a white crystalline solid. Yield: 2.91 g after recrystallization. 1H NMR 
(500 MHz, CDCl3): δ 6.28 (t, J = 1.7 Hz, 2H), 5.14 (m, 1H), 3.28 (t, J = 1.7 Hz, 2H), 2.97 (s, 
3H), 2.70 (d, J = 1.1 Hz, 2H), 1.52 (dt, J1 = 9.9 Hz, J2 = 1.5 Hz, 1H), 1.20 (d, J = 9.9 Hz, 1H). 
13C NMR (500 MHz, CDCl3): δ 178.4, 138.0, 48.2, 45.4, 43.1, 24.8. ESI-MS: calculated for 
[M+H+]: 178.0868, found 178.0870. 
M8. N-(1-methyl-1,1-di(hydroxymethyl))-cis-5-norbornene-exo-2,3-dicarboximide was 
first synthesized from cis-5-norbornene-exo-2,3-dicarboxylic anhydride and 2-amino-2-methyl-
1,3-propanediol according to a literature procedure._ENREF_4443 The above compound (1.25 g, 5 
mmol) was dissolved in DCM (30 mL). The solution was added 2,2-dimethoxypropane (6 mL, 
excess) and p-TsOH (50 mg, catalytical), and was stirred until the reaction was complete, 
indicated by TLC. The DCM layer was washed by saturated aqueous NaHCO3 (100 mL) for 2 
times, brine once, dried over Na2SO4 and concentrated to an light-yellow oil. The purity of the 
product was usually enough for successful ROMP, but it can be further purified by flash 
chromatography (EtOAc/hexanes, 1:3) to yield a colorless oil, which could turn to a white solid 
upon thorough drying and cooling to low temperature (-20 oC).Yield: 1.36 g. 1H NMR (400 MHz, 
CDCl3): δ 6.28 (s, 2H), 4.39 (m, 1H), 4.82 (d, J = 12.1 Hz, 2H), 3.85 (d, J = 12.1 Hz, 2H), 3.28 
(s, 2H), 2.59 (s, 2H), 1.47-1.54 (m, 2H), 1.43 (s, 3H), 1.38 (s, 3H), 1.37 (s, 3H). 13C NMR (500 
MHz, CDCl3): δ179.4, 138.1, 98.5, 65.2, 57.9, 47.8, 46.0, 42.9, 25.6, 22.0, 18.7. ESI-MS: 
calculated for [M+Na+]: 314.1368, found 314.1369.  
M9. cis-5-norbornene-exo-2,3-dicarboximide was first synthesized from cis-5-
norbornene-exo-2,3-dicarboxylic anhydride and urea according to a literature procedure.44 The 
dicarboximide (3.26 g, 20 mmol) was dissolved in 40 mL of anhydrous THF, followed by the 
addition of K2CO3 (5.52 g, 40 mmol), dibenzo-18-crown-6 (10 mg, catalytical) and 1-chloro-3-
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methyl-2-butene (prenyl chloride, 2.30 g, 22 mmol). The reaction was refluxed overnight. 
Solvent was removed under reduced pressure, and the residue was partitioned between ethyl 
acetate (50 mL) and water (100 mL). Organic layer was isolated and further washed by water 
and brine, dried over Na2SO4, and evaporated. The crude residue was purified by column 
chromatography (EtOAc/hexanes, 1:6 to 1:4) to give a white solid. Yield: 3.61 g. 1H NMR (500 
MHz, CDCl3): δ 6.28 (t, J = 1.7 Hz, 2H), 5.14 (m, 1H), 4.05 (d, J = 7.1 Hz, 2H), 3.26 (s, 2H), 
2.66 (d, J = 1.3 Hz, 2H), 1.76 (s, 3H), 1.69 (s, 3H), 1.49 (dt, J1 = 9.8 Hz, J2 = 1.3 Hz, 1H), 1.22 
(d, J = 9.8 Hz, 1H). 13C NMR (500 MHz, CDCl3): δ 178.0, 138.1, 137.8, 117.6, 48.0, 45.4, 42.9, 
36.8, 25.8, 18.2. ESI-MS: calculated for [M+H+]: 232.1338, found 232.1341. 
Synthesis of “Imaginative Monomers” 
 IM1, IM3, IM4, IM5, IM9 and IM11. These 6 “imaginative monomers” were synthesized 
from their corresponding monomers according to a general procedure. Monomer (one from M3-
M7 and M9) was dissolved in 1 mL of mixed solvents (acetone/t-butanol, 3:1 v/v) in a 7-mL vial 
equipped with a magnetic stirbar. N-methylmorpholine N-oxide (50% wt in water) was added to 
the solution, followed by a catalytic amount of K2OsO4. Upon completion (monitored by TLC), 
the solvent was removed under reduced pressure, and the residue was re-dissolved in methanol. 
The solution was used in LC-MS analysis after further dilution in methanol. 
 IM2 and IM10. The crude IM1 residue was re-dissolved in 0.1M aqueous HCl. The 
deprotection was monitored by TLC (typically a few hours). Upon completion, the solution was 
carefully neutralized with NaOH solution. The solution was used in LC-MS analysis after further 
dilution in methanol. 
 IM6, IM7 and IM8. These 3 compounds were synthesized from their corresponding 
precursor “imaginative monomers” according to a general procedure as shown below. The crude 
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residue of IM3, IM4 or IM5 was re-dissolved in 1M aqueous NaOH. The deprotection was 
monitored by TLC (typically overnight). Upon completion, the solution was carefully neutralized 
with HCl solution. The solution was used in LC-MS analysis after further dilution in methanol. 
Preparation of ONPs with Different Functional Groups 
 Typical procedure for polymerization. M1 (31.8 mg, 0.10 mmol, 25 eq), M2 (5.4 mg, 
0.008 mmol, 2 eq) and M3 (55.4 mg, 0.20 mmol, 50 eq) were dissolved in anhydrous 
dichloromethane (5 mL). The solution was roughly degassed by bubbling with N2 for 30 sec. 
With fast stirring, pyridine-modified Grubbs 2nd Generation catalyst (stock solution, 0.025 M in 
DCM, 0.160 mL, 0.004 mmol, 1 eq) was quickly added. The solution was stirred at room 
temperature for 5 minutes and NHBoc-CTA (0.125 M in DCM, 0.16 mL, 5 eq) was added. The 
solution was stirred for 3 h and butyl vinyl ether (1 mL) was added to quench the catalyst. 
Solvent was removed under reduced pressure. The solid residue was re-dissolved in DCM (1.5 
mL) and precipitated in ether (12 mL) in a 15-mL polypropylene centrifuge tube. The mixture 
was sonicated, centrifuged, and the supernatant was discarded. The solid was further triturated, 
sonicated, and centrifuged in ether for another 2 times before the solid was dried under reduced 
pressure to give an off-white solid. Yield: 82 mg. Note: the CTA functionalization was optional. 
If the single reactive group is not needed, the polymerization can be directly quenched by adding 
2 mL of butyl vinyl ether after polymerization. 
 Typical procedure for functionalization with triallyl-Tris. The poly(activated ester) from 
the previous step (80 mg) was dissolved in a mixture of DCM (6 mL) and nitrobenzene (0.1 mL) 
in a 20-mL vial. Triallyl-Tris (0.12 mL) was added. The vial was capped and sealed by parafilm, 
and the solution was stirred in a 40 oC aluminum heating block overnight. Most of the solvent 
was removed under reduced pressure, and the viscous residue was redissolved in DCM (1.5 mL) 
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and precipitated in a 2:1 (v/v) mixture of cold ether-hexanes (-15 oC) in a 15-mL polypropylene 
centrifuge tube. The mixture was sonicated, centrifuged, and the supernatant was discarded. The 
solid was further triturated, sonicated, and centrifuged in ether for another 2 times before the 
solid was dried under reduced pressure to give an off-white solid. Yield: 69 mg. 
Typical procedure for intramolecular crosslinking by RCM. A 1 L round-bottom 
flask was filled with 450 mL of anhydrous DCM under nitrogen atmosphere. Allyl polymer from 
previous step (60 mg) was dissolved in 1 mL of DCM, and 12 mg of 1st Generation Grubbs 
catalyst in 1 mL of DCM. 0.5 mL of the polymer solution was added into the 1 L flask, stirred at 
room temperature for 5 min, and 0.5 mL of the catalyst solution was added. After 3 hours, the 
remaining polymer and catalyst solutions were added. The solution was kept stirring at room 
temperature, and 6 mg catalyst added was added after 6h, and another 6 mg after 18 h. The 
mixture was stirred for a total time of 40 h after the first catalyst addition, and 1 mL of butyl 
vinyl ether was added to quench the catalyst.  The solution was stirred 15 min and evaporated 
under reduced pressure. The solid residue was dissolved in DCM, precipitated in diethyl ether to 
remove most of the catalyst, then dried on a rotary evaporator. The polymer was further purified 
by passing through silica gel eluted by DCM in a glass pipette. Solvent was evaporated, and the 
residue was redissolved in DCM (1.0 mL) then precipitated in ether (12 mL). The precipitates 
were collected after centrifuge, further washed with ether, and dried under vacuum to gave a 
greyish-white powder. Yield: 57 mg. 
Typical procedure for dihydroxylation of the alkene ONPs. In a 20 mL glass vial, 50 
mg of alkene ONP was suspended in a mixture of water (3 mL) and acetone (12 mL). NMO (50% 
wt in H2O, 0.5 mL) and K2OsO4 (1 mg) was added to the mixture. The vial was loosely capped 
and heated in a 40 oC aluminum heating block for several hours, then the cap was removed and 
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the vial was covered by a piece of chemical paper wipe so that acetone can freely and slowly 
evaporate. Heating and stirring was continued for another 5-6 h after most of the acetone was 
evaporated (and the solution should be homogeneous at this time), and the solution decanted to 
remove insoluble residue (black, if there was any). The green solution was further purified by 
dialysis against water using a membrane (Spectra/Por 7 Membrane Tubing, MWCO = 1000 kDa) 
and the solution was lyophilized to yield a yellow to yellowish-white to greyish-white solid. 
Yield: 46 mg. If further deprotection was needed, the product solution could be briefly dialyzed 
for 3 hours and directly used in the next step without lyophilization (see below). 
Typical procedure for acid-deprotection of the dihydroxylated ONPs. Briefly 
dialyzed ONP solution (containing 40-50 mg of ONP) was added 3M HCl to bring the pH to 1. 
The homogeneous solution became a suspension instantly. The suspension was warmed to 30 oC, 
and was stirred until the solution became clear. Insoluble stuff was filtered off, and the solution 
was directly dialyzed against water using a membrane (Spectra/Por 7 Membrane Tubing, 
MWCO = 1000 kDa) and the solution was lyophilized to yield a yellow to yellowish-white solid. 
Yield: 27-40 mg. 
Typical procedure for base-deprotection of the dihydroxylated ONPs. Briefly 
dialyzed ONP solution (containing 40-50 mg of ONP) was added 1M NaOH to bring the pH to 
13. The homogeneous solution was stirred overnight. The resulting solution was directly 
dialyzed against water using a membrane (Spectra/Por 7 Membrane Tubing, MWCO = 1000 kDa) 
and the solution was lyophilized to yield a yellow to yellowish-white solid. Yield: 30-45 mg. 
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8.6. Figures 
Table 8.1.  Molecular weight and fluorescence intensity comparison of selected ONPs. 
ONP 
Expected MW 
of parent linear 
polymers (kDa)a 
Experimental 
MW of parent 
linear polymers 
by MALLS 
(kDa)b 
MW of final 
ONP (kDa)c 
Relative 
fluorescence 
intensityd 
ONP275 23.5 21.0 24.4 1.17 
ONP675 22.1 21.9 25.3 0.90 
ONP775 22.8 23.5 27.0 0.85 
ONP875 23.5 24.3 27.8 0.86 
ONP975 18.5 15.8 20.8 0.94 
ONP1075 24.2 24.8 28.7 1.01 
ONP1175 21.2 18.5 25.1 1.00 
ONP1275 22.4 21.5 25.6 0.90 
 
[a] The poly(activated ester)s, based on monomer feed ratio and monomer/initiator ratio. [b] Multi-
angel Laser Light Scattering (MALLS) technique allows the detection of absolute (true) 
molecular weights of linear, non-fluorescent polymers, without the need of calibration of any 
polymer standards. Note: the protected fluorescein (fluorescein diacetate) moieties are not 
fluorescent without protection. Thus these polymers can be characterized by MALLS without 
fluorescence interference. [c] Calculated based on experimental molecular weight of the parent 
linear polymers. [d] ONPs all had a concentration of 1µM, in 0.1 M aqueous NaOH. Excitation 
was at 499 nm. Fluorescence intensity was calculated by integrating emission from 510-530 nm. 
ONP1175 was set as the reference (intensity = 1.00). 
Table 8.2.  LC-MS retention time of different imaginative monomers 
ONP IM2 IM6 IM7 IM8 IM9 IM11 
LC-MS 
Retention 
Time (min) 
 3.02 ± 0.41 4.71 ± 0.11 5.10  ± 0.10 2.47  ± 0.27 4.9  ± 0.15 4.69  ± 0.17 
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Figure 8.1. Schematic illustration of the organic nanoparticles with different surface functional 
groups to fine-tune lipophilicity. 
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Figure 8.2. Chemical formulas of the surface functional monomers (a) and the “imaginative 
monomers” (b). 
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Figure 8.3. Overlaid GPC curves of parent poly(activated ester) of ONP275 (red line) and 
ONP275 before oxidation (blue line) (DMF, 0.1 M LiBr, eluent).   
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Figure 8.4. (a) Schematic illustration of ONPs synthesized from different “imaginative 
monomers” with different carbon chain length used in the serum-free cell uptake study. (b) The 
cell-associated fluorescence intensities of HeLa cells and fluorescent ONPs treated HeLa cells 
using flow cytometry. HeLa cells were treated with 2 µM ONPs in DMEM medium for 3 hours 
incubation at 37 ˚C. (c) A graph showing the relationship between mean fluorescence intensities 
of ONP-treated HeLa cells and the corresponding type of ONP. The results showed that the cell 
internalization ability of ONP increased with the increase of carbon chain length. 
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Figure 8.5. (a) Schematic illustration of ONPs synthesized from different “imaginative 
monomers” with 0, 1, and 2 hydroxyl groups used in the serum-free cell uptake study. (b) The 
cell-associated fluorescence intensities of HeLa cells and fluorescent ONPs treated HeLa cells 
using flow cytometry. HeLa cells were treated with 2 µM ONPs in DMEM medium for 3 hours 
incubation at 37 ˚C. (c) A graph showing the relationship between mean fluorescence intensities 
of ONP-treated HeLa cells and the corresponding type of ONP. The results showed that the cell 
internalization ability of ONP decreased with the increase of number of hydroxyl groups. 
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Figure 8.6. (a) Schematic illustration of ONPs of different molecular weight used in the serum-
free cell uptake study. (b) The cell-associated fluorescence intensities of HeLa cells and 
fluorescent ONPs treated HeLa cells using flow cytometry. HeLa cells were treated with 2 µM 
ONPs in DMEM medium for 3 hours incubation at 37 ˚C. (c) A graph showing the relationship 
between mean fluorescence intensities of ONP-treated HeLa cells and different sized ONPs. The 
results showed that the cell internalization ability of ONP increased with the decrease of 
molecular weight. 
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Figure 8.7. The serum-containing cell uptake study for different ONPs samples using HeLa cells. 
The cell-associated fluorescence intensities of HeLa cells and fluorescent ONPs treated HeLa 
cells and the corresponding graph showing the relationship between mean fluorescence 
intensities of ONP-treated HeLa cells and the corresponding ONPs using flow cytometry. HeLa 
cells were treated with 2 µM ONPs in DMEM with 10% FBS medium for 3 hours incubation at 
37 ˚C. (a) ONP from 0-OH monomer showed highest cell internalization ability. (b) cell 
internalization ability of ONP increased with the increase of carbon chain length. (c) ONP of the 
smallest molecular weight showed highest cell internalization ability. 
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Figure 8.8. The effect of the monomer lipophilicity on cellular uptake ability of ONP with 
corresponding monomer in serum free (blue) and 10% FBS DMEM medium (red). The 
lipophilicity of the monomer is determined by LC-MS retention time. A clear trend shows that 
with the increase of monomer hydrophobicity the amount of ONPs internalized increased. 
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Figure 8.9. 1H NMR spectrum of parent poly(activated ester) polymer of ONP175/ONP275. 
 
 
 
Figure 8.10. 1H NMR spectrum of parent polyallyl polymer of ONP175/ONP275. 
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Figure 8.11. 1H NMR spectrum of ONP175/ONP275 before dihydroxylation (poly-alkene ONP, 
water-insoluble). 
 
 
Figure 8.12. 1H NMR spectrum of ONP275 in water. 
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Figure 8.13. 1H NMR spectrum of parent poly(activated ester) polymer of ONP375/ONP675. 
 
 
 
Figure 8.14. 1H NMR spectrum of ONP675 in water. 
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Figure 8.15. 1H NMR spectrum of parent poly(activated ester) polymer of ONP475/ONP775. 
 
 
 
Figure 8.16. 1H NMR spectrum of ONP775 in water. 
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Figure 8.17. 1H NMR spectrum of parent poly(activated ester) polymer of ONP575/ONP875..  
 
 
 
Figure 8.18. 1H NMR spectrum of ONP875 in water. 
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Figure 8.19. 1H NMR spectrum of parent poly(activated ester) polymer of ONP975. 
 
 
 
Figure 8.20. 1H NMR spectrum of ONP975 in water. 
304 
 
 
 
Figure 8.21. 1H NMR spectrum of parent poly(activated ester) polymer of ONP1075. 
  
 
 
Figure 8.22. 1H NMR spectrum of ONP1075 in water. 
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Figure 8.23. 1H NMR spectrum of parent poly(activated ester) polymer of ONP1175. 
 
 
 
Figure 8.24. 1H NMR spectrum of ONP1175 in water.  
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Figure 8.25. 1H NMR spectrum of parent poly(activated ester) polymer of ONP1275. 
 
 
 
Figure 8.26. 1H NMR spectrum of ONP1275 in water. 
